<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00256750</url>
  </required_header>
  <id_info>
    <org_study_id>IM103-008</org_study_id>
    <nct_id>NCT00256750</nct_id>
    <nct_alias>NCT00432497</nct_alias>
  </id_info>
  <brief_title>Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT)</brief_title>
  <acronym>BENEFIT</acronym>
  <official_title>Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial (BENEFIT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn if Belatacept can provide protection from organ
      rejection following kidney transplantation while avoiding some of the toxic effects of
      standard immunosuppressive medications such as kidney damage. Effects on kidney function and
      patient survival as well as drug safety will also be studied.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Participants Surviving With a Functioning Graft by Month 12</measure>
    <time_frame>Day 1 to Month 12</time_frame>
    <description>Graft loss was defined as either functional loss or physical loss (nephrectomy). Functional loss was defined as a sustained level of serum creatinine (SCr) ≥ 6.0 milligrams per deciliter (mg/dL) or 530 micromolar per liter (μmol/L) as determined by the central laboratory for ≥ 4 weeks or ≥ 56 consecutive days of dialysis or impairment of renal function to such a degree that the participant underwent retransplant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of Participants With a Composite of Measured Glomerular Filtration Rate (mGFR) Less Than 60 mL/Min/1.73 m^2 at Month 12 or With a Decrease in mGFR Greater Than or Equal to 10 mL/Min/1.73m^2 From Month 3 to Month 12</measure>
    <time_frame>Month 12; Month 3 to Month 12</time_frame>
    <description>Measured glomerular filtration rate (mGFR) is the direct measurement of renal function and was assessed by measurement of the clearance of a true glomerular filtration marker (non-radiolabeled iothalamate) using a validated procedure. A GFR of 60 mL/min/1.73 m^2 was used as the approximate equal of the threshold values of serum creatinine (SCr) of 1.5 mg/dL. A change in GFR of at least 10 mL/min/1.73 m^2 was used as the approximate change in SCr of at least 0.3 mg/dL. The change component of the composite renal endpoint was assessed from Month 3 to Month 12, since post-transplant renal function is largely stable by Month 3.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of Participants Experiencing Acute Rejection (AR) Post-transplant by Month 12</measure>
    <time_frame>Day 1 to Month 12</time_frame>
    <description>Acute rejection was defined as a clinico-pathological event requiring clinical evidence and biopsy confirmation. Clinical evidence was defined if either a or b was satisfied: a: an unexplained rise of serum creatinine ≥ 25% from baseline creatinine; b: an unexplained decreased urine output; or fever and graft tenderness; or a serum creatinine that remains elevated within 14 days post-transplantation and clinical suspicion of acute rejection exists. Allograft biopsies were evaluated by a blinded central independent pathologist using Banff 97 working classification of kidney transplant pathology. Banff 97 diagnostic category for renal allograft biopsies is an international standardized histopathological classification. AR was defined by a renal biopsy demonstrating a Banff 97 classification of Grade IA or greater, with higher scores indicating more severe rejection. Only the episode with the highest Banff grade for each participant was counted.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Value of the Measured Glomerular Filtration Rate (mGFR)</measure>
    <time_frame>Months 3, 12, 24</time_frame>
    <description>Measured glomerular filtration rate (mGFR) is the direct measurement of renal function and was assessed by measurement of the clearance of a true glomerular filtration marker (non-radiolabeled iothalamate) using a validated procedure. Missing mGRF assessments were imputed to assess renal function. The overall imputation strategy involved a primary imputation method (linear extrapolation and quartile method) followed by 2 secondary imputation methods (regression method and graded quartile method) to assess the robustness of conclusions obtained from the application of the primary imputation method. All imputation methods entailed replacing a missing value with a value drawn from a plausible distribution incorporating theoretical and observed aspects of the data. GFR was measured as mL/min/1.73 m^2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With Prevalence of Chronic Allograft Nephropathy (CAN) at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>Prevalence of CAN = if participant met any of the following conditions: a: CAN observed in a biopsy either prior to 12 months (including baseline biopsy) or first post 12 months biopsy; b: participant had graft loss during the first year post transplant; c: no biopsy was available post 12 months and CAN not observed in biopsies prior to 12 months, but the measured GFR from Month 3 to Month 12 decreased at least 10 mL/min/1.73m^2; d: no biopsy available either prior to or post 12 months, and the measured GFR (incorporated missing data imputation) from Month 3 to Month 12 decreased at least 10 mL/min/1.73m^2. CAN = All allograft biopsies evaluated for presence and severity of CAN by a blinded central independent pathologist using Banff 97 working classification of kidney transplant pathology. Onset of CAN determined by the biopsy date when it was observed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious Adverse Events, Death, Discontinuation Due to Adverse Events by Month 84</measure>
    <time_frame>Randomization to Month 84</time_frame>
    <description>Adverse event (AE) defined: any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. Serious adverse event (SAE) defined: a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events of Special Interest by Month 84</measure>
    <time_frame>Randomization to Month 84</time_frame>
    <description>Prospectively identified events of special interest which were a subset of all AEs, and were either SAEs or non-serious AEs, included the following categories: Serious Infections and Infestations, Thrombolic/embolic events, and Malignancy. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/ abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Time frame is from randomization to the event date, or to the last dose date+56, or to Month 84 (Day 2548), whichever is the earliest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Blood Pressure at Month 84</measure>
    <time_frame>Month 84</time_frame>
    <description>Blood pressure was measured in millimeters of mercury (mmHg). Blood pressure was measured soon after the participant arrived and sat quietly at rest for 10 minutes. 3 consecutive seated blood pressure readings were made at least 1 minute apart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Meeting Marked Laboratory Abnormality Criteria Post-transplant by Month 36</measure>
    <time_frame>Baseline to Month 36</time_frame>
    <description>Upper limit of normal (ULN). Units per Liter (U/L). Cells per microliter (c/µL). Grams per deciliter (g/dL). Milligrams per deciliter (mg/dL).Cells per Liter (c/L). Milliequivalents/Liter (mEq/L).
Hemoglobin (low): &lt;8.0 g/dL; Platelet count: &lt;50*10^9 c/L; Leukocytes: &lt;2*10^3 c/µL; Alkaline phosphatase (ALP): &gt;5.0*ULN U/L; Alanine aminotransferase (ALT): &gt;5.0*ULN U/L; Asparate aminotransferase (AST): &gt;5.0*ULN U/L; Bilirubin Total: &gt;3.0*ULN mg/dL; Creatinine: &gt;3.0*ULN mg/dL; Calcium Total: low if &lt;7.0 mg/dL or high if &gt;12.5 mg/dL; Bicarbonate: &lt;11.0 mEq/L; Potassium serum: low if &lt;3.0 mEq/L or high if &gt;6.0 mEq/L; Magnesium serum: low is &lt;0.8 mEq/L or high if &gt;2.46 mEq/L; Sodium serum: low if &lt;130.0 mEq/L or high if &gt;155.0 mEq/L; Phosphorus inorganic: &lt;2.0 mg/dL; Albumin: &lt;2 g/dL; Uric acid: &gt;10 mg/dL; Protein urine: &gt;=3+</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With Development of Anti-Donor HLA Positive Antibodies by Month 84</measure>
    <time_frame>Randomization to Month 84</time_frame>
    <description>Only participants who had non-missing test result for Class I or Class II anti-donor HLA antibodies were included in analysis and only participants who had at least one non-NA test result or finding were counted. This was a cumulative summary (excluding baseline) and once a participant was positive, that participant remained positive for the later time point. Acute rejection (AR) defined: a clinico-pathological event requiring clinical evidence and biopsy confirmation. Clinical evidence defined: if either a or b was satisfied: a: an unexplained rise of serum creatinine ≥ 25% from baseline creatinine; b: an unexplained decreased urine output; or fever and graft tenderness; or a serum creatinine that remains elevated within 14 days post-transplantation and clinical suspicion of acute rejection exists. AR defined as allograft biopsies of Banff 97 classification Grade IA or greater (higher scores indicate more severe rejection). Evaluated by blinded central independent pathologist.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change of the Measured Glomerular Filtration Rate (mGFR) From Month 3 to Month 12 and From Month 3 to Month 24</measure>
    <time_frame>Month 3 to Month 12; Month 3 to Month 24</time_frame>
    <description>Measured glomerular filtration rate (mGFR) is the direct measurement of renal function and was assessed by measurement of the clearance of a true glomerular filtration marker (non-radiolabeled iothalamate) using a validated procedure. Missing mGRF assessments were imputed to assess renal function. The overall imputation strategy involved a primary imputation method (linear extrapolation and quartile method) followed by 2 secondary imputation methods (regression method and graded quartile method) to assess the robustness of conclusions obtained from the application of the primary imputation method. All imputation methods entailed replacing a missing value with a value drawn from a plausible distribution incorporating theoretical and observed aspects of the data. GFR was measured as mL/min/1.73 m^2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With a Decrease in Measured Glomerular Filtration Rate (mGFR) Greater Than or Equal to 10mL/Min/1.73m^2 From Month 3 to Month 12</measure>
    <time_frame>Month 3 to Month 12</time_frame>
    <description>Measured glomerular filtration rate (mGFR) is the direct measurement of renal function and was assessed by measurement of the clearance of a true glomerular filtration marker (non-radiolabeled iothalamate) using a validated procedure. A change in GFR of at least 10 mL/min/1.73 m^2 was used as the approximate change in serum creatinine (SCr) of at least 0.3 mg/dL. The change component of the composite renal endpoint was assessed from Month 3 to Month 12, since post-transplant renal function is largely stable by Month 3. Month 3 = baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With a Measured Glomerular Filtration Rate (mGFR) Less Than 60 mL/Min/1.73 m^2 at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>Measured glomerular filtration rate (mGFR) is the direct measurement of renal function and was assessed by measurement of the clearance of a true glomerular filtration marker (non-radiolabeled iothalamate) using a validated procedure. A GFR of 60 mL/min/1.73 m^2 was used as the approximate equal of the threshold values of serum creatinine (SCr) of 1.5 milligrams per deciliter (mg/dL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Value of the Calculated Glomerular Filtration Rate (cGFR) With Imputation</measure>
    <time_frame>Months 6, 12, 24, 36</time_frame>
    <description>Calculated glomerular filtration rate (cGFR) was used to assess renal function (as measured by the estimated creatinine clearance) using the following modification of diet in renal disease (MDRD) formula: MDRD: GFR = 170 x [SCr/0.95]^(-0.999) x [Age]^(-0.176) x [0.762 if participant is female] x [1.180 if participant is black] x [BUN]^(-0.170) x [Alb]^(+0.318); Age in years; Alb = Albumin in g/dL; SCr = Serum creatinine in mg/dL; BUN = Blood urea nitrogen in mg/dL; cGFR = mL/min/1.73m2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Calculated Glomerular Filtration Rate (cGFR) From Month 6 to Month 12</measure>
    <time_frame>Month 6 to Month 12</time_frame>
    <description>Calculated glomerular filtration rate (cGFR) was used to assess renal function (as measured by the estimated creatinine clearance) using the following modification of diet in renal disease (MDRD) formula: MDRD: GFR = 170 x [SCr/0.95]^(-0.999) x [Age]^(-0.176) x [0.762 if participant is female] x [1.180 if participant is black] x [BUN]^(-0.170) x [Alb]^(+0.318); Age in years; Alb = Albumin in g/dL; SCr = Serum creatinine in mg/dL; BUN = Blood urea nitrogen in mg/dL; cGFR = mL/min/1.73m^2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With Incidence of New Onset Diabetes Mellitus by Month 36</measure>
    <time_frame>Week 4 post-transplantation to Month 36</time_frame>
    <description>The incidence of new onset diabetes mellitus defined as participants who developed diabetes mellitus after randomization and transplantation. Participants that did not have diabetes prior to randomization were determined to have new onset diabetes mellitus if (i) the participant received an anti-diabetic medication for a duration of at least 30 days or (ii) at least two fasting plasma glucose (FPG) tests indicate that FPG is &gt;=126 mg/dL (7.0 mmol/L). New onset diabetes mellitus (NODM) = post-transplant diabetes mellitus (PTDM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants Using At Least One Anti-Hypertensive Medication to Control Hypertension at Month 36</measure>
    <time_frame>Month 36</time_frame>
    <description>This analysis was based on all participants who had been followed up at least 1092 days after transplantation. Hypertension was defined in according to the Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure for participants with chronic kidney disease. This definition was based upon SBP ≥ 130 mm Hg or DBP ≥ 80 mm Hg. In addition, all participants who had a SBP &lt; 130 mm Hg and a DBP &lt; 80 mm Hg who received an antihypertensive medication(s) for the indication of hypertension or with a medical history of hypertension were included in this definition. Systolic blood pressure = SBP; Diastolic blood pressure = DBP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With Incidence of Hypertension Post-Transplantation at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>The incidence of hypertension was defined as the proportion of participants who developed hypertension after randomization and transplantation. Specifically, the incidence of hypertension was assessed only after the Week 4 visit. This period allowed for adequate stabilization and resolution of transient changes. If participants received antihypertensive medication for the indication of hypertension at this (or later) time point, they were considered to have developed hypertension. Hypertension was defined according to the Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure for subjects with chronic kidney disease. This definition was based upon SBP ≥ 130 mm Hg or DBP ≥ 80 mm Hg. Systolic blood pressure = SBP; Diastolic blood pressure = DBP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With Prevalence of Hypertension Post-Transplantation at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>The prevalence of hypertension was defined as the proportion of participants at any given time who meet the definition of hypertension. Hypertension defined according to the Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure for participants with chronic kidney disease. This definition is based upon SBP ≥ 130 mm Hg or DBP ≥ 80 mm Hg. Systolic blood pressure = SBP; Diastolic blood pressure = DBP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Systolic Blood Pressure and Diastolic Blood Pressure</measure>
    <time_frame>Months 12, 24, 36</time_frame>
    <description>Blood pressure was measured in millimeters of mercury (mmHg). Blood pressure was measured soon after the participant arrived and sat quietly at rest for 10 minutes. 3 consecutive seated blood pressure readings were made at least 1 minute apart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants at Baseline With Controlled Hypertension Post Transplantation by Month 12</measure>
    <time_frame>Day 1 to Month 12</time_frame>
    <description>Controlled hypertension was defined as a SBP &lt; 130 mm Hg and a DBP &lt; 80 mm Hg while receiving an antihypertensive medication for the indication of hypertension or receiving an antihypertensive medication for another indication with a medical history of hypertension. Participants with a SBP &lt; 130 mm Hg and a DBP &lt; 80 mm Hg who were prescribed an antihypertensive medication(s) for an indication(s) other than hypertension (eg, beta blockers for migraine prophylaxis) with no medical history of hypertension were not considered to have either hypertension or controlled hypertension. Systolic blood pressure = SBP; Diastolic blood pressure = DBP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With Prevalence of Controlled Hypertension at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>The prevalence of controlled hypertension was defined as the proportion of participants at any given time who met the definition of controlled hypertension. Controlled hypertension was defined as a SBP &lt; 130 mm Hg and a DBP &lt; 80 mm Hg while receiving an antihypertensive medication for the indication of hypertension or receiving an antihypertensive medication for another indication with a medical history of hypertension. Participants with a SBP &lt; 130 mm Hg and a DBP &lt; 80 mm Hg who were prescribed an antihypertensive medication(s) for an indication(s) other than hypertension (eg, beta blockers for migraine prophylaxis) with no medical history of hypertension were not considered to have either hypertension or controlled hypertension. Systolic blood pressure = SBP; Diastolic blood pressure = DBP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Non-dyslipidemic Participants With Incidence of Dyslipidemia Post-Transplantation by Month 12</measure>
    <time_frame>Randomization to Month 12</time_frame>
    <description>Incidence of dyslipidemia was defined as the proportion of participants who developed dyslipidemia after randomization and transplantation. Dyslipidemia was defined in accordance with recent guidelines from the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF-K/DOQI). Dyslipidemia = hypertriglyceridemia (TGs &gt;= 500 milligrams/deciliter (mg/dL) [5.65 mmol/L]), hypercholesterolemia (LDL &gt;= 100 mg/dL [2.59 mmol/L]), or elevated non-HDL (non-HDL &gt;= 130 mg/dL [3.36 mmol/L]) in the presence of high TGs (TGs &gt;= 200 mg/dL [2.26 mmol/L]). The TG = triglyceride; LDL = low density lipoprotein; HDL = high density lipoprotein; millimole/Liter (mmol/L). For 95% CI within each group, normal approximation is used if N &gt;=5. Otherwise exact method is used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With Prevalence of Dyslipidemia at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>The prevalence of dyslipidemia was defined as the proportion of participants at any given time who met the definition of dyslipidemia. Dyslipidemia defined in accordance with recent guidelines from the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF-K/DOQI). Dyslipidemia defined as hypertriglyceridemia (TGs &gt;= 500 milligrams/deciliter (mg/dL) [5.65 mmol/L]), hypercholesterolemia (LDL &gt;= 100 mg/dL [2.59 mmol/L]), or elevated non-HDL (non-HDL &gt;= 130 mg/dL [3.36 mmol/L]) in the presence of high TGs (TGs &gt;= 200 mg/dL [2.26 mmol/L]). TG = triglyceride; LDL = low density lipoprotein; HDL = high density lipoprotein; millimole/Liter (mmol/L). For 95% CI within each group, normal approximation is used if N &gt;=5. Otherwise exact method is used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With Controlled Dyslipidemia at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>Prevalence of controlled dyslipidemia = the proportion of participants at any given time who met the stated definition of dyslipidemia. Dyslipidemia defined in accordance with recent guidelines from the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF-K/DOQI). Dyslipidemia defined as hypertriglyceridemia (TGs &gt;= 500 milligrams/deciliter (mg/dL) [5.65 mmol/L]), hypercholesterolemia (LDL &gt;= 100 mg/dL [2.59 mmol/L]), or elevated non-HDL (non-HDL &gt;= 130 mg/dL [3.36 mmol/L]) in the presence of high TGs (TGs &gt;= 200 mg/dL [2.26 mmol/L]). Controlled dyslipidemia defined as participants who received successful pharmacologic treatment for 1 of the above stated dyslipidemias, and their lipid values fell below the thresholds described. TG = triglyceride; LDL = low density lipoprotein; HDL = high density lipoprotein; millimole/Liter (mmol/L). For 95% CI within each group, normal approximation is used if N &gt;=5. Otherwise exact method is used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Antihyperlipidemic Medication by Intensity Level</measure>
    <time_frame>Month 36</time_frame>
    <description>An intensity level was associated with the dose level of the statin based anti-hyperlipidemic agent. Any other agent (i.e., non-statin therapy) used as an antihyperlipidemic were considered Level I treatment intensity. Multiple daily dose levels during a period were averaged to compute the daily dose during that period. Level I = 20 mg fluvastatin (flu), 10 mg lovastatin (lova), 10 mg pravastatin (prav), 5-10 mg simvastatin (sim); Level II = 10 mg atorvastatin (atorv), 40 mg flu, 20 mg lova, 20 mg prav, 5 mg rosuvastatin (rosu), 20 mg sim, 10/10 vytorin; Level III = 20 mg atorv, 80 mg flu, 40 mg lova, 40 mg prav, 10 mg rosu, 40 mg sim, 10/20 vytorin; Level IV = 40 mg atorv, 80 mg lova, 80 mg prav, 20 mg rosu, 80 mg sim, 10/40 vytorin; Level V = 80 mg atorv, 40 mg rosu, 10/80 vytorin. Concomitant use of a statin and an agent of another class elevated the intensity level of the statin therapy by 1 level; therefore, an intensity level of greater than V was possible.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants Using At Least One Anti-Hyperlipidemic Medication</measure>
    <time_frame>Month 36</time_frame>
    <description>This analysis is based on all participants who were followed up at least 1092 days after transplantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Value of Lipid Parameters</measure>
    <time_frame>Months 12, 24, 36</time_frame>
    <description>Lipid parameters included total cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol, non-HDL cholesterol, and triglycerides (TGs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With Prevalence of Acute Rejection (AR) by Month 36</measure>
    <time_frame>Randomization to Month 36</time_frame>
    <description>Prevalence of AR = participants with the stated definition of AR at any given time. AR defined as a clinico-pathological event requiring clinical evidence and renal biopsy confirmation demonstrating a Banff 97 classification of Grade IA or greater, with higher scores indicating more severe rejection. Only the episode with the highest Banff grade for each participant was counted. Clinical evidence = if either a or b was satisfied: a: an unexplained rise of serum creatinine ≥ 25% from baseline creatinine; b: an unexplained decreased urine output; or fever and graft tenderness; or a serum creatinine that remains elevated within 14 days post-transplantation and clinical suspicion of acute rejection exists. Allograft biopsies were evaluated by a blinded central independent pathologist using Banff 97 working classification of kidney transplant pathology. Banff 97 diagnostic category for renal allograft biopsies is an international standardized histopathological classification.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Acute Rejection (AR) Post-transplant in Terms of Severity Using Banff Grades by Month 36</measure>
    <time_frame>Randomization to Month 36</time_frame>
    <description>Acute rejection was defined as a clinico-pathological event requiring clinical evidence and renal biopsy confirmation demonstrating a Banff 97 classification of Grade IA or greater, with higher scores indicating more severe rejection. Clinical evidence defined: if either a or b was satisfied: a) an unexplained rise of serum creatinine ≥ 25% from baseline creatinine; b) an unexplained decreased urine output; or fever and graft tenderness; or a serum creatinine that remains elevated within 14 days post-transplantation and clinical suspicion of acute rejection exists. Allograft biopsies were evaluated by a blinded central independent pathologist using Banff 97 working classification of kidney transplant pathology. Banff 97 diagnostic category for renal allograft biopsies is an international standardized histopathological classification. Only the episode with the highest Banff grade for each participant was counted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants Using Polyclonal Antilymphocyte Preparations for Impaired Renal Function and Anticipated Delayed Graft Function by Month 12</measure>
    <time_frame>Randomization to Month 12</time_frame>
    <description>A participant was considered to have delayed graft function (DGF), if treated with dialysis within the first week (Day 1 - 8) after transplantation. The use of polyclonal antilymphocyte preparations (LDT) was permitted only for participants randomized to cyclosporine (CsA) who experienced impaired renal allograft function and anticipated DGF following transplantation and were not permitted in belatacept-treated participants, except for the treatment of acute rejection. Participants treated with LDT began CsA at the discretion of the investigator by Day 7. LDT could also have been used in participants who met &gt;= 1 of the following criteria, observed in the presence of a transplant artery and vein and no evidence of hydronephrosis by sonogram: Urine output &lt; 250 mL/12 hours, no significant improvement (&lt; 1 milligram per deciliter (mg/dL)) in serum creatinine from baseline value over the first 24 - 72 hours post-transplant, or dialysis treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants Using Lymphocyte Depleting Therapy (LDT) for the Initial Treatment of Acute Rejection (AR) by Month 36</measure>
    <time_frame>Randomization to Month 36</time_frame>
    <description>The use of LDT (thymoglobulin or antithymocyte gamma globulin [ATGAM]) was permitted only for participants randomized to cyclosporine (CsA) who experienced impaired renal allograft function and anticipated delayed graft function following transplantation. Acute rejection (AR) defined as a clinico-pathological event requiring clinical evidence (an unexplained rise of serum creatinine ≥ 25% from baseline creatinine or an unexplained decreased urine output; or fever and graft tenderness; or a serum creatinine that remained elevated within 14 days post-transplantation and clinical suspicion of acute rejection existed) and biopsy confirmation. AR defined by a renal biopsy demonstrating a Banff 97 classification of Grade IA or greater, with higher scores indicating more severe rejection. Banff 97 diagnostic category for renal allograft biopsies is an international standardized histopathological classification. Only the episode with the highest Banff grade for each participant was counted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With Corticosteroid Resistant Acute Rejection (AR) by Month 36</measure>
    <time_frame>Randomization to Month 36</time_frame>
    <description>Steroid-resistant acute rejection (AR) defined as the use of lymphocyte-depletion therapy following treatment with corticosteroids. AR defined as a clinico-pathological event requiring clinical evidence and renal biopsy confirmation demonstrating a Banff 97 classification of Grade IA or greater, with higher scores indicating more severe rejection. Clinical evidence defined: either a or b was satisfied: a) an unexplained rise of serum creatinine ≥ 25% from baseline creatinine; b) an unexplained decreased urine output; or fever and graft tenderness; or a serum creatinine that remained elevated within 14 days post-transplantation and clinical suspicion of acute rejection existed. Allograft biopsies were evaluated by a blinded central independent pathologist using Banff 97 international standardized histopathological working classification of kidney transplant pathology. Only the episode with the highest Banff grade for each participant was counted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Recovered Completely From an Episode of Acute Rejection (AR) by Month 12</measure>
    <time_frame>Randomization to Month 12</time_frame>
    <description>Acute rejection (AR) = a clinico-pathological event requiring clinical evidence and renal biopsy confirmation demonstrating a Banff 97 classification of Grade IA or greater. Clinical evidence = if either a or b was satisfied: a: an unexplained rise of serum creatinine ≥ 25% from baseline creatinine; b: an unexplained decreased urine output; or fever and graft tenderness; or a serum creatinine that remains elevated within 14 days post-transplantation and clinical suspicion of acute rejection exists. Complete recovery following AR defined as serum creatinine [SCr] levels returned to baseline. Recovery calculated using 2 algorithms: Algorithm 1 = last laboratory measurement prior to onset of AR (baseline and first laboratory measurement after 84 days since onset of AR = resolution); Algorithm 2 = lowest laboratory measurement on or after transplantation and prior to onset day of AR (baseline and lowest laboratory measurement after onset on first AR up to Month 12 = resolution)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With Subclinical Rejection at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>Subclinical rejection defined as histological findings by the central pathologist consistent with acute rejection, but lacking its clinical correlate. Acute rejection defined as a clinico-pathological event requiring clinical evidence and renal biopsy confirmation demonstrating a Banff 97 classification of Grade IA or greater, with higher scores indicating more severe rejection. Only the episode with the highest Banff grade for each participant was counted. Clinical evidence defined if either a or b was satisfied: a) an unexplained rise of serum creatinine ≥ 25% from baseline creatinine; b) an unexplained decreased urine output; or fever and graft tenderness; or a serum creatinine that remained elevated within 14 days post-transplantation and clinical suspicion of acute rejection existed. Allograft biopsies were evaluated by a blinded central independent pathologist using Banff 97 working classification of kidney transplant pathology.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Treated for Acute Rejection (AR) Regardless of Histological Findings by Month 36</measure>
    <time_frame>Randomization to Month 36</time_frame>
    <description>Allograft rejection includes any episode of rejection including: clinically suspected rejection, treated rejection, any central biopsy-proven acute rejection (BPAR), and acute rejection (AR: a subset of BPAR) defined as central biopsy-proven rejection that was either clinically suspected by protocol-defined reasons or by other reasons and was treated. Acute rejection (AR) defined as a clinico-pathological event requiring clinical evidence ( either an unexplained rise of serum creatinine ≥ 25% from baseline creatinine or an unexplained decreased urine output; or fever and graft tenderness; or a serum creatinine that remained elevated within 14 days post-transplantation and clinical suspicion of AR) and renal biopsy confirmation biopsy demonstrating a Banff 97 working classification of kidney transplant pathology classification of Grade IA or greater, with higher scores indicating more severe rejection. Only the highest Banff grade for each participant was counted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Value of Physical and Mental Components Using SF-36 Questionnaire</measure>
    <time_frame>Months 6, 12, 24, 36</time_frame>
    <description>SF-36 was a Participant-Reported Quality of Life (QoL) Short Form (SF) questionnaire measuring health-related quality of life (HRQL) covering 2 scale measures: physical component summary (PCS) and mental component summary (MCS). PCS represented by 4 domains: physical function, role limitations due to physical problems, pain, and general health perception. MCS represented by 4 domains: vitality, social function, role limitations due to emotional problems, and mental health. Their scores were computed based on weighted combinations of the 8 domain scores, which were transformed to a range from 0 to 100; 0= worst HRQL, 100=best HRQL. Higher scores reflect better health-related functional status. Scoring is standardized using the norm-based scoring method where data is scored in relation to the U.S. general population having a mean of 50 and a standard deviation of 10. Scores below 50 are below the U.S. general population norm and above 50 are above the U.S. general population norm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Value of the Eight Domain Scores of Quality of Life Using SF-36 Questionnaire</measure>
    <time_frame>Months 6, 12, 24, 36</time_frame>
    <description>SF-36 was a Participant-Reported Quality of Life (QoL) Short Form (SF) questionnaire measuring health-related quality of life (HRQL) covering 2 scale measures: physical component summary (PCS) and mental component summary (MCS). PCS represented by 4 domains: physical function, role limitations due to physical problems, pain, and general health perception. MCS represented by 4 domains: vitality, social function, role limitations due to emotional problems, and mental health. Their scores were computed based on weighted combinations of the 8 domain scores, which were transformed to a range from 0 to 100; 0= worst HRQL, 100=best HRQL. Higher scores reflect better health-related functional status. Scoring is standardized using the norm-based scoring method where data is scored in relation to the U.S. general population having a mean of 50 and a standard deviation of 10. Scores below 50 are below the U.S. general population norm and above 50 are above the U.S. general population norm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Relative to an Identified Distribution (Ridit) Value of Symptom Occurrence and Symptom Distress Using Modified Transplant Symptom Occurrence and Symptom Distress Scale (MTSOSDS-59R)</measure>
    <time_frame>Months 6, 12, 24, 36</time_frame>
    <description>The Modified Transplant Symptom Occurrence and Symptom Distress Scale (MTSOSD-59R) was used to assess the occurrence (never, occasionally, regularly, almost always, always) and distress (0=no distress to 4=terrible distress) of symptoms associated with immunosuppressive therapies. Ridit (relative to an identified distribution) analysis (Fleiss JL. Statistical methods for rates and proportions. New York: John Wiley &amp; Sons, Inc. 1991) was used. Ridit scores were calculated at baseline and at 6, 12, 24, and 36 months for overall symptom occurrence score and overall symptom distress. The Ridit score reflects the probability that a score observed for an individual randomly selected from a group would be higher (worse symptom) than a score observed for a randomly selected individual from the reference group. The reference group was constituted by the frequency distribution of the responses of all participants on all items at baseline. The ridit of the reference group is by definition, 0.5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Changes in the Value of Physical and Mental Components Using SF-36 From Baseline Up To Months 6, 12, 24, and 36</measure>
    <time_frame>Baseline to Months 6, 12, 24,and 36</time_frame>
    <description>SF-36 was a Participant-Reported Quality of Life (QoL) Short Form (SF) questionnaire measuring health-related quality of life (HRQL) covering 2 scale measures: physical component summary (PCS) and mental component summary (MCS). PCS represented by 4 domains: physical function, role limitations due to physical problems, pain, and general health perception. MCS represented by 4 domains: vitality, social function, role limitations due to emotional problems, and mental health. Their scores were computed based on weighted combinations of the 8 domain scores, which were transformed to a range from 0 to 100; 0= worst HRQL, 100=best HRQL. Higher scores reflect better health-related functional status. Scoring is standardized using the norm-based scoring method where data is scored in relation to the U.S. general population having a mean of 50 and a standard deviation of 10. Scores below 50 are below the U.S. general population norm and above 50 are above the U.S. general population norm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in the Value of the Eight Domain Scores Using SF-36 From Baseline Up To Months 6, 12, 24, and 36</measure>
    <time_frame>Baseline to Months 6, 12, 24, and 36</time_frame>
    <description>SF-36 was a Participant-Reported Quality of Life (QoL) Short Form (SF) questionnaire measuring health-related quality of life (HRQL) covering 2 scale measures: physical component summary (PCS) and mental component summary (MCS). PCS represented by 4 domains: physical function, role limitations due to physical problems, pain, and general health perception. MCS represented by 4 domains: vitality, social function, role limitations due to emotional problems, and mental health. Their scores were computed based on weighted combinations of the 8 domain scores, which were transformed to a range from 0 to 100; 0= worst HRQL, 100=best HRQL. Higher scores reflect better health-related functional status. Scoring is standardized using the norm-based scoring method where data is scored in relation to the U.S. general population having a mean of 50 and a standard deviation of 10. Scores below 50 are below the U.S. general population norm and above 50 are above the U.S. general population norm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants Surviving With a Functioning Graft</measure>
    <time_frame>Months 24, 36</time_frame>
    <description>Graft loss was defined as either functional loss or physical loss (nephrectomy). Functional loss was defined as a sustained level of serum creatinine (SCr) ≥ 6.0 milligrams per deciliter (mg/dL) or 530 micromoles per liter (μmol/L) as determined by the central laboratory for ≥ 4 weeks or ≥ 56 consecutive days of dialysis or impairment of renal function to such a degree that the participant underwent retransplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With Composite Endpoint or Death, Graft Loss or Acute Rejection by Month 36</measure>
    <time_frame>Randomization to Month 36</time_frame>
    <description>Graft loss was defined as either functional loss or physical loss (nephrectomy). Functional loss was defined as a sustained level of serum creatinine (SCr) ≥ 6.0 milligrams per deciliter (mg/dL) or 530 micromoles per liter (μmol/L) as determined by the central laboratory for ≥ 4 weeks or ≥ 56 consecutive days of dialysis or impairment of renal function to such a degree that the participant underwent retransplant. Acute rejection was defined as central biopsy proven rejection that was either (1) clinically suspected by protocol defined reasons or (2) clinically suspected by other reasons and treated. Death and graft loss were not imputed.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">738</enrollment>
  <condition>Kidney Transplantation</condition>
  <condition>Chronic Kidney Failure</condition>
  <arm_group>
    <arm_group_label>Cyclosporine (CsA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Belatacept LI (less intensive)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Belatacept MI (more intensive)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine (CsA)</intervention_name>
    <description>tablet, oral, 1st month target: 150-300 ng/mL, after 1st month target: 100-250 ng/mL, daily, 36 months (ST), 100-250 ng/mL, daily, 24 months (LT)</description>
    <arm_group_label>Cyclosporine (CsA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belatacept LI (less intensive)</intervention_name>
    <description>solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
    <arm_group_label>Belatacept LI (less intensive)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belatacept MI (more intensive)</intervention_name>
    <description>solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
    <arm_group_label>Belatacept MI (more intensive)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject is a recipient of a living donor or deceased donor kidney transplant.

          -  Male or Female, 18 or older

        Exclusion Criteria:

          -  First time recipient, PRA &gt;- 50% or for retransplantation PRA &gt;- 30%.

          -  If retransplantation, previous graft loss cannot be due to acute rejection.

          -  Positive cross match.

          -  Subject receiving extended criteria donor (ECD) organ

          -  For Long-term extension study-Subjects who have completed three years of study
             treatment (through Week 156)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Of Alabama At Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Medical Center-Transplantation Institu</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Institute Of Renal Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of California San Francisco Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Colorado Health Sciences Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University School Of Medicine-Yale New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College Of Georgia</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Chicago Hospitals</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Iowa Hospitals And Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Indiana</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Tranplant Program</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western New England Renal &amp; Transplant Associates, Pc</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital, Transplant Institute</name>
      <address>
        <city>Detriot</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School Of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Recanati/Miller Transplantation Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University College Of Physicians &amp; Surgeons</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of North Carolina At Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Div Of Multi-Organ Trans, Hepato-Biliary-Pancreatic Surgery</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Musc</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>27232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fletcher Allen Health Care</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inova Transplant Center</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sacred Heart Medical Ctr Providence Medical Research Ctr</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Froedtert Memorial Lutheran Hospital</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Capital Federal</city>
        <state>Buenos Aires</state>
        <zip>C1425APQ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>La Plata</city>
        <state>Buenos Aires</state>
        <zip>1900</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cordoba, Crd</city>
        <state>Cordoba</state>
        <zip>X5016KEH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1155APP</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Santa Fe</city>
        <zip>S3000EPV</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Innsbuck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rio De Janeiro / Rj</city>
        <state>Rio De Janeiro</state>
        <zip>21041</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Porto Alegre/rs</city>
        <state>Rio Grande Do Sul</state>
        <zip>90035</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90035</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Campinas</city>
        <state>Sao Paulo</state>
        <zip>13033</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sao Paulo/sp</city>
        <state>Sao Paulo</state>
        <zip>04038</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05403</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2S2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 2W5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7M 0Z9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Praha 4</city>
        <zip>140 21</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Brest Cedex</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Grenoble Cedex 9</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nante Cedex 01</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Toulouse</city>
        <zip>31054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Szeged</city>
        <zip>H-6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Gujarat</city>
        <state>Ahmedabad</state>
        <zip>380016</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nadiad</city>
        <state>Gujarat</state>
        <zip>387001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujrat</state>
        <zip>380052</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cochin</city>
        <state>Kerala</state>
        <zip>682304</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400 026</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400016</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Chandigarh</city>
        <zip>160012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Chennai</city>
        <zip>600 006</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lucknow</city>
        <zip>226000</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>New Delhi</city>
        <zip>110076</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Petah Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cuernavaca</city>
        <state>Morelos</state>
        <zip>62448</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Aguascalientes</city>
        <zip>20000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Distrito Federal</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>San Luis Potosi</city>
        <zip>78240</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Poznan</city>
        <zip>60-479</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Szczecin</city>
        <zip>70-111</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Observatory</city>
        <state>Cape Town</state>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0002</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Durban</city>
        <state>Kwa Zulu Natal</state>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Goteborg</city>
        <zip>SE-413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Antalya</city>
        <zip>07059</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Chile</country>
    <country>Norway</country>
    <country>Portugal</country>
    <country>United Kingdom</country>
  </removed_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2005</study_first_submitted>
  <study_first_submitted_qc>November 18, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2005</study_first_posted>
  <results_first_submitted>May 24, 2016</results_first_submitted>
  <results_first_submitted_qc>July 12, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 19, 2016</results_first_posted>
  <disposition_first_submitted>April 29, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>April 29, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 3, 2010</disposition_first_posted>
  <last_update_submitted>July 12, 2016</last_update_submitted>
  <last_update_submitted_qc>July 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>738 participants enrolled, 686 randomized. Reasons for non-randomization include 5 participants withdrew consent, 1 lost to follow-up, 34 no longer met study criteria, and 12 for other non-listed reasons. 666 participants randomized, but not transplanted. 20 not transplanted; 10, 4, 6 in the CsA, Belatacept LI, Belatacept MI, respectively.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cyclosporine</title>
          <description>Cyclosporine (CsA): tablet, oral
1st month target: 150-300 nanogram/meter (ng/m) After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)</description>
        </group>
        <group group_id="P2">
          <title>Belatacept LI</title>
          <description>Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
        </group>
        <group group_id="P3">
          <title>Belatacept MI</title>
          <description>Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 milligrams/kilogram (mg/kg) every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Transplanted Pre-Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="221"/>
                <participants group_id="P2" count="226"/>
                <participants group_id="P3" count="219"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="215"/>
                <participants group_id="P2" count="226"/>
                <participants group_id="P3" count="219"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Post-Transplant Treated (12 Months)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="215"/>
                <participants group_id="P2" count="226"/>
                <participants group_id="P3" count="219"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="174"/>
                <participants group_id="P2" count="183"/>
                <participants group_id="P3" count="173"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="46"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="27"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Post-Transplant Treated (24 Months)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="174"/>
                <participants group_id="P2" count="183"/>
                <participants group_id="P3" count="173"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="153"/>
                <participants group_id="P2" count="176"/>
                <participants group_id="P3" count="164"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Post-Transplant Treated (36 Months)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="153"/>
                <participants group_id="P2" count="176"/>
                <participants group_id="P3" count="164"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="143"/>
                <participants group_id="P2" count="170"/>
                <participants group_id="P3" count="158"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject no longer meets study criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Long Term Extension (LTE; 84 Months)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="136">Participants on drug through month 36 eligible to enroll in LTE; 2 ineligible, 5 withdrew or refused</participants>
                <participants group_id="P2" count="166">Participants on drug through month 36 were eligible to enroll in LTE; 4 withdrew or refused.</participants>
                <participants group_id="P3" count="155">Participants on drug through month 36 were eligible to enroll in LTE; 3 withdrew or refused.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="89"/>
                <participants group_id="P2" count="136"/>
                <participants group_id="P3" count="127"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="28"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor/Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative Reason By Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline characteristics of transplant recipients: All randomized and transplanted participants, intent to treat (ITT) population</population>
      <group_list>
        <group group_id="B1">
          <title>Cyclosporine</title>
          <description>Cyclosporine (CsA): tablet, oral
1st month target: 150-300 nanogram/meter (ng/m) After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)</description>
        </group>
        <group group_id="B2">
          <title>Belatacept LI</title>
          <description>Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
        </group>
        <group group_id="B3">
          <title>Belatacept MI</title>
          <description>Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="221"/>
            <count group_id="B2" value="226"/>
            <count group_id="B3" value="219"/>
            <count group_id="B4" value="666"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.5" spread="14.3"/>
                    <measurement group_id="B2" value="42.6" spread="13.4"/>
                    <measurement group_id="B3" value="43.6" spread="14.6"/>
                    <measurement group_id="B4" value="43.2" spread="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Between 18 and 45 years:</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="111"/>
                    <measurement group_id="B4" value="345"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 46 and 65 years:</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="93"/>
                    <measurement group_id="B4" value="287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 65 years:</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="68"/>
                    <measurement group_id="B4" value="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="165"/>
                    <measurement group_id="B2" value="146"/>
                    <measurement group_id="B3" value="151"/>
                    <measurement group_id="B4" value="462"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Number of Transplant</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="208"/>
                    <measurement group_id="B2" value="218"/>
                    <measurement group_id="B3" value="210"/>
                    <measurement group_id="B4" value="636"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants Surviving With a Functioning Graft by Month 12</title>
        <description>Graft loss was defined as either functional loss or physical loss (nephrectomy). Functional loss was defined as a sustained level of serum creatinine (SCr) ≥ 6.0 milligrams per deciliter (mg/dL) or 530 micromolar per liter (μmol/L) as determined by the central laboratory for ≥ 4 weeks or ≥ 56 consecutive days of dialysis or impairment of renal function to such a degree that the participant underwent retransplant.</description>
        <time_frame>Day 1 to Month 12</time_frame>
        <population>All randomized, transplanted, and treated participants; intent to treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA): tablet, oral
1st month target: 150-300 nanogram/meter (ng/m) After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)</description>
          </group>
          <group group_id="O2">
            <title>Belatacept LI</title>
            <description>Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
          <group group_id="O3">
            <title>Belatacept MI</title>
            <description>Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Surviving With a Functioning Graft by Month 12</title>
          <description>Graft loss was defined as either functional loss or physical loss (nephrectomy). Functional loss was defined as a sustained level of serum creatinine (SCr) ≥ 6.0 milligrams per deciliter (mg/dL) or 530 micromolar per liter (μmol/L) as determined by the central laboratory for ≥ 4 weeks or ≥ 56 consecutive days of dialysis or impairment of renal function to such a degree that the participant underwent retransplant.</description>
          <population>All randomized, transplanted, and treated participants; intent to treat (ITT) population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="221"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.8" lower_limit="89.3" upper_limit="96.2"/>
                    <measurement group_id="O2" value="96.5" lower_limit="94.1" upper_limit="98.9"/>
                    <measurement group_id="O3" value="95.4" lower_limit="92.7" upper_limit="98.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A non-inferiority margin of 10% for the co-primary endpoint of participant and graft survival was used. Determination of a margin for non-inferiority based on 'preservation of benefit' is not feasible, given the low rate of patient death and/or graft loss in the first year post-transplantation, and the absence of published, adequately sized, parallel-group trials with which to assess the effect of CsA on patient death and/or graft loss in the setting of MMF/steroids/basiliximab.</non_inferiority_desc>
            <param_type>Difference in Percent</param_type>
            <param_value>3.7</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>9.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A non-inferiority margin of 10% for the co-primary endpoint of participant and graft survival was used. Determination of a margin for non-inferiority based on ‘preservation of benefit’ is not feasible, given the low rate of patient death and/or graft loss in the first year post-transplantation, and the absence of published, adequately sized, parallel-group trials with which to assess the effect of CsA on patient death and/or graft loss in the setting of MMF/steroids/basiliximab.</non_inferiority_desc>
            <param_type>Difference in Percent</param_type>
            <param_value>2.7</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.5</ci_lower_limit>
            <ci_upper_limit>8.1</ci_upper_limit>
            <estimate_desc>If the lower bound of the CI (belatacept-CsA) was &gt; -10%, then the corresponding belatacept regimen was considered non-inferior to CsA.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants With a Composite of Measured Glomerular Filtration Rate (mGFR) Less Than 60 mL/Min/1.73 m^2 at Month 12 or With a Decrease in mGFR Greater Than or Equal to 10 mL/Min/1.73m^2 From Month 3 to Month 12</title>
        <description>Measured glomerular filtration rate (mGFR) is the direct measurement of renal function and was assessed by measurement of the clearance of a true glomerular filtration marker (non-radiolabeled iothalamate) using a validated procedure. A GFR of 60 mL/min/1.73 m^2 was used as the approximate equal of the threshold values of serum creatinine (SCr) of 1.5 mg/dL. A change in GFR of at least 10 mL/min/1.73 m^2 was used as the approximate change in SCr of at least 0.3 mg/dL. The change component of the composite renal endpoint was assessed from Month 3 to Month 12, since post-transplant renal function is largely stable by Month 3.</description>
        <time_frame>Month 12; Month 3 to Month 12</time_frame>
        <population>All randomized, transplanted, and treated participants; intent to treat (ITT) population with measurable component</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA): tablet, oral
1st month target: 150-300 nanogram/meter (ng/m) After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)</description>
          </group>
          <group group_id="O2">
            <title>Belatacept LI</title>
            <description>Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
          <group group_id="O3">
            <title>Belatacept MI</title>
            <description>Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With a Composite of Measured Glomerular Filtration Rate (mGFR) Less Than 60 mL/Min/1.73 m^2 at Month 12 or With a Decrease in mGFR Greater Than or Equal to 10 mL/Min/1.73m^2 From Month 3 to Month 12</title>
          <description>Measured glomerular filtration rate (mGFR) is the direct measurement of renal function and was assessed by measurement of the clearance of a true glomerular filtration marker (non-radiolabeled iothalamate) using a validated procedure. A GFR of 60 mL/min/1.73 m^2 was used as the approximate equal of the threshold values of serum creatinine (SCr) of 1.5 mg/dL. A change in GFR of at least 10 mL/min/1.73 m^2 was used as the approximate change in SCr of at least 0.3 mg/dL. The change component of the composite renal endpoint was assessed from Month 3 to Month 12, since post-transplant renal function is largely stable by Month 3.</description>
          <population>All randomized, transplanted, and treated participants; intent to treat (ITT) population with measurable component</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="214"/>
                <count group_id="O3" value="209"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.9" lower_limit="72.4" upper_limit="83.5"/>
                    <measurement group_id="O2" value="54.2" lower_limit="47.5" upper_limit="60.9"/>
                    <measurement group_id="O3" value="55.0" lower_limit="48.3" upper_limit="61.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Chi-squared, Corrected</method>
            <method_desc>A continuity-corrected Chi-square test at significance level 0.027 was performed for the difference between the belatacept regimen and cyclosporine</method_desc>
            <param_type>Difference in Percent</param_type>
            <param_value>-23.7</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-33.3</ci_lower_limit>
            <ci_upper_limit>-13.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Chi-squared, Corrected</method>
            <method_desc>A continuity-corrected Chi-square test at significance level 0.027 was performed for the difference between the belatacept regimen and cyclosporine</method_desc>
            <param_type>Difference in Percent</param_type>
            <param_value>-22.9</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-32.6</ci_lower_limit>
            <ci_upper_limit>-12.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants Experiencing Acute Rejection (AR) Post-transplant by Month 12</title>
        <description>Acute rejection was defined as a clinico-pathological event requiring clinical evidence and biopsy confirmation. Clinical evidence was defined if either a or b was satisfied: a: an unexplained rise of serum creatinine ≥ 25% from baseline creatinine; b: an unexplained decreased urine output; or fever and graft tenderness; or a serum creatinine that remains elevated within 14 days post-transplantation and clinical suspicion of acute rejection exists. Allograft biopsies were evaluated by a blinded central independent pathologist using Banff 97 working classification of kidney transplant pathology. Banff 97 diagnostic category for renal allograft biopsies is an international standardized histopathological classification. AR was defined by a renal biopsy demonstrating a Banff 97 classification of Grade IA or greater, with higher scores indicating more severe rejection. Only the episode with the highest Banff grade for each participant was counted.</description>
        <time_frame>Day 1 to Month 12</time_frame>
        <population>All randomized, transplanted, and treated participants; intent to treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA): tablet, oral
1st month target: 150-300 nanogram/meter (ng/m) After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)</description>
          </group>
          <group group_id="O2">
            <title>Belatacept LI</title>
            <description>Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
          <group group_id="O3">
            <title>Belatacept MI</title>
            <description>Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Experiencing Acute Rejection (AR) Post-transplant by Month 12</title>
          <description>Acute rejection was defined as a clinico-pathological event requiring clinical evidence and biopsy confirmation. Clinical evidence was defined if either a or b was satisfied: a: an unexplained rise of serum creatinine ≥ 25% from baseline creatinine; b: an unexplained decreased urine output; or fever and graft tenderness; or a serum creatinine that remains elevated within 14 days post-transplantation and clinical suspicion of acute rejection exists. Allograft biopsies were evaluated by a blinded central independent pathologist using Banff 97 working classification of kidney transplant pathology. Banff 97 diagnostic category for renal allograft biopsies is an international standardized histopathological classification. AR was defined by a renal biopsy demonstrating a Banff 97 classification of Grade IA or greater, with higher scores indicating more severe rejection. Only the episode with the highest Banff grade for each participant was counted.</description>
          <population>All randomized, transplanted, and treated participants; intent to treat (ITT) population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="221"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" lower_limit="3.8" upper_limit="10.7"/>
                    <measurement group_id="O2" value="17.3" lower_limit="12.3" upper_limit="22.2"/>
                    <measurement group_id="O3" value="21.9" lower_limit="16.4" upper_limit="27.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A 20% margin for non-inferiority was used and provides 99% power to ascertain that the upper bound of the 97.3% 2-sided confidence intervals for the absolute difference between each belatacept regimen and cyclosporine, assuming the true acute rejection rate by 12 months is 15% for all three regimens</non_inferiority_desc>
            <param_type>Difference in Percent</param_type>
            <param_value>10.0</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.3</ci_lower_limit>
            <ci_upper_limit>17.1</ci_upper_limit>
            <estimate_desc>For 97.3% CI of difference, normal approximation is used if N&gt;=5 in both arms. Otherwise exact method is used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A 20% margin for non-inferiority was used and provides 99% power to ascertain that the upper bound of the 97.3% 2-sided confidence intervals for the absolute difference between each belatacept regimen and cyclosporine, assuming the true acute rejection rate by 12 months is 15% for all three regimens. The 20% non-inferiority margin was not met in the belatacept MI group.</non_inferiority_desc>
            <param_type>Difference in Percent</param_type>
            <param_value>14.7</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.5</ci_lower_limit>
            <ci_upper_limit>22.2</ci_upper_limit>
            <estimate_desc>For 97.3% CI of difference, normal approximation is used if N&gt;=5 in both arms. Otherwise exact method is used.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Value of the Measured Glomerular Filtration Rate (mGFR)</title>
        <description>Measured glomerular filtration rate (mGFR) is the direct measurement of renal function and was assessed by measurement of the clearance of a true glomerular filtration marker (non-radiolabeled iothalamate) using a validated procedure. Missing mGRF assessments were imputed to assess renal function. The overall imputation strategy involved a primary imputation method (linear extrapolation and quartile method) followed by 2 secondary imputation methods (regression method and graded quartile method) to assess the robustness of conclusions obtained from the application of the primary imputation method. All imputation methods entailed replacing a missing value with a value drawn from a plausible distribution incorporating theoretical and observed aspects of the data. GFR was measured as mL/min/1.73 m^2.</description>
        <time_frame>Months 3, 12, 24</time_frame>
        <population>All randomized, transplanted, and treated participants; intent to treat (ITT) population with measurable component</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA): tablet, oral
1st month target: 150-300 nanogram/meter (ng/m) After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)</description>
          </group>
          <group group_id="O2">
            <title>Belatacept LI</title>
            <description>Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
          <group group_id="O3">
            <title>Belatacept MI</title>
            <description>Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Value of the Measured Glomerular Filtration Rate (mGFR)</title>
          <description>Measured glomerular filtration rate (mGFR) is the direct measurement of renal function and was assessed by measurement of the clearance of a true glomerular filtration marker (non-radiolabeled iothalamate) using a validated procedure. Missing mGRF assessments were imputed to assess renal function. The overall imputation strategy involved a primary imputation method (linear extrapolation and quartile method) followed by 2 secondary imputation methods (regression method and graded quartile method) to assess the robustness of conclusions obtained from the application of the primary imputation method. All imputation methods entailed replacing a missing value with a value drawn from a plausible distribution incorporating theoretical and observed aspects of the data. GFR was measured as mL/min/1.73 m^2.</description>
          <population>All randomized, transplanted, and treated participants; intent to treat (ITT) population with measurable component</population>
          <units>mL/min/1.73m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="215"/>
                <count group_id="O3" value="209"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3 (n=201, 215, 209)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.9" spread="21.09"/>
                    <measurement group_id="O2" value="61.7" spread="25.43"/>
                    <measurement group_id="O3" value="59.9" spread="28.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=199, 206, 200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.4" spread="18.71"/>
                    <measurement group_id="O2" value="63.4" spread="27.66"/>
                    <measurement group_id="O3" value="65.0" spread="30.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (n=185, 199, 192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.5" spread="20.52"/>
                    <measurement group_id="O2" value="67.9" spread="29.90"/>
                    <measurement group_id="O3" value="65.0" spread="27.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Time Frame = Day 1 to Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>To account for missing measured GFR due to graft loss or death, an ANOVA model on the ranks of measured GFR (with imputed missing values) at Months 12 with factor for randomization group was applied. Measured GFR missing were assigned the worst rank.</p_value_desc>
            <method>Kruskal-Wallis</method>
            <method_desc>Tests comparing a belatacept to CsA were based on the Kruskal-Wallis test (using a chi-square approximation of the distribution of the test statistic)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>13.0</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.3</ci_lower_limit>
            <ci_upper_limit>18.7</ci_upper_limit>
            <estimate_desc>Test were conducted at a level of 0.027 (2-sided).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Time Frame = Day 1 to Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>To account for missing measured GFR due to graft loss or death, an ANOVA model on the ranks of measured GFR (with imputed missing values) at Months 12 with factor for randomization group was applied. Measured GFR missing were assigned the worst rank.</p_value_desc>
            <method>Kruskal-Wallis</method>
            <method_desc>Tests comparing a belatacept to CsA were based on the Kruskal-Wallis test (using a chi-square approximation of the distribution of the test statistic)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>14.6</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.9</ci_lower_limit>
            <ci_upper_limit>20.4</ci_upper_limit>
            <estimate_desc>Test were conducted at a level of 0.027 (2-sided).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Time Frame = Day 1 to Month 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>To account for missing measured GFR due to graft loss or death, an ANOVA model on the ranks of measured GFR (with imputed missing values) at Months 24 with factor for randomization group was applied. Measured GFR missing were assigned the worst rank.</p_value_desc>
            <method>Kruskal-Wallis</method>
            <method_desc>Tests comparing a belatacept to CsA were based on the Kruskal-Wallis test (using a chi-square approximation of the distribution of the test statistic)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>17.4</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11.5</ci_lower_limit>
            <ci_upper_limit>23.4</ci_upper_limit>
            <estimate_desc>Test were conducted at a level of 0.027 (2-sided).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Time Frame = Day 1 to Month 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>To account for missing measured GFR due to graft loss or death, an ANOVA model on the ranks of measured GFR (with imputed missing values) at Months 24 with factor for randomization group was applied. Measured GFR missing were assigned the worst rank.</p_value_desc>
            <method>Kruskal-Wallis</method>
            <method_desc>Tests comparing a belatacept to CsA were based on the Kruskal-Wallis test (using a chi-square approximation of the distribution of the test statistic)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>14.5</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.5</ci_lower_limit>
            <ci_upper_limit>20.5</ci_upper_limit>
            <estimate_desc>Test were conducted at a level of 0.027 (2-sided).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With Prevalence of Chronic Allograft Nephropathy (CAN) at Month 12</title>
        <description>Prevalence of CAN = if participant met any of the following conditions: a: CAN observed in a biopsy either prior to 12 months (including baseline biopsy) or first post 12 months biopsy; b: participant had graft loss during the first year post transplant; c: no biopsy was available post 12 months and CAN not observed in biopsies prior to 12 months, but the measured GFR from Month 3 to Month 12 decreased at least 10 mL/min/1.73m^2; d: no biopsy available either prior to or post 12 months, and the measured GFR (incorporated missing data imputation) from Month 3 to Month 12 decreased at least 10 mL/min/1.73m^2. CAN = All allograft biopsies evaluated for presence and severity of CAN by a blinded central independent pathologist using Banff 97 working classification of kidney transplant pathology. Onset of CAN determined by the biopsy date when it was observed.</description>
        <time_frame>Month 12</time_frame>
        <population>All randomized, transplanted, and treated participants; intent to treat (ITT) population with measurable component; Any participant not meeting CAN criteria and who has no biopsy either prior to or post 12 months and no GFR assessment (either measured or calculated) available were excluded from the analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA): tablet, oral
1st month target: 150-300 nanogram/meter (ng/m) After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)</description>
          </group>
          <group group_id="O2">
            <title>Belatacept LI</title>
            <description>Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
          <group group_id="O3">
            <title>Belatacept MI</title>
            <description>Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Prevalence of Chronic Allograft Nephropathy (CAN) at Month 12</title>
          <description>Prevalence of CAN = if participant met any of the following conditions: a: CAN observed in a biopsy either prior to 12 months (including baseline biopsy) or first post 12 months biopsy; b: participant had graft loss during the first year post transplant; c: no biopsy was available post 12 months and CAN not observed in biopsies prior to 12 months, but the measured GFR from Month 3 to Month 12 decreased at least 10 mL/min/1.73m^2; d: no biopsy available either prior to or post 12 months, and the measured GFR (incorporated missing data imputation) from Month 3 to Month 12 decreased at least 10 mL/min/1.73m^2. CAN = All allograft biopsies evaluated for presence and severity of CAN by a blinded central independent pathologist using Banff 97 working classification of kidney transplant pathology. Onset of CAN determined by the biopsy date when it was observed.</description>
          <population>All randomized, transplanted, and treated participants; intent to treat (ITT) population with measurable component; Any participant not meeting CAN criteria and who has no biopsy either prior to or post 12 months and no GFR assessment (either measured or calculated) available were excluded from the analyses.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.4" lower_limit="26.2" upper_limit="38.6"/>
                    <measurement group_id="O2" value="23.9" lower_limit="18.3" upper_limit="29.5"/>
                    <measurement group_id="O3" value="18.3" lower_limit="13.1" upper_limit="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Test of superiority using DerSimonian-Laird statistic at 0.027 level of significance.</non_inferiority_desc>
            <p_value>0.0581</p_value>
            <method>Chi-squared, Corrected</method>
            <method_desc>A continuity corrected chi-square test at a significance level of 0.027 was performed.</method_desc>
            <param_type>Difference in Percent</param_type>
            <param_value>-8.5</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.9</ci_lower_limit>
            <ci_upper_limit>0.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Test of superiority using DerSimonian-Laird statistic at 0.027 level of significance.</non_inferiority_desc>
            <p_value>0.0010</p_value>
            <method>Chi-squared, Corrected</method>
            <method_desc>A continuity corrected chi-square test at a significance level of 0.027 was performed.</method_desc>
            <param_type>Difference in Percent</param_type>
            <param_value>-14.2</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-23.2</ci_lower_limit>
            <ci_upper_limit>-5.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious Adverse Events, Death, Discontinuation Due to Adverse Events by Month 84</title>
        <description>Adverse event (AE) defined: any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. Serious adverse event (SAE) defined: a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.</description>
        <time_frame>Randomization to Month 84</time_frame>
        <population>All randomized, transplanted, and treated participants from the original intent-to-treat (ITT) population who continued on assigned therapy into the long-term extension phase (ITT-LTE)</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA): tablet, oral
1st month target: 150-300 nanogram/meter (ng/m) After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)</description>
          </group>
          <group group_id="O2">
            <title>Belatacept LI</title>
            <description>Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
          <group group_id="O3">
            <title>Belatacept MI</title>
            <description>Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Events, Death, Discontinuation Due to Adverse Events by Month 84</title>
          <description>Adverse event (AE) defined: any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. Serious adverse event (SAE) defined: a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.</description>
          <population>All randomized, transplanted, and treated participants from the original intent-to-treat (ITT) population who continued on assigned therapy into the long-term extension phase (ITT-LTE)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="166"/>
                <count group_id="O3" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107"/>
                    <measurement group_id="O2" value="113"/>
                    <measurement group_id="O3" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinued due to SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinued due to AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events of Special Interest by Month 84</title>
        <description>Prospectively identified events of special interest which were a subset of all AEs, and were either SAEs or non-serious AEs, included the following categories: Serious Infections and Infestations, Thrombolic/embolic events, and Malignancy. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/ abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Time frame is from randomization to the event date, or to the last dose date+56, or to Month 84 (Day 2548), whichever is the earliest.</description>
        <time_frame>Randomization to Month 84</time_frame>
        <population>All randomized, transplanted, and treated participants from the original intent-to-treat (ITT) population who continued on assigned therapy into the long-term extension phase (ITT-LTE)</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA): tablet, oral
1st month target: 150-300 nanogram/meter (ng/m) After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)</description>
          </group>
          <group group_id="O2">
            <title>Belatacept LI</title>
            <description>Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
          <group group_id="O3">
            <title>Belatacept MI</title>
            <description>Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events of Special Interest by Month 84</title>
          <description>Prospectively identified events of special interest which were a subset of all AEs, and were either SAEs or non-serious AEs, included the following categories: Serious Infections and Infestations, Thrombolic/embolic events, and Malignancy. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/ abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Time frame is from randomization to the event date, or to the last dose date+56, or to Month 84 (Day 2548), whichever is the earliest.</description>
          <population>All randomized, transplanted, and treated participants from the original intent-to-treat (ITT) population who continued on assigned therapy into the long-term extension phase (ITT-LTE)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="166"/>
                <count group_id="O3" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Malignancies</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cytomegalovirus (CMV) Infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BK Polyoma Virus Infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Herpes Virus Infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fungal Infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tuberculosis Infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Central Nervous System (CNS) Infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulmonary edema or Congestive Heart Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Auto-immune Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Blood Pressure at Month 84</title>
        <description>Blood pressure was measured in millimeters of mercury (mmHg). Blood pressure was measured soon after the participant arrived and sat quietly at rest for 10 minutes. 3 consecutive seated blood pressure readings were made at least 1 minute apart.</description>
        <time_frame>Month 84</time_frame>
        <population>All randomized, transplanted, and treated participants from the original intent-to-treat (ITT) population who continued on assigned therapy into the long-term extension phase (ITT-LTE).</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA): tablet, oral
1st month target: 150-300 nanogram/meter (ng/m) After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)</description>
          </group>
          <group group_id="O2">
            <title>Belatacept LI</title>
            <description>Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
          <group group_id="O3">
            <title>Belatacept MI</title>
            <description>Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Blood Pressure at Month 84</title>
          <description>Blood pressure was measured in millimeters of mercury (mmHg). Blood pressure was measured soon after the participant arrived and sat quietly at rest for 10 minutes. 3 consecutive seated blood pressure readings were made at least 1 minute apart.</description>
          <population>All randomized, transplanted, and treated participants from the original intent-to-treat (ITT) population who continued on assigned therapy into the long-term extension phase (ITT-LTE).</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="166"/>
                <count group_id="O3" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diastolic Blood Pressure (n=82, 125, 112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.6" spread="11.03"/>
                    <measurement group_id="O2" value="75.8" spread="10.56"/>
                    <measurement group_id="O3" value="75.1" spread="10.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic Blood Pressure (n=82, 125, 112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129.0" spread="15.83"/>
                    <measurement group_id="O2" value="126.7" spread="18.17"/>
                    <measurement group_id="O3" value="126.0" spread="17.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Meeting Marked Laboratory Abnormality Criteria Post-transplant by Month 36</title>
        <description>Upper limit of normal (ULN). Units per Liter (U/L). Cells per microliter (c/µL). Grams per deciliter (g/dL). Milligrams per deciliter (mg/dL).Cells per Liter (c/L). Milliequivalents/Liter (mEq/L).
Hemoglobin (low): &lt;8.0 g/dL; Platelet count: &lt;50*10^9 c/L; Leukocytes: &lt;2*10^3 c/µL; Alkaline phosphatase (ALP): &gt;5.0*ULN U/L; Alanine aminotransferase (ALT): &gt;5.0*ULN U/L; Asparate aminotransferase (AST): &gt;5.0*ULN U/L; Bilirubin Total: &gt;3.0*ULN mg/dL; Creatinine: &gt;3.0*ULN mg/dL; Calcium Total: low if &lt;7.0 mg/dL or high if &gt;12.5 mg/dL; Bicarbonate: &lt;11.0 mEq/L; Potassium serum: low if &lt;3.0 mEq/L or high if &gt;6.0 mEq/L; Magnesium serum: low is &lt;0.8 mEq/L or high if &gt;2.46 mEq/L; Sodium serum: low if &lt;130.0 mEq/L or high if &gt;155.0 mEq/L; Phosphorus inorganic: &lt;2.0 mg/dL; Albumin: &lt;2 g/dL; Uric acid: &gt;10 mg/dL; Protein urine: &gt;=3+</description>
        <time_frame>Baseline to Month 36</time_frame>
        <population>All randomized, transplanted, and treated participants from the original intent-to-treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA): tablet, oral
1st month target: 150-300 nanogram/meter (ng/m) After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)</description>
          </group>
          <group group_id="O2">
            <title>Belatacept LI</title>
            <description>Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
          <group group_id="O3">
            <title>Belatacept MI</title>
            <description>Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Meeting Marked Laboratory Abnormality Criteria Post-transplant by Month 36</title>
          <description>Upper limit of normal (ULN). Units per Liter (U/L). Cells per microliter (c/µL). Grams per deciliter (g/dL). Milligrams per deciliter (mg/dL).Cells per Liter (c/L). Milliequivalents/Liter (mEq/L).
Hemoglobin (low): &lt;8.0 g/dL; Platelet count: &lt;50*10^9 c/L; Leukocytes: &lt;2*10^3 c/µL; Alkaline phosphatase (ALP): &gt;5.0*ULN U/L; Alanine aminotransferase (ALT): &gt;5.0*ULN U/L; Asparate aminotransferase (AST): &gt;5.0*ULN U/L; Bilirubin Total: &gt;3.0*ULN mg/dL; Creatinine: &gt;3.0*ULN mg/dL; Calcium Total: low if &lt;7.0 mg/dL or high if &gt;12.5 mg/dL; Bicarbonate: &lt;11.0 mEq/L; Potassium serum: low if &lt;3.0 mEq/L or high if &gt;6.0 mEq/L; Magnesium serum: low is &lt;0.8 mEq/L or high if &gt;2.46 mEq/L; Sodium serum: low if &lt;130.0 mEq/L or high if &gt;155.0 mEq/L; Phosphorus inorganic: &lt;2.0 mg/dL; Albumin: &lt;2 g/dL; Uric acid: &gt;10 mg/dL; Protein urine: &gt;=3+</description>
          <population>All randomized, transplanted, and treated participants from the original intent-to-treat (ITT) population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="221"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hemoglobin, low (n=213, 226, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count, low (n=213, 226, 218)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes, low (n=213, 226, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline phosphatase, high (n=214, 226, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine aminotransferase, high (n=214, 226, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate aminotransferase, high (n=214, 226, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin total, high (n=214, 226, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, high (n=213, 223, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium total, low (n=214, 226, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium total, high (n=214, 226, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate, low (n=214, 226, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate, high (n=214, 226, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium serum, low (n=213, 223, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium serum, high (n=213, 223, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Magnessium serum, low (n=214, 225, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Magnessium serum, high (n=214, 225, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium serum, low (n=214, 226, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium serum, high (n=214, 226, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphorus inorganic, low (n=213, 224, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin, low (n=214, 226, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric acid, high (n=214, 226, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein in urine, high (n=213, 224, 217)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With Development of Anti-Donor HLA Positive Antibodies by Month 84</title>
        <description>Only participants who had non-missing test result for Class I or Class II anti-donor HLA antibodies were included in analysis and only participants who had at least one non-NA test result or finding were counted. This was a cumulative summary (excluding baseline) and once a participant was positive, that participant remained positive for the later time point. Acute rejection (AR) defined: a clinico-pathological event requiring clinical evidence and biopsy confirmation. Clinical evidence defined: if either a or b was satisfied: a: an unexplained rise of serum creatinine ≥ 25% from baseline creatinine; b: an unexplained decreased urine output; or fever and graft tenderness; or a serum creatinine that remains elevated within 14 days post-transplantation and clinical suspicion of acute rejection exists. AR defined as allograft biopsies of Banff 97 classification Grade IA or greater (higher scores indicate more severe rejection). Evaluated by blinded central independent pathologist.</description>
        <time_frame>Randomization to Month 84</time_frame>
        <population>All randomized, transplanted, and treated participants; intent to treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA): tablet, oral
1st month target: 150-300 nanogram/meter (ng/m) After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)</description>
          </group>
          <group group_id="O2">
            <title>Belatacept LI</title>
            <description>Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
          <group group_id="O3">
            <title>Belatacept MI</title>
            <description>Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Development of Anti-Donor HLA Positive Antibodies by Month 84</title>
          <description>Only participants who had non-missing test result for Class I or Class II anti-donor HLA antibodies were included in analysis and only participants who had at least one non-NA test result or finding were counted. This was a cumulative summary (excluding baseline) and once a participant was positive, that participant remained positive for the later time point. Acute rejection (AR) defined: a clinico-pathological event requiring clinical evidence and biopsy confirmation. Clinical evidence defined: if either a or b was satisfied: a: an unexplained rise of serum creatinine ≥ 25% from baseline creatinine; b: an unexplained decreased urine output; or fever and graft tenderness; or a serum creatinine that remains elevated within 14 days post-transplantation and clinical suspicion of acute rejection exists. AR defined as allograft biopsies of Banff 97 classification Grade IA or greater (higher scores indicate more severe rejection). Evaluated by blinded central independent pathologist.</description>
          <population>All randomized, transplanted, and treated participants; intent to treat (ITT) population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" lower_limit="7.34" upper_limit="15.91"/>
                    <measurement group_id="O2" value="3.1" lower_limit="0.84" upper_limit="5.36"/>
                    <measurement group_id="O3" value="1.4" lower_limit="0.28" upper_limit="3.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percent treatment difference measured as Belatacept - LI minus Cyclosporine</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percent</param_type>
            <param_value>-8.5</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.6</ci_lower_limit>
            <ci_upper_limit>-3.3</ci_upper_limit>
            <estimate_desc>For 97.3% CI of difference, normal approximation is used if N&gt;=5 in both arms. Otherwise exact method is used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Percent treatment difference measured as Belatacept - LI minus Cyclosporine</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percent</param_type>
            <param_value>-10.3</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.1</ci_lower_limit>
            <ci_upper_limit>-5.1</ci_upper_limit>
            <estimate_desc>For 97.3% CI of difference, normal approximation is used if N&gt;=5 in both arms. Otherwise exact method is used.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change of the Measured Glomerular Filtration Rate (mGFR) From Month 3 to Month 12 and From Month 3 to Month 24</title>
        <description>Measured glomerular filtration rate (mGFR) is the direct measurement of renal function and was assessed by measurement of the clearance of a true glomerular filtration marker (non-radiolabeled iothalamate) using a validated procedure. Missing mGRF assessments were imputed to assess renal function. The overall imputation strategy involved a primary imputation method (linear extrapolation and quartile method) followed by 2 secondary imputation methods (regression method and graded quartile method) to assess the robustness of conclusions obtained from the application of the primary imputation method. All imputation methods entailed replacing a missing value with a value drawn from a plausible distribution incorporating theoretical and observed aspects of the data. GFR was measured as mL/min/1.73 m^2.</description>
        <time_frame>Month 3 to Month 12; Month 3 to Month 24</time_frame>
        <population>All randomized, transplanted, and treated participants; intent to treat (ITT) population with measurable component</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA): tablet, oral
1st month target: 150-300 nanogram/meter (ng/m) After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)</description>
          </group>
          <group group_id="O2">
            <title>Belatacept LI</title>
            <description>Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
          <group group_id="O3">
            <title>Belatacept MI</title>
            <description>Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change of the Measured Glomerular Filtration Rate (mGFR) From Month 3 to Month 12 and From Month 3 to Month 24</title>
          <description>Measured glomerular filtration rate (mGFR) is the direct measurement of renal function and was assessed by measurement of the clearance of a true glomerular filtration marker (non-radiolabeled iothalamate) using a validated procedure. Missing mGRF assessments were imputed to assess renal function. The overall imputation strategy involved a primary imputation method (linear extrapolation and quartile method) followed by 2 secondary imputation methods (regression method and graded quartile method) to assess the robustness of conclusions obtained from the application of the primary imputation method. All imputation methods entailed replacing a missing value with a value drawn from a plausible distribution incorporating theoretical and observed aspects of the data. GFR was measured as mL/min/1.73 m^2.</description>
          <population>All randomized, transplanted, and treated participants; intent to treat (ITT) population with measurable component</population>
          <units>mL/min/1.73m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="206"/>
                <count group_id="O3" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Month 3) to Month 12 (n=195, 206, 200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="21.58"/>
                    <measurement group_id="O2" value="1.2" spread="30.43"/>
                    <measurement group_id="O3" value="4.4" spread="31.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline (Month 3) to Month 24 (n=184, 199, 192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="25.23"/>
                    <measurement group_id="O2" value="5.3" spread="33.03"/>
                    <measurement group_id="O3" value="4.2" spread="30.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With a Decrease in Measured Glomerular Filtration Rate (mGFR) Greater Than or Equal to 10mL/Min/1.73m^2 From Month 3 to Month 12</title>
        <description>Measured glomerular filtration rate (mGFR) is the direct measurement of renal function and was assessed by measurement of the clearance of a true glomerular filtration marker (non-radiolabeled iothalamate) using a validated procedure. A change in GFR of at least 10 mL/min/1.73 m^2 was used as the approximate change in serum creatinine (SCr) of at least 0.3 mg/dL. The change component of the composite renal endpoint was assessed from Month 3 to Month 12, since post-transplant renal function is largely stable by Month 3. Month 3 = baseline</description>
        <time_frame>Month 3 to Month 12</time_frame>
        <population>All randomized, transplanted, and treated participants; intent to treat (ITT) population with measurable component</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA): tablet, oral
1st month target: 150-300 nanogram/meter (ng/m) After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)</description>
          </group>
          <group group_id="O2">
            <title>Belatacept LI</title>
            <description>Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
          <group group_id="O3">
            <title>Belatacept MI</title>
            <description>Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With a Decrease in Measured Glomerular Filtration Rate (mGFR) Greater Than or Equal to 10mL/Min/1.73m^2 From Month 3 to Month 12</title>
          <description>Measured glomerular filtration rate (mGFR) is the direct measurement of renal function and was assessed by measurement of the clearance of a true glomerular filtration marker (non-radiolabeled iothalamate) using a validated procedure. A change in GFR of at least 10 mL/min/1.73 m^2 was used as the approximate change in serum creatinine (SCr) of at least 0.3 mg/dL. The change component of the composite renal endpoint was assessed from Month 3 to Month 12, since post-transplant renal function is largely stable by Month 3. Month 3 = baseline</description>
          <population>All randomized, transplanted, and treated participants; intent to treat (ITT) population with measurable component</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="214"/>
                <count group_id="O3" value="209"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.2" lower_limit="22.1" upper_limit="34.2"/>
                    <measurement group_id="O2" value="23.4" lower_limit="17.7" upper_limit="29.0"/>
                    <measurement group_id="O3" value="23.0" lower_limit="17.3" upper_limit="28.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With a Measured Glomerular Filtration Rate (mGFR) Less Than 60 mL/Min/1.73 m^2 at Month 12</title>
        <description>Measured glomerular filtration rate (mGFR) is the direct measurement of renal function and was assessed by measurement of the clearance of a true glomerular filtration marker (non-radiolabeled iothalamate) using a validated procedure. A GFR of 60 mL/min/1.73 m^2 was used as the approximate equal of the threshold values of serum creatinine (SCr) of 1.5 milligrams per deciliter (mg/dL).</description>
        <time_frame>Month 12</time_frame>
        <population>All randomized, transplanted, and treated participants; intent to treat (ITT) population with measurable component</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA): tablet, oral
1st month target: 150-300 nanogram/meter (ng/m) After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)</description>
          </group>
          <group group_id="O2">
            <title>Belatacept LI</title>
            <description>Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
          <group group_id="O3">
            <title>Belatacept MI</title>
            <description>Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With a Measured Glomerular Filtration Rate (mGFR) Less Than 60 mL/Min/1.73 m^2 at Month 12</title>
          <description>Measured glomerular filtration rate (mGFR) is the direct measurement of renal function and was assessed by measurement of the clearance of a true glomerular filtration marker (non-radiolabeled iothalamate) using a validated procedure. A GFR of 60 mL/min/1.73 m^2 was used as the approximate equal of the threshold values of serum creatinine (SCr) of 1.5 milligrams per deciliter (mg/dL).</description>
          <population>All randomized, transplanted, and treated participants; intent to treat (ITT) population with measurable component</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="214"/>
                <count group_id="O3" value="209"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.6" lower_limit="61.3" upper_limit="73.9"/>
                    <measurement group_id="O2" value="43" lower_limit="36.4" upper_limit="49.6"/>
                    <measurement group_id="O3" value="43.5" lower_limit="36.8" upper_limit="50.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Value of the Calculated Glomerular Filtration Rate (cGFR) With Imputation</title>
        <description>Calculated glomerular filtration rate (cGFR) was used to assess renal function (as measured by the estimated creatinine clearance) using the following modification of diet in renal disease (MDRD) formula: MDRD: GFR = 170 x [SCr/0.95]^(-0.999) x [Age]^(-0.176) x [0.762 if participant is female] x [1.180 if participant is black] x [BUN]^(-0.170) x [Alb]^(+0.318); Age in years; Alb = Albumin in g/dL; SCr = Serum creatinine in mg/dL; BUN = Blood urea nitrogen in mg/dL; cGFR = mL/min/1.73m2</description>
        <time_frame>Months 6, 12, 24, 36</time_frame>
        <population>All randomized, transplanted, and treated participants; intent to treat (ITT) population with measurable component</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA): tablet, oral
1st month target: 150-300 nanogram/meter (ng/m) After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)</description>
          </group>
          <group group_id="O2">
            <title>Belatacept LI</title>
            <description>Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
          <group group_id="O3">
            <title>Belatacept MI</title>
            <description>Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Value of the Calculated Glomerular Filtration Rate (cGFR) With Imputation</title>
          <description>Calculated glomerular filtration rate (cGFR) was used to assess renal function (as measured by the estimated creatinine clearance) using the following modification of diet in renal disease (MDRD) formula: MDRD: GFR = 170 x [SCr/0.95]^(-0.999) x [Age]^(-0.176) x [0.762 if participant is female] x [1.180 if participant is black] x [BUN]^(-0.170) x [Alb]^(+0.318); Age in years; Alb = Albumin in g/dL; SCr = Serum creatinine in mg/dL; BUN = Blood urea nitrogen in mg/dL; cGFR = mL/min/1.73m2</description>
          <population>All randomized, transplanted, and treated participants; intent to treat (ITT) population with measurable component</population>
          <units>mL/min/1.73 m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="201"/>
                <count group_id="O3" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6 (n=189, 185, 170)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.8" spread="19.22"/>
                    <measurement group_id="O2" value="62.6" spread="20.41"/>
                    <measurement group_id="O3" value="62.4" spread="20.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=199, 200, 201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.1" spread="21.06"/>
                    <measurement group_id="O2" value="65.4" spread="22.94"/>
                    <measurement group_id="O3" value="65.2" spread="23.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (n=182, 201, 191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.9" spread="23.00"/>
                    <measurement group_id="O2" value="65.4" spread="25.22"/>
                    <measurement group_id="O3" value="65.5" spread="24.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36 (n=171, 190, 186)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.4" spread="23.58"/>
                    <measurement group_id="O2" value="65.8" spread="27.00"/>
                    <measurement group_id="O3" value="65.2" spread="26.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>15.3</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.3</ci_lower_limit>
            <ci_upper_limit>20.3</ci_upper_limit>
            <estimate_desc>ANOVA model: GFR = treatment</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>15.1</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.1</ci_lower_limit>
            <ci_upper_limit>20.1</ci_upper_limit>
            <estimate_desc>ANOVA model: GFR = treatment</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Month 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>17.5</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12.0</ci_lower_limit>
            <ci_upper_limit>23.1</ci_upper_limit>
            <estimate_desc>ANOVA model: GFR = treatment</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Month 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>17.6</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12.0</ci_lower_limit>
            <ci_upper_limit>23.3</ci_upper_limit>
            <estimate_desc>ANOVA model: GFR = treatment</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Month 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>21.4</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>15.4</ci_lower_limit>
            <ci_upper_limit>27.4</ci_upper_limit>
            <estimate_desc>ANOVA model: GFR = treatment</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Month 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>20.8</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>14.8</ci_lower_limit>
            <ci_upper_limit>26.9</ci_upper_limit>
            <estimate_desc>ANOVA model: GFR = treatment</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Calculated Glomerular Filtration Rate (cGFR) From Month 6 to Month 12</title>
        <description>Calculated glomerular filtration rate (cGFR) was used to assess renal function (as measured by the estimated creatinine clearance) using the following modification of diet in renal disease (MDRD) formula: MDRD: GFR = 170 x [SCr/0.95]^(-0.999) x [Age]^(-0.176) x [0.762 if participant is female] x [1.180 if participant is black] x [BUN]^(-0.170) x [Alb]^(+0.318); Age in years; Alb = Albumin in g/dL; SCr = Serum creatinine in mg/dL; BUN = Blood urea nitrogen in mg/dL; cGFR = mL/min/1.73m^2</description>
        <time_frame>Month 6 to Month 12</time_frame>
        <population>All randomized, transplanted, and treated participants; intent to treat (ITT) population with measurable component</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA): tablet, oral
1st month target: 150-300 nanogram/meter (ng/m) After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)</description>
          </group>
          <group group_id="O2">
            <title>Belatacept LI</title>
            <description>Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
          <group group_id="O3">
            <title>Belatacept MI</title>
            <description>Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Calculated Glomerular Filtration Rate (cGFR) From Month 6 to Month 12</title>
          <description>Calculated glomerular filtration rate (cGFR) was used to assess renal function (as measured by the estimated creatinine clearance) using the following modification of diet in renal disease (MDRD) formula: MDRD: GFR = 170 x [SCr/0.95]^(-0.999) x [Age]^(-0.176) x [0.762 if participant is female] x [1.180 if participant is black] x [BUN]^(-0.170) x [Alb]^(+0.318); Age in years; Alb = Albumin in g/dL; SCr = Serum creatinine in mg/dL; BUN = Blood urea nitrogen in mg/dL; cGFR = mL/min/1.73m^2</description>
          <population>All randomized, transplanted, and treated participants; intent to treat (ITT) population with measurable component</population>
          <units>mL/Min/1.73 m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="169"/>
                <count group_id="O3" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="10.09"/>
                    <measurement group_id="O2" value="4.7" spread="11.52"/>
                    <measurement group_id="O3" value="5.1" spread="11.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With Incidence of New Onset Diabetes Mellitus by Month 36</title>
        <description>The incidence of new onset diabetes mellitus defined as participants who developed diabetes mellitus after randomization and transplantation. Participants that did not have diabetes prior to randomization were determined to have new onset diabetes mellitus if (i) the participant received an anti-diabetic medication for a duration of at least 30 days or (ii) at least two fasting plasma glucose (FPG) tests indicate that FPG is &gt;=126 mg/dL (7.0 mmol/L). New onset diabetes mellitus (NODM) = post-transplant diabetes mellitus (PTDM)</description>
        <time_frame>Week 4 post-transplantation to Month 36</time_frame>
        <population>All randomized, transplanted, and treated participants; intent to treat (ITT) population with measurable component</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA): tablet, oral
1st month target: 150-300 nanogram/meter (ng/m) After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)</description>
          </group>
          <group group_id="O2">
            <title>Belatacept LI</title>
            <description>Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
          <group group_id="O3">
            <title>Belatacept MI</title>
            <description>Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Incidence of New Onset Diabetes Mellitus by Month 36</title>
          <description>The incidence of new onset diabetes mellitus defined as participants who developed diabetes mellitus after randomization and transplantation. Participants that did not have diabetes prior to randomization were determined to have new onset diabetes mellitus if (i) the participant received an anti-diabetic medication for a duration of at least 30 days or (ii) at least two fasting plasma glucose (FPG) tests indicate that FPG is &gt;=126 mg/dL (7.0 mmol/L). New onset diabetes mellitus (NODM) = post-transplant diabetes mellitus (PTDM)</description>
          <population>All randomized, transplanted, and treated participants; intent to treat (ITT) population with measurable component</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="168"/>
                <count group_id="O3" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.9" lower_limit="5.3" upper_limit="14.5"/>
                    <measurement group_id="O2" value="4.2" lower_limit="1.1" upper_limit="7.2"/>
                    <measurement group_id="O3" value="7.1" lower_limit="3.0" upper_limit="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" lower_limit="5.8" upper_limit="15.2"/>
                    <measurement group_id="O2" value="5.4" lower_limit="2.0" upper_limit="8.8"/>
                    <measurement group_id="O3" value="8.3" lower_limit="4.0" upper_limit="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" lower_limit="6.3" upper_limit="16.0"/>
                    <measurement group_id="O2" value="6.5" lower_limit="2.8" upper_limit="10.3"/>
                    <measurement group_id="O3" value="10.3" lower_limit="5.5" upper_limit="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0687</p_value>
            <p_value_desc>Normal approximation is used if N&gt;=5 in both arms. Otherwise, exact method is used.</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Difference in Percent</param_type>
            <param_value>-5.7</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.6</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4825</p_value>
            <p_value_desc>Normal approximation is used if N&gt;=5 in both arms. Otherwise, exact method is used.</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Difference in Percent</param_type>
            <param_value>-2.8</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.2</ci_lower_limit>
            <ci_upper_limit>4.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Month 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1267</p_value>
            <p_value_desc>Normal approximation is used if N&gt;=5 in both arms. Otherwise, exact method is used.</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Difference in Percent</param_type>
            <param_value>-5.1</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.3</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Month 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6405</p_value>
            <p_value_desc>Normal approximation is used if N&gt;=5 in both arms. Otherwise, exact method is used.</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Difference in Percent</param_type>
            <param_value>-2.2</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.8</ci_lower_limit>
            <ci_upper_limit>5.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Month 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2043</p_value>
            <method>Chi-squared</method>
            <method_desc>Normal approximation is used if N&gt;=5 in both arms. Otherwise, exact method is used.</method_desc>
            <param_type>Difference in Percent</param_type>
            <param_value>-4.6</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.0</ci_lower_limit>
            <ci_upper_limit>2.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Month 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9481</p_value>
            <p_value_desc>Normal approximation is used if N&gt;=5 in both arms. Otherwise, exact method is used.</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Difference in Percent</param_type>
            <param_value>-0.9</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.8</ci_lower_limit>
            <ci_upper_limit>7.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants Using At Least One Anti-Hypertensive Medication to Control Hypertension at Month 36</title>
        <description>This analysis was based on all participants who had been followed up at least 1092 days after transplantation. Hypertension was defined in according to the Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure for participants with chronic kidney disease. This definition was based upon SBP ≥ 130 mm Hg or DBP ≥ 80 mm Hg. In addition, all participants who had a SBP &lt; 130 mm Hg and a DBP &lt; 80 mm Hg who received an antihypertensive medication(s) for the indication of hypertension or with a medical history of hypertension were included in this definition. Systolic blood pressure = SBP; Diastolic blood pressure = DBP</description>
        <time_frame>Month 36</time_frame>
        <population>All randomized, transplanted, and treated participants; intent to treat (ITT) population with measurable component</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA): tablet, oral
1st month target: 150-300 nanogram/meter (ng/m) After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)</description>
          </group>
          <group group_id="O2">
            <title>Belatacept LI</title>
            <description>Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
          <group group_id="O3">
            <title>Belatacept MI</title>
            <description>Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 milligrams/kilogram (mg/kg) every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Using At Least One Anti-Hypertensive Medication to Control Hypertension at Month 36</title>
          <description>This analysis was based on all participants who had been followed up at least 1092 days after transplantation. Hypertension was defined in according to the Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure for participants with chronic kidney disease. This definition was based upon SBP ≥ 130 mm Hg or DBP ≥ 80 mm Hg. In addition, all participants who had a SBP &lt; 130 mm Hg and a DBP &lt; 80 mm Hg who received an antihypertensive medication(s) for the indication of hypertension or with a medical history of hypertension were included in this definition. Systolic blood pressure = SBP; Diastolic blood pressure = DBP</description>
          <population>All randomized, transplanted, and treated participants; intent to treat (ITT) population with measurable component</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="182"/>
                <count group_id="O2" value="199"/>
                <count group_id="O3" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.9" lower_limit="89.12" upper_limit="96.60"/>
                    <measurement group_id="O2" value="81.9" lower_limit="76.56" upper_limit="87.36"/>
                    <measurement group_id="O3" value="83.9" lower_limit="78.65" upper_limit="89.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.5</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.31</ci_lower_limit>
            <ci_upper_limit>0.74</ci_upper_limit>
            <estimate_desc>Odds ratio is estimated by a cumulative logit model.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0092</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio, log</param_type>
            <param_value>0.6</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.38</ci_lower_limit>
            <ci_upper_limit>0.92</ci_upper_limit>
            <estimate_desc>Odds ratio is estimated by a cumulative logit model.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With Incidence of Hypertension Post-Transplantation at Month 12</title>
        <description>The incidence of hypertension was defined as the proportion of participants who developed hypertension after randomization and transplantation. Specifically, the incidence of hypertension was assessed only after the Week 4 visit. This period allowed for adequate stabilization and resolution of transient changes. If participants received antihypertensive medication for the indication of hypertension at this (or later) time point, they were considered to have developed hypertension. Hypertension was defined according to the Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure for subjects with chronic kidney disease. This definition was based upon SBP ≥ 130 mm Hg or DBP ≥ 80 mm Hg. Systolic blood pressure = SBP; Diastolic blood pressure = DBP</description>
        <time_frame>Month 12</time_frame>
        <population>All randomized, transplanted, and treated participants; intent to treat (ITT) population with measurable component</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA): tablet, oral
1st month target: 150-300 nanogram/meter (ng/m) After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)</description>
          </group>
          <group group_id="O2">
            <title>Belatacept LI</title>
            <description>Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
          <group group_id="O3">
            <title>Belatacept MI</title>
            <description>Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Incidence of Hypertension Post-Transplantation at Month 12</title>
          <description>The incidence of hypertension was defined as the proportion of participants who developed hypertension after randomization and transplantation. Specifically, the incidence of hypertension was assessed only after the Week 4 visit. This period allowed for adequate stabilization and resolution of transient changes. If participants received antihypertensive medication for the indication of hypertension at this (or later) time point, they were considered to have developed hypertension. Hypertension was defined according to the Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure for subjects with chronic kidney disease. This definition was based upon SBP ≥ 130 mm Hg or DBP ≥ 80 mm Hg. Systolic blood pressure = SBP; Diastolic blood pressure = DBP</description>
          <population>All randomized, transplanted, and treated participants; intent to treat (ITT) population with measurable component</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0" lower_limit="19.4" upper_limit="99.4"/>
                    <measurement group_id="O2" value="53.8" lower_limit="26.7" upper_limit="80.9"/>
                    <measurement group_id="O3" value="57.1" lower_limit="18.4" upper_limit="90.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percent</param_type>
            <param_value>-21.2</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-67.6</ci_lower_limit>
            <ci_upper_limit>43.2</ci_upper_limit>
            <estimate_desc>For 97.3% CI of difference, normal approximation is used if N&gt;=5 in both arms. Otherwise exact method is used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percent</param_type>
            <param_value>-17.9</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-72.3</ci_lower_limit>
            <ci_upper_limit>52.2</ci_upper_limit>
            <estimate_desc>For 97.3% CI of difference, normal approximation is used if N&gt;=5 in both arms. Otherwise exact method is used.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With Prevalence of Hypertension Post-Transplantation at Month 12</title>
        <description>The prevalence of hypertension was defined as the proportion of participants at any given time who meet the definition of hypertension. Hypertension defined according to the Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure for participants with chronic kidney disease. This definition is based upon SBP ≥ 130 mm Hg or DBP ≥ 80 mm Hg. Systolic blood pressure = SBP; Diastolic blood pressure = DBP</description>
        <time_frame>Month 12</time_frame>
        <population>All randomized, transplanted, and treated participants; intent to treat (ITT) population with measurable component</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA): tablet, oral
1st month target: 150-300 nanogram/meter (ng/m) After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)</description>
          </group>
          <group group_id="O2">
            <title>Belatacept LI</title>
            <description>Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
          <group group_id="O3">
            <title>Belatacept MI</title>
            <description>Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Prevalence of Hypertension Post-Transplantation at Month 12</title>
          <description>The prevalence of hypertension was defined as the proportion of participants at any given time who meet the definition of hypertension. Hypertension defined according to the Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure for participants with chronic kidney disease. This definition is based upon SBP ≥ 130 mm Hg or DBP ≥ 80 mm Hg. Systolic blood pressure = SBP; Diastolic blood pressure = DBP</description>
          <population>All randomized, transplanted, and treated participants; intent to treat (ITT) population with measurable component</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="221"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.0" lower_limit="87.17" upper_limit="94.73"/>
                    <measurement group_id="O2" value="89.8" lower_limit="85.88" upper_limit="93.76"/>
                    <measurement group_id="O3" value="88.6" lower_limit="84.37" upper_limit="92.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percent</param_type>
            <param_value>-1.13</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.51</ci_lower_limit>
            <ci_upper_limit>5.23</ci_upper_limit>
            <estimate_desc>For 97.3% CI of difference, normal approximation is used if N&gt;=5 in both arms. Otherwise exact method is used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percent</param_type>
            <param_value>-2.37</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.01</ci_lower_limit>
            <ci_upper_limit>4.15</ci_upper_limit>
            <estimate_desc>For 97.3% CI of difference, normal approximation is used if N&gt;=5 in both arms. Otherwise exact method is used.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Systolic Blood Pressure and Diastolic Blood Pressure</title>
        <description>Blood pressure was measured in millimeters of mercury (mmHg). Blood pressure was measured soon after the participant arrived and sat quietly at rest for 10 minutes. 3 consecutive seated blood pressure readings were made at least 1 minute apart.</description>
        <time_frame>Months 12, 24, 36</time_frame>
        <population>All randomized, transplanted, and treated participants; intent to treat (ITT) population with measurable component</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA): tablet, oral
1st month target: 150-300 nanogram/meter (ng/m) After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)</description>
          </group>
          <group group_id="O2">
            <title>Belatacept LI</title>
            <description>Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
          <group group_id="O3">
            <title>Belatacept MI</title>
            <description>Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Systolic Blood Pressure and Diastolic Blood Pressure</title>
          <description>Blood pressure was measured in millimeters of mercury (mmHg). Blood pressure was measured soon after the participant arrived and sat quietly at rest for 10 minutes. 3 consecutive seated blood pressure readings were made at least 1 minute apart.</description>
          <population>All randomized, transplanted, and treated participants; intent to treat (ITT) population with measurable component</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="193"/>
                <count group_id="O3" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic; Month 12 (n=188, 193, 191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138.7" spread="19.98"/>
                    <measurement group_id="O2" value="131.4" spread="16.54"/>
                    <measurement group_id="O3" value="132.7" spread="16.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic; Month 12 (n=188, 193, 191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.9" spread="11.10"/>
                    <measurement group_id="O2" value="78.7" spread="10.91"/>
                    <measurement group_id="O3" value="79.3" spread="11.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic; Month 24 (n=160, 185, 174)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135.4" spread="19.71"/>
                    <measurement group_id="O2" value="130.5" spread="17.35"/>
                    <measurement group_id="O3" value="129.8" spread="16.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic; Month 24 (n=160, 185, 174)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.3" spread="10.20"/>
                    <measurement group_id="O2" value="78.3" spread="10.51"/>
                    <measurement group_id="O3" value="77.8" spread="10.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic; Month 36 (n=145, 180, 166)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133.5" spread="17.93"/>
                    <measurement group_id="O2" value="127.7" spread="16.48"/>
                    <measurement group_id="O3" value="126.0" spread="16.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic; Month 36 (n=145, 180, 166)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.5" spread="9.16"/>
                    <measurement group_id="O2" value="76.6" spread="9.75"/>
                    <measurement group_id="O3" value="76.1" spread="11.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Systolic, Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>-7.3</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.4</ci_lower_limit>
            <ci_upper_limit>-3.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Systolic, Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>-6.0</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.1</ci_lower_limit>
            <ci_upper_limit>-2.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Diastolic, Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>-3.2</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.8</ci_lower_limit>
            <ci_upper_limit>-0.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Diastolic, Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>-2.6</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.1</ci_lower_limit>
            <ci_upper_limit>0.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Systolic, Month 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>-4.9</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.2</ci_lower_limit>
            <ci_upper_limit>-0.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Systolic, Month 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>-5.5</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.9</ci_lower_limit>
            <ci_upper_limit>-1.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Diastolic, Month 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>-1.9</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.4</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Diastolic, Month 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>-2.4</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.0</ci_lower_limit>
            <ci_upper_limit>0.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Systolic, Month 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>-5.8</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.0</ci_lower_limit>
            <ci_upper_limit>-1.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Systolic, Month 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>-7.5</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.7</ci_lower_limit>
            <ci_upper_limit>-3.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Diastolic, Month 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>-2.9</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.4</ci_lower_limit>
            <ci_upper_limit>-0.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Diastolic, Month 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>-3.4</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.0</ci_lower_limit>
            <ci_upper_limit>-0.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants at Baseline With Controlled Hypertension Post Transplantation by Month 12</title>
        <description>Controlled hypertension was defined as a SBP &lt; 130 mm Hg and a DBP &lt; 80 mm Hg while receiving an antihypertensive medication for the indication of hypertension or receiving an antihypertensive medication for another indication with a medical history of hypertension. Participants with a SBP &lt; 130 mm Hg and a DBP &lt; 80 mm Hg who were prescribed an antihypertensive medication(s) for an indication(s) other than hypertension (eg, beta blockers for migraine prophylaxis) with no medical history of hypertension were not considered to have either hypertension or controlled hypertension. Systolic blood pressure = SBP; Diastolic blood pressure = DBP</description>
        <time_frame>Day 1 to Month 12</time_frame>
        <population>All randomized, transplanted, and treated participants; intent to treat (ITT) population with baseline hypertension</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA): tablet, oral
1st month target: 150-300 nanogram/meter (ng/m) After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)</description>
          </group>
          <group group_id="O2">
            <title>Belatacept LI</title>
            <description>Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
          <group group_id="O3">
            <title>Belatacept MI</title>
            <description>Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants at Baseline With Controlled Hypertension Post Transplantation by Month 12</title>
          <description>Controlled hypertension was defined as a SBP &lt; 130 mm Hg and a DBP &lt; 80 mm Hg while receiving an antihypertensive medication for the indication of hypertension or receiving an antihypertensive medication for another indication with a medical history of hypertension. Participants with a SBP &lt; 130 mm Hg and a DBP &lt; 80 mm Hg who were prescribed an antihypertensive medication(s) for an indication(s) other than hypertension (eg, beta blockers for migraine prophylaxis) with no medical history of hypertension were not considered to have either hypertension or controlled hypertension. Systolic blood pressure = SBP; Diastolic blood pressure = DBP</description>
          <population>All randomized, transplanted, and treated participants; intent to treat (ITT) population with baseline hypertension</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="182"/>
                <count group_id="O2" value="182"/>
                <count group_id="O3" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.4" lower_limit="15.5" upper_limit="27.4"/>
                    <measurement group_id="O2" value="28.6" lower_limit="22.0" upper_limit="35.1"/>
                    <measurement group_id="O3" value="24.6" lower_limit="18.4" upper_limit="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percent</param_type>
            <param_value>7.1</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.9</ci_lower_limit>
            <ci_upper_limit>17.1</ci_upper_limit>
            <estimate_desc>A continuity-corrected Chi-square test at significance level 0.027 was performed for the difference between the belatacept regimen and cyclosporine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percent</param_type>
            <param_value>3.2</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.6</ci_lower_limit>
            <ci_upper_limit>12.9</ci_upper_limit>
            <estimate_desc>A continuity-corrected Chi-square test at significance level 0.027 was performed for the difference between the belatacept regimen and cyclosporine</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With Prevalence of Controlled Hypertension at Month 12</title>
        <description>The prevalence of controlled hypertension was defined as the proportion of participants at any given time who met the definition of controlled hypertension. Controlled hypertension was defined as a SBP &lt; 130 mm Hg and a DBP &lt; 80 mm Hg while receiving an antihypertensive medication for the indication of hypertension or receiving an antihypertensive medication for another indication with a medical history of hypertension. Participants with a SBP &lt; 130 mm Hg and a DBP &lt; 80 mm Hg who were prescribed an antihypertensive medication(s) for an indication(s) other than hypertension (eg, beta blockers for migraine prophylaxis) with no medical history of hypertension were not considered to have either hypertension or controlled hypertension. Systolic blood pressure = SBP; Diastolic blood pressure = DBP</description>
        <time_frame>Month 12</time_frame>
        <population>All randomized, transplanted, and treated participants; intent to treat (ITT) population with measurable component</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA): tablet, oral
1st month target: 150-300 nanogram/meter (ng/m) After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)</description>
          </group>
          <group group_id="O2">
            <title>Belatacept LI</title>
            <description>Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
          <group group_id="O3">
            <title>Belatacept MI</title>
            <description>Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Prevalence of Controlled Hypertension at Month 12</title>
          <description>The prevalence of controlled hypertension was defined as the proportion of participants at any given time who met the definition of controlled hypertension. Controlled hypertension was defined as a SBP &lt; 130 mm Hg and a DBP &lt; 80 mm Hg while receiving an antihypertensive medication for the indication of hypertension or receiving an antihypertensive medication for another indication with a medical history of hypertension. Participants with a SBP &lt; 130 mm Hg and a DBP &lt; 80 mm Hg who were prescribed an antihypertensive medication(s) for an indication(s) other than hypertension (eg, beta blockers for migraine prophylaxis) with no medical history of hypertension were not considered to have either hypertension or controlled hypertension. Systolic blood pressure = SBP; Diastolic blood pressure = DBP</description>
          <population>All randomized, transplanted, and treated participants; intent to treat (ITT) population with measurable component</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="193"/>
                <count group_id="O3" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.0" lower_limit="15.12" upper_limit="26.82"/>
                    <measurement group_id="O2" value="28.0" lower_limit="21.65" upper_limit="34.31"/>
                    <measurement group_id="O3" value="24.7" lower_limit="18.60" upper_limit="30.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percent</param_type>
            <param_value>7.01</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.79</ci_lower_limit>
            <ci_upper_limit>16.71</ci_upper_limit>
            <estimate_desc>A continuity-corrected Chi-square test at significance level 0.027 was performed for the difference between the belatacept regimen and cyclosporine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percent</param_type>
            <param_value>3.77</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.86</ci_lower_limit>
            <ci_upper_limit>13.35</ci_upper_limit>
            <estimate_desc>A continuity-corrected Chi-square test at significance level 0.027 was performed for the difference between the belatacept regimen and cyclosporine</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Non-dyslipidemic Participants With Incidence of Dyslipidemia Post-Transplantation by Month 12</title>
        <description>Incidence of dyslipidemia was defined as the proportion of participants who developed dyslipidemia after randomization and transplantation. Dyslipidemia was defined in accordance with recent guidelines from the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF-K/DOQI). Dyslipidemia = hypertriglyceridemia (TGs &gt;= 500 milligrams/deciliter (mg/dL) [5.65 mmol/L]), hypercholesterolemia (LDL &gt;= 100 mg/dL [2.59 mmol/L]), or elevated non-HDL (non-HDL &gt;= 130 mg/dL [3.36 mmol/L]) in the presence of high TGs (TGs &gt;= 200 mg/dL [2.26 mmol/L]). The TG = triglyceride; LDL = low density lipoprotein; HDL = high density lipoprotein; millimole/Liter (mmol/L). For 95% CI within each group, normal approximation is used if N &gt;=5. Otherwise exact method is used.</description>
        <time_frame>Randomization to Month 12</time_frame>
        <population>All randomized, transplanted, and treated participants; intent to treat (ITT) population with measurable component</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA): tablet, oral
1st month target: 150-300 nanogram/meter (ng/m) After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)</description>
          </group>
          <group group_id="O2">
            <title>Belatacept LI</title>
            <description>Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
          <group group_id="O3">
            <title>Belatacept MI</title>
            <description>Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 milligrams/kilogram (mg/kg) every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Non-dyslipidemic Participants With Incidence of Dyslipidemia Post-Transplantation by Month 12</title>
          <description>Incidence of dyslipidemia was defined as the proportion of participants who developed dyslipidemia after randomization and transplantation. Dyslipidemia was defined in accordance with recent guidelines from the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF-K/DOQI). Dyslipidemia = hypertriglyceridemia (TGs &gt;= 500 milligrams/deciliter (mg/dL) [5.65 mmol/L]), hypercholesterolemia (LDL &gt;= 100 mg/dL [2.59 mmol/L]), or elevated non-HDL (non-HDL &gt;= 130 mg/dL [3.36 mmol/L]) in the presence of high TGs (TGs &gt;= 200 mg/dL [2.26 mmol/L]). The TG = triglyceride; LDL = low density lipoprotein; HDL = high density lipoprotein; millimole/Liter (mmol/L). For 95% CI within each group, normal approximation is used if N &gt;=5. Otherwise exact method is used.</description>
          <population>All randomized, transplanted, and treated participants; intent to treat (ITT) population with measurable component</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="94"/>
                <count group_id="O3" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0" lower_limit="70.9" upper_limit="89.1"/>
                    <measurement group_id="O2" value="63.8" lower_limit="54.1" upper_limit="73.5"/>
                    <measurement group_id="O3" value="70.9" lower_limit="60.9" upper_limit="80.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With Prevalence of Dyslipidemia at Month 12</title>
        <description>The prevalence of dyslipidemia was defined as the proportion of participants at any given time who met the definition of dyslipidemia. Dyslipidemia defined in accordance with recent guidelines from the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF-K/DOQI). Dyslipidemia defined as hypertriglyceridemia (TGs &gt;= 500 milligrams/deciliter (mg/dL) [5.65 mmol/L]), hypercholesterolemia (LDL &gt;= 100 mg/dL [2.59 mmol/L]), or elevated non-HDL (non-HDL &gt;= 130 mg/dL [3.36 mmol/L]) in the presence of high TGs (TGs &gt;= 200 mg/dL [2.26 mmol/L]). TG = triglyceride; LDL = low density lipoprotein; HDL = high density lipoprotein; millimole/Liter (mmol/L). For 95% CI within each group, normal approximation is used if N &gt;=5. Otherwise exact method is used.</description>
        <time_frame>Month 12</time_frame>
        <population>All randomized, transplanted, and treated participants; intent to treat (ITT) population with measurable component</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA): tablet, oral
1st month target: 150-300 nanogram/meter (ng/m) After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)</description>
          </group>
          <group group_id="O2">
            <title>Belatacept LI</title>
            <description>Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
          <group group_id="O3">
            <title>Belatacept MI</title>
            <description>Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 milligrams/kilogram (mg/kg) every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Prevalence of Dyslipidemia at Month 12</title>
          <description>The prevalence of dyslipidemia was defined as the proportion of participants at any given time who met the definition of dyslipidemia. Dyslipidemia defined in accordance with recent guidelines from the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF-K/DOQI). Dyslipidemia defined as hypertriglyceridemia (TGs &gt;= 500 milligrams/deciliter (mg/dL) [5.65 mmol/L]), hypercholesterolemia (LDL &gt;= 100 mg/dL [2.59 mmol/L]), or elevated non-HDL (non-HDL &gt;= 130 mg/dL [3.36 mmol/L]) in the presence of high TGs (TGs &gt;= 200 mg/dL [2.26 mmol/L]). TG = triglyceride; LDL = low density lipoprotein; HDL = high density lipoprotein; millimole/Liter (mmol/L). For 95% CI within each group, normal approximation is used if N &gt;=5. Otherwise exact method is used.</description>
          <population>All randomized, transplanted, and treated participants; intent to treat (ITT) population with measurable component</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="221"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.9" lower_limit="46.4" upper_limit="59.5"/>
                    <measurement group_id="O2" value="44.7" lower_limit="38.2" upper_limit="51.2"/>
                    <measurement group_id="O3" value="46.1" lower_limit="39.5" upper_limit="52.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With Controlled Dyslipidemia at Month 12</title>
        <description>Prevalence of controlled dyslipidemia = the proportion of participants at any given time who met the stated definition of dyslipidemia. Dyslipidemia defined in accordance with recent guidelines from the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF-K/DOQI). Dyslipidemia defined as hypertriglyceridemia (TGs &gt;= 500 milligrams/deciliter (mg/dL) [5.65 mmol/L]), hypercholesterolemia (LDL &gt;= 100 mg/dL [2.59 mmol/L]), or elevated non-HDL (non-HDL &gt;= 130 mg/dL [3.36 mmol/L]) in the presence of high TGs (TGs &gt;= 200 mg/dL [2.26 mmol/L]). Controlled dyslipidemia defined as participants who received successful pharmacologic treatment for 1 of the above stated dyslipidemias, and their lipid values fell below the thresholds described. TG = triglyceride; LDL = low density lipoprotein; HDL = high density lipoprotein; millimole/Liter (mmol/L). For 95% CI within each group, normal approximation is used if N &gt;=5. Otherwise exact method is used.</description>
        <time_frame>Month 12</time_frame>
        <population>All randomized and transplanted participants, intent-to-treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA): tablet, oral
1st month target: 150-300 nanogram/meter (ng/m) After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)</description>
          </group>
          <group group_id="O2">
            <title>Belatacept LI</title>
            <description>Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
          <group group_id="O3">
            <title>Belatacept MI</title>
            <description>Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 milligrams/kilogram (mg/kg) every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Controlled Dyslipidemia at Month 12</title>
          <description>Prevalence of controlled dyslipidemia = the proportion of participants at any given time who met the stated definition of dyslipidemia. Dyslipidemia defined in accordance with recent guidelines from the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF-K/DOQI). Dyslipidemia defined as hypertriglyceridemia (TGs &gt;= 500 milligrams/deciliter (mg/dL) [5.65 mmol/L]), hypercholesterolemia (LDL &gt;= 100 mg/dL [2.59 mmol/L]), or elevated non-HDL (non-HDL &gt;= 130 mg/dL [3.36 mmol/L]) in the presence of high TGs (TGs &gt;= 200 mg/dL [2.26 mmol/L]). Controlled dyslipidemia defined as participants who received successful pharmacologic treatment for 1 of the above stated dyslipidemias, and their lipid values fell below the thresholds described. TG = triglyceride; LDL = low density lipoprotein; HDL = high density lipoprotein; millimole/Liter (mmol/L). For 95% CI within each group, normal approximation is used if N &gt;=5. Otherwise exact method is used.</description>
          <population>All randomized and transplanted participants, intent-to-treat (ITT) population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="221"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.1" lower_limit="13.0" upper_limit="23.2"/>
                    <measurement group_id="O2" value="15.5" lower_limit="10.8" upper_limit="20.2"/>
                    <measurement group_id="O3" value="15.5" lower_limit="10.7" upper_limit="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Antihyperlipidemic Medication by Intensity Level</title>
        <description>An intensity level was associated with the dose level of the statin based anti-hyperlipidemic agent. Any other agent (i.e., non-statin therapy) used as an antihyperlipidemic were considered Level I treatment intensity. Multiple daily dose levels during a period were averaged to compute the daily dose during that period. Level I = 20 mg fluvastatin (flu), 10 mg lovastatin (lova), 10 mg pravastatin (prav), 5-10 mg simvastatin (sim); Level II = 10 mg atorvastatin (atorv), 40 mg flu, 20 mg lova, 20 mg prav, 5 mg rosuvastatin (rosu), 20 mg sim, 10/10 vytorin; Level III = 20 mg atorv, 80 mg flu, 40 mg lova, 40 mg prav, 10 mg rosu, 40 mg sim, 10/20 vytorin; Level IV = 40 mg atorv, 80 mg lova, 80 mg prav, 20 mg rosu, 80 mg sim, 10/40 vytorin; Level V = 80 mg atorv, 40 mg rosu, 10/80 vytorin. Concomitant use of a statin and an agent of another class elevated the intensity level of the statin therapy by 1 level; therefore, an intensity level of greater than V was possible.</description>
        <time_frame>Month 36</time_frame>
        <population>All randomized and transplanted participants that received at least one hyperlipidemic medication; Completer analysis is based on all participants who have been followed up at least 1092 days after transplantation.</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA): tablet, oral
1st month target: 150-300 nanogram/meter (ng/m) After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)</description>
          </group>
          <group group_id="O2">
            <title>Belatacept LI</title>
            <description>Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
          <group group_id="O3">
            <title>Belatacept MI</title>
            <description>Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 milligrams/kilogram (mg/kg) every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Antihyperlipidemic Medication by Intensity Level</title>
          <description>An intensity level was associated with the dose level of the statin based anti-hyperlipidemic agent. Any other agent (i.e., non-statin therapy) used as an antihyperlipidemic were considered Level I treatment intensity. Multiple daily dose levels during a period were averaged to compute the daily dose during that period. Level I = 20 mg fluvastatin (flu), 10 mg lovastatin (lova), 10 mg pravastatin (prav), 5-10 mg simvastatin (sim); Level II = 10 mg atorvastatin (atorv), 40 mg flu, 20 mg lova, 20 mg prav, 5 mg rosuvastatin (rosu), 20 mg sim, 10/10 vytorin; Level III = 20 mg atorv, 80 mg flu, 40 mg lova, 40 mg prav, 10 mg rosu, 40 mg sim, 10/20 vytorin; Level IV = 40 mg atorv, 80 mg lova, 80 mg prav, 20 mg rosu, 80 mg sim, 10/40 vytorin; Level V = 80 mg atorv, 40 mg rosu, 10/80 vytorin. Concomitant use of a statin and an agent of another class elevated the intensity level of the statin therapy by 1 level; therefore, an intensity level of greater than V was possible.</description>
          <population>All randomized and transplanted participants that received at least one hyperlipidemic medication; Completer analysis is based on all participants who have been followed up at least 1092 days after transplantation.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="92"/>
                <count group_id="O3" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Intensity Level I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intensity Level II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intensity Level III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intensity Level IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intensity Level V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intensity Level VI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants Using At Least One Anti-Hyperlipidemic Medication</title>
        <description>This analysis is based on all participants who were followed up at least 1092 days after transplantation.</description>
        <time_frame>Month 36</time_frame>
        <population>All randomized and transplanted participants, intent-to-treat (ITT) population; Completer analysis is based on all participants who have been followed up at least 1092 days after transplantation.</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA): tablet, oral
1st month target: 150-300 nanogram/meter (ng/m) After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)</description>
          </group>
          <group group_id="O2">
            <title>Belatacept LI</title>
            <description>Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
          <group group_id="O3">
            <title>Belatacept MI</title>
            <description>Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 milligrams/kilogram (mg/kg) every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Using At Least One Anti-Hyperlipidemic Medication</title>
          <description>This analysis is based on all participants who were followed up at least 1092 days after transplantation.</description>
          <population>All randomized and transplanted participants, intent-to-treat (ITT) population; Completer analysis is based on all participants who have been followed up at least 1092 days after transplantation.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="182"/>
                <count group_id="O2" value="199"/>
                <count group_id="O3" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.6" lower_limit="49.4" upper_limit="63.8"/>
                    <measurement group_id="O2" value="46.2" lower_limit="39.3" upper_limit="53.2"/>
                    <measurement group_id="O3" value="47.9" lower_limit="40.9" upper_limit="55.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percent</param_type>
            <param_value>-10.4</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.4</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percent</param_type>
            <param_value>-8.7</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.9</ci_lower_limit>
            <ci_upper_limit>2.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Value of Lipid Parameters</title>
        <description>Lipid parameters included total cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol, non-HDL cholesterol, and triglycerides (TGs).</description>
        <time_frame>Months 12, 24, 36</time_frame>
        <population>All randomized and transplanted participants, intent-to-treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA): tablet, oral
1st month target: 150-300 nanogram/meter (ng/m) After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)</description>
          </group>
          <group group_id="O2">
            <title>Belatacept LI</title>
            <description>Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
          <group group_id="O3">
            <title>Belatacept MI</title>
            <description>Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Value of Lipid Parameters</title>
          <description>Lipid parameters included total cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol, non-HDL cholesterol, and triglycerides (TGs).</description>
          <population>All randomized and transplanted participants, intent-to-treat (ITT) population</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="189"/>
                <count group_id="O2" value="195"/>
                <count group_id="O3" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>non-HDL Cholesterol; Month 12 (n=189, 195, 192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144.1" spread="47.31"/>
                    <measurement group_id="O2" value="131.5" spread="38.18"/>
                    <measurement group_id="O3" value="131.7" spread="36.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Cholesterol; Month 12 (n=189, 195, 192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="191.5" spread="49.29"/>
                    <measurement group_id="O2" value="182.4" spread="39.78"/>
                    <measurement group_id="O3" value="181.3" spread="39.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL Cholesterol; Month 12 (n=189, 195, 192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.4" spread="13.33"/>
                    <measurement group_id="O2" value="50.8" spread="15.98"/>
                    <measurement group_id="O3" value="49.7" spread="15.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL Cholesterol; Month 12 (n=187, 186, 183)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.3" spread="39.60"/>
                    <measurement group_id="O2" value="102.1" spread="33.40"/>
                    <measurement group_id="O3" value="100.8" spread="29.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglyceride; Month 12 (n=187, 186, 183)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="184.6" spread="106.42"/>
                    <measurement group_id="O2" value="149.4" spread="87.25"/>
                    <measurement group_id="O3" value="155.0" spread="85.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>non-HDL Cholesterol; Month 24 (n=166, 190, 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145.1" spread="39.52"/>
                    <measurement group_id="O2" value="126.7" spread="38.48"/>
                    <measurement group_id="O3" value="127.0" spread="36.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Cholesterol; Month 24 (n=166, 190, 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="193.5" spread="40.23"/>
                    <measurement group_id="O2" value="175.3" spread="42.38"/>
                    <measurement group_id="O3" value="175.4" spread="40.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL ; Month 24 (n=166, 190, 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.4" spread="13.74"/>
                    <measurement group_id="O2" value="48.6" spread="15.28"/>
                    <measurement group_id="O3" value="48.5" spread="14.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL Cholesterol; Month 24 (n=164, 186, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.1" spread="35.92"/>
                    <measurement group_id="O2" value="98.6" spread="33.71"/>
                    <measurement group_id="O3" value="96.5" spread="30.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglyceride; Month 24 (n=164, 186, 168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179.5" spread="97.51"/>
                    <measurement group_id="O2" value="143.4" spread="88.97"/>
                    <measurement group_id="O3" value="151.2" spread="95.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>non-HDL Cholesterol; Month 36 (n=154, 184, 176)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142.2" spread="43.19"/>
                    <measurement group_id="O2" value="122.4" spread="40.12"/>
                    <measurement group_id="O3" value="122.1" spread="38.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Cholesterol; Month 36 (n=154, 184, 176)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190.7" spread="45.28"/>
                    <measurement group_id="O2" value="171.3" spread="45.78"/>
                    <measurement group_id="O3" value="170.7" spread="43.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL Cholesterol; Month 36 (n=154, 184, 176)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.5" spread="14.27"/>
                    <measurement group_id="O2" value="48.9" spread="15.37"/>
                    <measurement group_id="O3" value="48.6" spread="16.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL Cholesterol; Month 36 (n=142, 170, 161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.6" spread="37.66"/>
                    <measurement group_id="O2" value="96.7" spread="36.53"/>
                    <measurement group_id="O3" value="92.5" spread="33.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglyceride; Month 36 (n=142, 170, 161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179.1" spread="97.07"/>
                    <measurement group_id="O2" value="132.7" spread="68.69"/>
                    <measurement group_id="O3" value="144.0" spread="81.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With Prevalence of Acute Rejection (AR) by Month 36</title>
        <description>Prevalence of AR = participants with the stated definition of AR at any given time. AR defined as a clinico-pathological event requiring clinical evidence and renal biopsy confirmation demonstrating a Banff 97 classification of Grade IA or greater, with higher scores indicating more severe rejection. Only the episode with the highest Banff grade for each participant was counted. Clinical evidence = if either a or b was satisfied: a: an unexplained rise of serum creatinine ≥ 25% from baseline creatinine; b: an unexplained decreased urine output; or fever and graft tenderness; or a serum creatinine that remains elevated within 14 days post-transplantation and clinical suspicion of acute rejection exists. Allograft biopsies were evaluated by a blinded central independent pathologist using Banff 97 working classification of kidney transplant pathology. Banff 97 diagnostic category for renal allograft biopsies is an international standardized histopathological classification.</description>
        <time_frame>Randomization to Month 36</time_frame>
        <population>All randomized and transplanted participants, intent to treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA): tablet, oral
1st month target: 150-300 nanogram/meter (ng/m) After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)</description>
          </group>
          <group group_id="O2">
            <title>Belatacept LI</title>
            <description>Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
          <group group_id="O3">
            <title>Belatacept MI</title>
            <description>Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 milligrams/kilogram (mg/kg) every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Prevalence of Acute Rejection (AR) by Month 36</title>
          <description>Prevalence of AR = participants with the stated definition of AR at any given time. AR defined as a clinico-pathological event requiring clinical evidence and renal biopsy confirmation demonstrating a Banff 97 classification of Grade IA or greater, with higher scores indicating more severe rejection. Only the episode with the highest Banff grade for each participant was counted. Clinical evidence = if either a or b was satisfied: a: an unexplained rise of serum creatinine ≥ 25% from baseline creatinine; b: an unexplained decreased urine output; or fever and graft tenderness; or a serum creatinine that remains elevated within 14 days post-transplantation and clinical suspicion of acute rejection exists. Allograft biopsies were evaluated by a blinded central independent pathologist using Banff 97 working classification of kidney transplant pathology. Banff 97 diagnostic category for renal allograft biopsies is an international standardized histopathological classification.</description>
          <population>All randomized and transplanted participants, intent to treat (ITT) population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="221"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6 (n=221, 226, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" lower_limit="2.4" upper_limit="8.4"/>
                    <measurement group_id="O2" value="16.8" lower_limit="11.9" upper_limit="21.7"/>
                    <measurement group_id="O3" value="21.9" lower_limit="16.4" upper_limit="27.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (n=221, 226, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" lower_limit="5.3" upper_limit="12.8"/>
                    <measurement group_id="O2" value="17.3" lower_limit="12.3" upper_limit="22.2"/>
                    <measurement group_id="O3" value="24.2" lower_limit="18.5" upper_limit="29.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36 (n=221, 226, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" lower_limit="5.6" upper_limit="13.4"/>
                    <measurement group_id="O2" value="17.3" lower_limit="12.3" upper_limit="22.2"/>
                    <measurement group_id="O3" value="24.2" lower_limit="18.5" upper_limit="29.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Month 6</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A 20% margin for non-inferiority was used and provides 99% power to ascertain that the upper bound of the 97.3% 2-sided confidence intervals for the absolute difference between each belatacept regimen and cyclosporine, assuming the true acute rejection rate by 12 months is 15% for all three regimens</non_inferiority_desc>
            <param_type>Difference in Percent</param_type>
            <param_value>11.4</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.0</ci_lower_limit>
            <ci_upper_limit>18.2</ci_upper_limit>
            <estimate_desc>For 97.3% CI of difference, normal approximation is used if N&gt;=5 in both arms. Otherwise exact method is used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Month 6</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A 20% margin for non-inferiority was used and provides 99% power to ascertain that the upper bound of the 97.3% 2-sided confidence intervals for the absolute difference between each belatacept regimen and cyclosporine, assuming the true acute rejection rate by 12 months is 15% for all three regimens</non_inferiority_desc>
            <param_type>Difference in Percent</param_type>
            <param_value>16.5</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.6</ci_lower_limit>
            <ci_upper_limit>23.8</ci_upper_limit>
            <estimate_desc>For 97.3% CI of difference, normal approximation is used if N&gt;=5 in both arms. Otherwise exact method is used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Month 24</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A 20% margin for non-inferiority was used and provides 99% power to ascertain that the upper bound of the 97.3% 2-sided confidence intervals for the absolute difference between each belatacept regimen and cyclosporine, assuming the true acute rejection rate by 12 months is 15% for all three regimens.</non_inferiority_desc>
            <param_type>Difference in Percent</param_type>
            <param_value>8.2</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.2</ci_lower_limit>
            <ci_upper_limit>15.4</ci_upper_limit>
            <estimate_desc>For 97.3% CI of difference, normal approximation is used if N&gt;=5 in both arms. Otherwise exact method is used</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Month 24</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A 20% margin for non-inferiority was used and provides 99% power to ascertain that the upper bound of the 97.3% 2-sided confidence intervals for the absolute difference between each belatacept regimen and cyclosporine, assuming the true acute rejection rate by 12 months is 15% for all three regimens.</non_inferiority_desc>
            <param_type>Difference in Percent</param_type>
            <param_value>15.2</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.5</ci_lower_limit>
            <ci_upper_limit>23.0</ci_upper_limit>
            <estimate_desc>For 97.3% CI of difference, normal approximation is used if N&gt;=5 in both arms. Otherwise exact method is used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Month 36</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A 20% margin for non-inferiority was used and provides 99% power to ascertain that the upper bound of the 97.3% 2-sided confidence intervals for the absolute difference between each belatacept regimen and cyclosporine, assuming the true acute rejection rate by 12 months is 15% for all three regimens.</non_inferiority_desc>
            <param_type>Difference in Percent</param_type>
            <param_value>7.8</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6</ci_lower_limit>
            <ci_upper_limit>15.0</ci_upper_limit>
            <estimate_desc>For 97.3% CI of difference, normal approximation is used if N&gt;=5 in both arms. Otherwise exact method is used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Month 36</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A 20% margin for non-inferiority was used and provides 99% power to ascertain that the upper bound of the 97.3% 2-sided confidence intervals for the absolute difference between each belatacept regimen and cyclosporine, assuming the true acute rejection rate by 12 months is 15% for all three regimens.</non_inferiority_desc>
            <param_type>Difference in Percent</param_type>
            <param_value>14.7</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.0</ci_lower_limit>
            <ci_upper_limit>22.6</ci_upper_limit>
            <estimate_desc>For 97.3% CI of difference, normal approximation is used if N&gt;=5 in both arms. Otherwise exact method is used.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Acute Rejection (AR) Post-transplant in Terms of Severity Using Banff Grades by Month 36</title>
        <description>Acute rejection was defined as a clinico-pathological event requiring clinical evidence and renal biopsy confirmation demonstrating a Banff 97 classification of Grade IA or greater, with higher scores indicating more severe rejection. Clinical evidence defined: if either a or b was satisfied: a) an unexplained rise of serum creatinine ≥ 25% from baseline creatinine; b) an unexplained decreased urine output; or fever and graft tenderness; or a serum creatinine that remains elevated within 14 days post-transplantation and clinical suspicion of acute rejection exists. Allograft biopsies were evaluated by a blinded central independent pathologist using Banff 97 working classification of kidney transplant pathology. Banff 97 diagnostic category for renal allograft biopsies is an international standardized histopathological classification. Only the episode with the highest Banff grade for each participant was counted.</description>
        <time_frame>Randomization to Month 36</time_frame>
        <population>All randomized and transplanted participants, intent to treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA): tablet, oral
1st month target: 150-300 nanogram/meter (ng/m) After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)</description>
          </group>
          <group group_id="O2">
            <title>Belatacept LI</title>
            <description>Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
          <group group_id="O3">
            <title>Belatacept MI</title>
            <description>Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Acute Rejection (AR) Post-transplant in Terms of Severity Using Banff Grades by Month 36</title>
          <description>Acute rejection was defined as a clinico-pathological event requiring clinical evidence and renal biopsy confirmation demonstrating a Banff 97 classification of Grade IA or greater, with higher scores indicating more severe rejection. Clinical evidence defined: if either a or b was satisfied: a) an unexplained rise of serum creatinine ≥ 25% from baseline creatinine; b) an unexplained decreased urine output; or fever and graft tenderness; or a serum creatinine that remains elevated within 14 days post-transplantation and clinical suspicion of acute rejection exists. Allograft biopsies were evaluated by a blinded central independent pathologist using Banff 97 working classification of kidney transplant pathology. Banff 97 diagnostic category for renal allograft biopsies is an international standardized histopathological classification. Only the episode with the highest Banff grade for each participant was counted.</description>
          <population>All randomized and transplanted participants, intent to treat (ITT) population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="221"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mild Acute (IA); Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild Acute (IB); Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate Acute (IIA); Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate Acute (IIB); Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Acute (III); Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild Acute (IA); Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild Acute (IB); Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate Acute (IIA); Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate Acute (IIB); Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Acute (III); Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild Acute (IA); Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild Acute (IB); Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate Acute (IIA); Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate Acute (IIB); Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Acute (III); Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild Acute (IA); Month 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild Acute (IB); Month 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate Acute (IIA); Month 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate Acute (IIB); Month 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Acute (III); Month 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants Using Polyclonal Antilymphocyte Preparations for Impaired Renal Function and Anticipated Delayed Graft Function by Month 12</title>
        <description>A participant was considered to have delayed graft function (DGF), if treated with dialysis within the first week (Day 1 - 8) after transplantation. The use of polyclonal antilymphocyte preparations (LDT) was permitted only for participants randomized to cyclosporine (CsA) who experienced impaired renal allograft function and anticipated DGF following transplantation and were not permitted in belatacept-treated participants, except for the treatment of acute rejection. Participants treated with LDT began CsA at the discretion of the investigator by Day 7. LDT could also have been used in participants who met &gt;= 1 of the following criteria, observed in the presence of a transplant artery and vein and no evidence of hydronephrosis by sonogram: Urine output &lt; 250 mL/12 hours, no significant improvement (&lt; 1 milligram per deciliter (mg/dL)) in serum creatinine from baseline value over the first 24 - 72 hours post-transplant, or dialysis treatment.</description>
        <time_frame>Randomization to Month 12</time_frame>
        <population>All randomized and transplanted participants, intent to treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA): tablet, oral
1st month target: 150-300 nanogram/meter (ng/m) After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)</description>
          </group>
          <group group_id="O2">
            <title>Belatacept LI</title>
            <description>Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
          <group group_id="O3">
            <title>Belatacept MI</title>
            <description>Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 milligrams/kilogram (mg/kg) every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Using Polyclonal Antilymphocyte Preparations for Impaired Renal Function and Anticipated Delayed Graft Function by Month 12</title>
          <description>A participant was considered to have delayed graft function (DGF), if treated with dialysis within the first week (Day 1 - 8) after transplantation. The use of polyclonal antilymphocyte preparations (LDT) was permitted only for participants randomized to cyclosporine (CsA) who experienced impaired renal allograft function and anticipated DGF following transplantation and were not permitted in belatacept-treated participants, except for the treatment of acute rejection. Participants treated with LDT began CsA at the discretion of the investigator by Day 7. LDT could also have been used in participants who met &gt;= 1 of the following criteria, observed in the presence of a transplant artery and vein and no evidence of hydronephrosis by sonogram: Urine output &lt; 250 mL/12 hours, no significant improvement (&lt; 1 milligram per deciliter (mg/dL)) in serum creatinine from baseline value over the first 24 - 72 hours post-transplant, or dialysis treatment.</description>
          <population>All randomized and transplanted participants, intent to treat (ITT) population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="221"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" lower_limit="1.2" upper_limit="6.1"/>
                    <measurement group_id="O2" value="0.4" lower_limit="0.0" upper_limit="2.4"/>
                    <measurement group_id="O3" value="0.5" lower_limit="0.0" upper_limit="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percent</param_type>
            <param_value>-3.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.6</ci_lower_limit>
            <ci_upper_limit>-0.6</ci_upper_limit>
            <estimate_desc>For 95% CI of difference, normal approximation is used if N&gt;=5 in both arms. Otherwise exact method is used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percent</param_type>
            <param_value>-3.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.6</ci_lower_limit>
            <ci_upper_limit>-0.6</ci_upper_limit>
            <estimate_desc>For 95% CI of difference, normal approximation is used if N&gt;=5 in both arms. Otherwise exact method is used.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants Using Lymphocyte Depleting Therapy (LDT) for the Initial Treatment of Acute Rejection (AR) by Month 36</title>
        <description>The use of LDT (thymoglobulin or antithymocyte gamma globulin [ATGAM]) was permitted only for participants randomized to cyclosporine (CsA) who experienced impaired renal allograft function and anticipated delayed graft function following transplantation. Acute rejection (AR) defined as a clinico-pathological event requiring clinical evidence (an unexplained rise of serum creatinine ≥ 25% from baseline creatinine or an unexplained decreased urine output; or fever and graft tenderness; or a serum creatinine that remained elevated within 14 days post-transplantation and clinical suspicion of acute rejection existed) and biopsy confirmation. AR defined by a renal biopsy demonstrating a Banff 97 classification of Grade IA or greater, with higher scores indicating more severe rejection. Banff 97 diagnostic category for renal allograft biopsies is an international standardized histopathological classification. Only the episode with the highest Banff grade for each participant was counted.</description>
        <time_frame>Randomization to Month 36</time_frame>
        <population>All randomized and transplanted participants, intent to treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA): tablet, oral
1st month target: 150-300 nanogram/meter (ng/m) After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)</description>
          </group>
          <group group_id="O2">
            <title>Belatacept LI</title>
            <description>Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
          <group group_id="O3">
            <title>Belatacept MI</title>
            <description>Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 milligrams/kilogram (mg/kg) every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Using Lymphocyte Depleting Therapy (LDT) for the Initial Treatment of Acute Rejection (AR) by Month 36</title>
          <description>The use of LDT (thymoglobulin or antithymocyte gamma globulin [ATGAM]) was permitted only for participants randomized to cyclosporine (CsA) who experienced impaired renal allograft function and anticipated delayed graft function following transplantation. Acute rejection (AR) defined as a clinico-pathological event requiring clinical evidence (an unexplained rise of serum creatinine ≥ 25% from baseline creatinine or an unexplained decreased urine output; or fever and graft tenderness; or a serum creatinine that remained elevated within 14 days post-transplantation and clinical suspicion of acute rejection existed) and biopsy confirmation. AR defined by a renal biopsy demonstrating a Banff 97 classification of Grade IA or greater, with higher scores indicating more severe rejection. Banff 97 diagnostic category for renal allograft biopsies is an international standardized histopathological classification. Only the episode with the highest Banff grade for each participant was counted.</description>
          <population>All randomized and transplanted participants, intent to treat (ITT) population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="221"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="4.4"/>
                    <measurement group_id="O3" value="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9"/>
                    <measurement group_id="O2" value="4.4"/>
                    <measurement group_id="O3" value="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="4.4"/>
                    <measurement group_id="O3" value="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                    <measurement group_id="O2" value="4.4"/>
                    <measurement group_id="O3" value="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With Corticosteroid Resistant Acute Rejection (AR) by Month 36</title>
        <description>Steroid-resistant acute rejection (AR) defined as the use of lymphocyte-depletion therapy following treatment with corticosteroids. AR defined as a clinico-pathological event requiring clinical evidence and renal biopsy confirmation demonstrating a Banff 97 classification of Grade IA or greater, with higher scores indicating more severe rejection. Clinical evidence defined: either a or b was satisfied: a) an unexplained rise of serum creatinine ≥ 25% from baseline creatinine; b) an unexplained decreased urine output; or fever and graft tenderness; or a serum creatinine that remained elevated within 14 days post-transplantation and clinical suspicion of acute rejection existed. Allograft biopsies were evaluated by a blinded central independent pathologist using Banff 97 international standardized histopathological working classification of kidney transplant pathology. Only the episode with the highest Banff grade for each participant was counted.</description>
        <time_frame>Randomization to Month 36</time_frame>
        <population>All randomized and transplanted participants, intent to treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA): tablet, oral
1st month target: 150-300 nanogram/meter (ng/m) After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)</description>
          </group>
          <group group_id="O2">
            <title>Belatacept LI</title>
            <description>Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
          <group group_id="O3">
            <title>Belatacept MI</title>
            <description>Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 milligrams/kilogram (mg/kg) every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Corticosteroid Resistant Acute Rejection (AR) by Month 36</title>
          <description>Steroid-resistant acute rejection (AR) defined as the use of lymphocyte-depletion therapy following treatment with corticosteroids. AR defined as a clinico-pathological event requiring clinical evidence and renal biopsy confirmation demonstrating a Banff 97 classification of Grade IA or greater, with higher scores indicating more severe rejection. Clinical evidence defined: either a or b was satisfied: a) an unexplained rise of serum creatinine ≥ 25% from baseline creatinine; b) an unexplained decreased urine output; or fever and graft tenderness; or a serum creatinine that remained elevated within 14 days post-transplantation and clinical suspicion of acute rejection existed. Allograft biopsies were evaluated by a blinded central independent pathologist using Banff 97 international standardized histopathological working classification of kidney transplant pathology. Only the episode with the highest Banff grade for each participant was counted.</description>
          <population>All randomized and transplanted participants, intent to treat (ITT) population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="221"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="4.0"/>
                    <measurement group_id="O3" value="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="5.3"/>
                    <measurement group_id="O3" value="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="5.3"/>
                    <measurement group_id="O3" value="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="5.3"/>
                    <measurement group_id="O3" value="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Recovered Completely From an Episode of Acute Rejection (AR) by Month 12</title>
        <description>Acute rejection (AR) = a clinico-pathological event requiring clinical evidence and renal biopsy confirmation demonstrating a Banff 97 classification of Grade IA or greater. Clinical evidence = if either a or b was satisfied: a: an unexplained rise of serum creatinine ≥ 25% from baseline creatinine; b: an unexplained decreased urine output; or fever and graft tenderness; or a serum creatinine that remains elevated within 14 days post-transplantation and clinical suspicion of acute rejection exists. Complete recovery following AR defined as serum creatinine [SCr] levels returned to baseline. Recovery calculated using 2 algorithms: Algorithm 1 = last laboratory measurement prior to onset of AR (baseline and first laboratory measurement after 84 days since onset of AR = resolution); Algorithm 2 = lowest laboratory measurement on or after transplantation and prior to onset day of AR (baseline and lowest laboratory measurement after onset on first AR up to Month 12 = resolution)</description>
        <time_frame>Randomization to Month 12</time_frame>
        <population>All randomized, transplanted, and treated participants; intent to treat (ITT) population with at least one episode of AR up to Month 12</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA): tablet, oral
1st month target: 150-300 nanogram/meter (ng/m) After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)</description>
          </group>
          <group group_id="O2">
            <title>Belatacept LI</title>
            <description>Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
          <group group_id="O3">
            <title>Belatacept MI</title>
            <description>Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 milligrams/kilogram (mg/kg) every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Recovered Completely From an Episode of Acute Rejection (AR) by Month 12</title>
          <description>Acute rejection (AR) = a clinico-pathological event requiring clinical evidence and renal biopsy confirmation demonstrating a Banff 97 classification of Grade IA or greater. Clinical evidence = if either a or b was satisfied: a: an unexplained rise of serum creatinine ≥ 25% from baseline creatinine; b: an unexplained decreased urine output; or fever and graft tenderness; or a serum creatinine that remains elevated within 14 days post-transplantation and clinical suspicion of acute rejection exists. Complete recovery following AR defined as serum creatinine [SCr] levels returned to baseline. Recovery calculated using 2 algorithms: Algorithm 1 = last laboratory measurement prior to onset of AR (baseline and first laboratory measurement after 84 days since onset of AR = resolution); Algorithm 2 = lowest laboratory measurement on or after transplantation and prior to onset day of AR (baseline and lowest laboratory measurement after onset on first AR up to Month 12 = resolution)</description>
          <population>All randomized, transplanted, and treated participants; intent to treat (ITT) population with at least one episode of AR up to Month 12</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Algorithm 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Algorithm 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With Subclinical Rejection at Month 12</title>
        <description>Subclinical rejection defined as histological findings by the central pathologist consistent with acute rejection, but lacking its clinical correlate. Acute rejection defined as a clinico-pathological event requiring clinical evidence and renal biopsy confirmation demonstrating a Banff 97 classification of Grade IA or greater, with higher scores indicating more severe rejection. Only the episode with the highest Banff grade for each participant was counted. Clinical evidence defined if either a or b was satisfied: a) an unexplained rise of serum creatinine ≥ 25% from baseline creatinine; b) an unexplained decreased urine output; or fever and graft tenderness; or a serum creatinine that remained elevated within 14 days post-transplantation and clinical suspicion of acute rejection existed. Allograft biopsies were evaluated by a blinded central independent pathologist using Banff 97 working classification of kidney transplant pathology.</description>
        <time_frame>Month 12</time_frame>
        <population>All randomized, transplanted, and treated participants; intent to treat (ITT) population with measurable component</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA): tablet, oral
1st month target: 150-300 nanogram/meter (ng/m) After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)</description>
          </group>
          <group group_id="O2">
            <title>Belatacept LI</title>
            <description>Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
          <group group_id="O3">
            <title>Belatacept MI</title>
            <description>Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 milligrams/kilogram (mg/kg) every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Subclinical Rejection at Month 12</title>
          <description>Subclinical rejection defined as histological findings by the central pathologist consistent with acute rejection, but lacking its clinical correlate. Acute rejection defined as a clinico-pathological event requiring clinical evidence and renal biopsy confirmation demonstrating a Banff 97 classification of Grade IA or greater, with higher scores indicating more severe rejection. Only the episode with the highest Banff grade for each participant was counted. Clinical evidence defined if either a or b was satisfied: a) an unexplained rise of serum creatinine ≥ 25% from baseline creatinine; b) an unexplained decreased urine output; or fever and graft tenderness; or a serum creatinine that remained elevated within 14 days post-transplantation and clinical suspicion of acute rejection existed. Allograft biopsies were evaluated by a blinded central independent pathologist using Banff 97 working classification of kidney transplant pathology.</description>
          <population>All randomized, transplanted, and treated participants; intent to treat (ITT) population with measurable component</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="170"/>
                <count group_id="O3" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" lower_limit="1.7" upper_limit="8.6"/>
                    <measurement group_id="O2" value="4.7" lower_limit="1.5" upper_limit="7.9"/>
                    <measurement group_id="O3" value="4.3" lower_limit="1.2" upper_limit="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percent</param_type>
            <param_value>-0.5</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.5</ci_lower_limit>
            <ci_upper_limit>5.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percent</param_type>
            <param_value>-0.9</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.9</ci_lower_limit>
            <ci_upper_limit>4.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Treated for Acute Rejection (AR) Regardless of Histological Findings by Month 36</title>
        <description>Allograft rejection includes any episode of rejection including: clinically suspected rejection, treated rejection, any central biopsy-proven acute rejection (BPAR), and acute rejection (AR: a subset of BPAR) defined as central biopsy-proven rejection that was either clinically suspected by protocol-defined reasons or by other reasons and was treated. Acute rejection (AR) defined as a clinico-pathological event requiring clinical evidence ( either an unexplained rise of serum creatinine ≥ 25% from baseline creatinine or an unexplained decreased urine output; or fever and graft tenderness; or a serum creatinine that remained elevated within 14 days post-transplantation and clinical suspicion of AR) and renal biopsy confirmation biopsy demonstrating a Banff 97 working classification of kidney transplant pathology classification of Grade IA or greater, with higher scores indicating more severe rejection. Only the highest Banff grade for each participant was counted.</description>
        <time_frame>Randomization to Month 36</time_frame>
        <population>All randomized and transplanted participants, intent to treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA): tablet, oral
1st month target: 150-300 nanogram/meter (ng/m) After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)</description>
          </group>
          <group group_id="O2">
            <title>Belatacept LI</title>
            <description>Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
          <group group_id="O3">
            <title>Belatacept MI</title>
            <description>Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 milligrams/kilogram (mg/kg) every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Treated for Acute Rejection (AR) Regardless of Histological Findings by Month 36</title>
          <description>Allograft rejection includes any episode of rejection including: clinically suspected rejection, treated rejection, any central biopsy-proven acute rejection (BPAR), and acute rejection (AR: a subset of BPAR) defined as central biopsy-proven rejection that was either clinically suspected by protocol-defined reasons or by other reasons and was treated. Acute rejection (AR) defined as a clinico-pathological event requiring clinical evidence ( either an unexplained rise of serum creatinine ≥ 25% from baseline creatinine or an unexplained decreased urine output; or fever and graft tenderness; or a serum creatinine that remained elevated within 14 days post-transplantation and clinical suspicion of AR) and renal biopsy confirmation biopsy demonstrating a Banff 97 working classification of kidney transplant pathology classification of Grade IA or greater, with higher scores indicating more severe rejection. Only the highest Banff grade for each participant was counted.</description>
          <population>All randomized and transplanted participants, intent to treat (ITT) population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="221"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="68"/>
                    <measurement group_id="O3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="72"/>
                    <measurement group_id="O3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="74"/>
                    <measurement group_id="O3" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="76"/>
                    <measurement group_id="O3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Value of Physical and Mental Components Using SF-36 Questionnaire</title>
        <description>SF-36 was a Participant-Reported Quality of Life (QoL) Short Form (SF) questionnaire measuring health-related quality of life (HRQL) covering 2 scale measures: physical component summary (PCS) and mental component summary (MCS). PCS represented by 4 domains: physical function, role limitations due to physical problems, pain, and general health perception. MCS represented by 4 domains: vitality, social function, role limitations due to emotional problems, and mental health. Their scores were computed based on weighted combinations of the 8 domain scores, which were transformed to a range from 0 to 100; 0= worst HRQL, 100=best HRQL. Higher scores reflect better health-related functional status. Scoring is standardized using the norm-based scoring method where data is scored in relation to the U.S. general population having a mean of 50 and a standard deviation of 10. Scores below 50 are below the U.S. general population norm and above 50 are above the U.S. general population norm.</description>
        <time_frame>Months 6, 12, 24, 36</time_frame>
        <population>All randomized and transplanted participants, intent to treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA): tablet, oral
1st month target: 150-300 nanogram/meter (ng/m) After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)</description>
          </group>
          <group group_id="O2">
            <title>Belatacept LI</title>
            <description>Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
          <group group_id="O3">
            <title>Belatacept MI</title>
            <description>Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 milligrams/kilogram (mg/kg) every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Value of Physical and Mental Components Using SF-36 Questionnaire</title>
          <description>SF-36 was a Participant-Reported Quality of Life (QoL) Short Form (SF) questionnaire measuring health-related quality of life (HRQL) covering 2 scale measures: physical component summary (PCS) and mental component summary (MCS). PCS represented by 4 domains: physical function, role limitations due to physical problems, pain, and general health perception. MCS represented by 4 domains: vitality, social function, role limitations due to emotional problems, and mental health. Their scores were computed based on weighted combinations of the 8 domain scores, which were transformed to a range from 0 to 100; 0= worst HRQL, 100=best HRQL. Higher scores reflect better health-related functional status. Scoring is standardized using the norm-based scoring method where data is scored in relation to the U.S. general population having a mean of 50 and a standard deviation of 10. Scores below 50 are below the U.S. general population norm and above 50 are above the U.S. general population norm.</description>
          <population>All randomized and transplanted participants, intent to treat (ITT) population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="203"/>
                <count group_id="O2" value="218"/>
                <count group_id="O3" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mental Component Score; Month 6 (n=191, 205, 189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.4" spread="11.08"/>
                    <measurement group_id="O2" value="49.9" spread="10.55"/>
                    <measurement group_id="O3" value="51.1" spread="10.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Score; Month 6 (n=191,205,189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.3" spread="8.91"/>
                    <measurement group_id="O2" value="48.9" spread="8.59"/>
                    <measurement group_id="O3" value="49.2" spread="7.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Score; Month 12 (n=198,210,194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.5" spread="10.78"/>
                    <measurement group_id="O2" value="50.3" spread="10.08"/>
                    <measurement group_id="O3" value="49.9" spread="10.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Score; Month 12 (n=198,210,194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.5" spread="9.34"/>
                    <measurement group_id="O2" value="49.6" spread="8.18"/>
                    <measurement group_id="O3" value="50.3" spread="8.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Score; Month 24 (n=200,214,198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.3" spread="11.14"/>
                    <measurement group_id="O2" value="49.6" spread="10.77"/>
                    <measurement group_id="O3" value="48.8" spread="11.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Score; Month 24 (n=200,214,198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.3" spread="9.50"/>
                    <measurement group_id="O2" value="49.0" spread="8.77"/>
                    <measurement group_id="O3" value="49.9" spread="8.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Score; Month 36 (n=203,218,201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.9" spread="11.60"/>
                    <measurement group_id="O2" value="48.7" spread="11.26"/>
                    <measurement group_id="O3" value="48.3" spread="11.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Score; Month 36 (n=203,218,201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.1" spread="9.47"/>
                    <measurement group_id="O2" value="49.2" spread="9.15"/>
                    <measurement group_id="O3" value="48.7" spread="8.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mental Component Score; Month 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6573</p_value>
            <p_value_desc>Baseline observations were not used for imputations at subsequent time points.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA model: Component Score = treatment. Missing values were imputed using last observation carried forward (LOCF) method.</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>2.6</ci_upper_limit>
            <estimate_desc>Statistical tests comparing each belatacept regimen to the CsA regimen were conducted at a significance level of 0.05. Subjects with only baseline observations were excluded from these summaries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Mental Component Score; Month 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1198</p_value>
            <p_value_desc>Baseline observations were not used for imputations at subsequent time points.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA model: Component Score = treatment. Missing values were imputed using last observation carried forward (LOCF) method.</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>3.9</ci_upper_limit>
            <estimate_desc>Statistical tests comparing each belatacept regimen to the CsA regimen were conducted at a significance level of 0.05. Subjects with only baseline observations were excluded from these summaries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Physical Component Score; Month 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0672</p_value>
            <p_value_desc>Baseline observations were not used for imputations at subsequent time points.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA model: Component Score = treatment. Missing values were imputed using last observation carried forward (LOCF) method.</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1</ci_lower_limit>
            <ci_upper_limit>3.2</ci_upper_limit>
            <estimate_desc>Statistical tests comparing each belatacept regimen to the CsA regimen were conducted at a significance level of 0.05. Subjects with only baseline observations were excluded from these summaries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Physical Component Score; Month 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0257</p_value>
            <p_value_desc>Baseline observations were not used for imputations at subsequent time points.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA model: Component Score = treatment. Missing values were imputed using last observation carried forward (LOCF) method.</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.2</ci_lower_limit>
            <ci_upper_limit>3.6</ci_upper_limit>
            <estimate_desc>Statistical tests comparing each belatacept regimen to the CsA regimen were conducted at a significance level of 0.05. Subjects with only baseline observations were excluded from these summaries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mental Component Score; Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4146</p_value>
            <p_value_desc>Baseline observations were not used for imputations at subsequent time points.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA model: Component Score = treatment. Missing values were imputed using last observation carried forward (LOCF) method.</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.2</ci_lower_limit>
            <ci_upper_limit>2.9</ci_upper_limit>
            <estimate_desc>Statistical tests comparing each belatacept regimen to the CsA regimen were conducted at a significance level of 0.05. Subjects with only baseline observations were excluded from these summaries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Mental Component Score; Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7327</p_value>
            <p_value_desc>Baseline observations were not used for imputations at subsequent time points.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA model: Component Score = treatment. Missing values were imputed using last observation carried forward (LOCF) method.</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>2.4</ci_upper_limit>
            <estimate_desc>Statistical tests comparing each belatacept regimen to the CsA regimen were conducted at a significance level of 0.05. Subjects with only baseline observations were excluded from these summaries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Physical Component Score; Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0144</p_value>
            <p_value_desc>Baseline observations were not used for imputations at subsequent time points.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA model: Component Score = treatment. Missing values were imputed using last observation carried forward (LOCF) method.</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>2.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.4</ci_lower_limit>
            <ci_upper_limit>3.8</ci_upper_limit>
            <estimate_desc>Statistical tests comparing each belatacept regimen to the CsA regimen were conducted at a significance level of 0.05. Subjects with only baseline observations were excluded from these summaries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Physical Component Score; Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0015</p_value>
            <p_value_desc>Baseline observations were not used for imputations at subsequent time points.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA model: Component Score = treatment. Missing values were imputed using last observation carried forward (LOCF) method.</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>2.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.1</ci_lower_limit>
            <ci_upper_limit>4.5</ci_upper_limit>
            <estimate_desc>Statistical tests comparing each belatacept regimen to the CsA regimen were conducted at a significance level of 0.05. Subjects with only baseline observations were excluded from these summaries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mental Component Score; Month 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2340</p_value>
            <p_value_desc>Baseline observations were not used for imputations at subsequent time points.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA model: Component Score = treatment. Missing values were imputed using last observation carried forward (LOCF) method.</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>3.4</ci_upper_limit>
            <estimate_desc>Statistical tests comparing each belatacept regimen to the CsA regimen were conducted at a significance level of 0.05. Subjects with only baseline observations were excluded from these summaries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Mental Component Score; Month 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6635</p_value>
            <p_value_desc>Baseline observations were not used for imputations at subsequent time points.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA model: Component Score = treatment. Missing values were imputed using last observation carried forward (LOCF) method.</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>2.6</ci_upper_limit>
            <estimate_desc>Statistical tests comparing each belatacept regimen to the CsA regimen were conducted at a significance level of 0.05. Subjects with only baseline observations were excluded from these summaries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Physical Component Score; Month 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0417</p_value>
            <p_value_desc>Baseline observations were not used for imputations at subsequent time points.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA model: Component Score = treatment. Missing values were imputed using last observation carried forward (LOCF) method.</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1</ci_lower_limit>
            <ci_upper_limit>3.5</ci_upper_limit>
            <estimate_desc>Statistical tests comparing each belatacept regimen to the CsA regimen were conducted at a significance level of 0.05. Subjects with only baseline observations were excluded from these summaries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Physical Component Score; Month 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0026</p_value>
            <p_value_desc>Baseline observations were not used for imputations at subsequent time points.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA model: Component Score = treatment. Missing values were imputed using last observation carried forward (LOCF) method.</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>2.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>4.4</ci_upper_limit>
            <estimate_desc>Statistical tests comparing each belatacept regimen to the CsA regimen were conducted at a significance level of 0.05. Subjects with only baseline observations were excluded from these summaries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mental Component Score; Month 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0953</p_value>
            <p_value_desc>Baseline observations were not used for imputations at subsequent time points.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA model: Component Score = treatment. Missing values were imputed using last observation carried forward (LOCF) method.</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>4.1</ci_upper_limit>
            <estimate_desc>Statistical tests comparing each belatacept regimen to the CsA regimen were conducted at a significance level of 0.05. Subjects with only baseline observations were excluded from these summaries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Mental Component Score; Month 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1961</p_value>
            <p_value_desc>Baseline observations were not used for imputations at subsequent time points.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA model: Component Score = treatment. Missing values were imputed using last observation carried forward (LOCF) method.</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>3.7</ci_upper_limit>
            <estimate_desc>Statistical tests comparing each belatacept regimen to the CsA regimen were conducted at a significance level of 0.05. Subjects with only baseline observations were excluded from these summaries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Physical Component Score; Month 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0191</p_value>
            <p_value_desc>Baseline observations were not used for imputations at subsequent time points.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA model: Component Score = treatment. Missing values were imputed using last observation carried forward (LOCF) method.</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>2.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.3</ci_lower_limit>
            <ci_upper_limit>3.9</ci_upper_limit>
            <estimate_desc>Statistical tests comparing each belatacept regimen to the CsA regimen were conducted at a significance level of 0.05. Subjects with only baseline observations were excluded from these summaries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Physical Component Score; Month 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0684</p_value>
            <p_value_desc>Baseline observations were not used for imputations at subsequent time points.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA model: Component Score = treatment. Missing values were imputed using last observation carried forward (LOCF) method.</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1</ci_lower_limit>
            <ci_upper_limit>3.5</ci_upper_limit>
            <estimate_desc>Statistical tests comparing each belatacept regimen to the CsA regimen were conducted at a significance level of 0.05. Subjects with only baseline observations were excluded from these summaries.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Value of the Eight Domain Scores of Quality of Life Using SF-36 Questionnaire</title>
        <description>SF-36 was a Participant-Reported Quality of Life (QoL) Short Form (SF) questionnaire measuring health-related quality of life (HRQL) covering 2 scale measures: physical component summary (PCS) and mental component summary (MCS). PCS represented by 4 domains: physical function, role limitations due to physical problems, pain, and general health perception. MCS represented by 4 domains: vitality, social function, role limitations due to emotional problems, and mental health. Their scores were computed based on weighted combinations of the 8 domain scores, which were transformed to a range from 0 to 100; 0= worst HRQL, 100=best HRQL. Higher scores reflect better health-related functional status. Scoring is standardized using the norm-based scoring method where data is scored in relation to the U.S. general population having a mean of 50 and a standard deviation of 10. Scores below 50 are below the U.S. general population norm and above 50 are above the U.S. general population norm.</description>
        <time_frame>Months 6, 12, 24, 36</time_frame>
        <population>All randomized and transplanted participants, intent to treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA): tablet, oral
1st month target: 150-300 nanogram/meter (ng/m) After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)</description>
          </group>
          <group group_id="O2">
            <title>Belatacept LI</title>
            <description>Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
          <group group_id="O3">
            <title>Belatacept MI</title>
            <description>Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 milligrams/kilogram (mg/kg) every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Value of the Eight Domain Scores of Quality of Life Using SF-36 Questionnaire</title>
          <description>SF-36 was a Participant-Reported Quality of Life (QoL) Short Form (SF) questionnaire measuring health-related quality of life (HRQL) covering 2 scale measures: physical component summary (PCS) and mental component summary (MCS). PCS represented by 4 domains: physical function, role limitations due to physical problems, pain, and general health perception. MCS represented by 4 domains: vitality, social function, role limitations due to emotional problems, and mental health. Their scores were computed based on weighted combinations of the 8 domain scores, which were transformed to a range from 0 to 100; 0= worst HRQL, 100=best HRQL. Higher scores reflect better health-related functional status. Scoring is standardized using the norm-based scoring method where data is scored in relation to the U.S. general population having a mean of 50 and a standard deviation of 10. Scores below 50 are below the U.S. general population norm and above 50 are above the U.S. general population norm.</description>
          <population>All randomized and transplanted participants, intent to treat (ITT) population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="219"/>
                <count group_id="O3" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bodily Pain, Month 6 (n=193, 207, 193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.6" spread="10.96"/>
                    <measurement group_id="O2" value="52.5" spread="10.10"/>
                    <measurement group_id="O3" value="52.7" spread="10.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Health, Month 6 (n=193, 207, 194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.9" spread="10.08"/>
                    <measurement group_id="O2" value="48.2" spread="9.67"/>
                    <measurement group_id="O3" value="49.0" spread="8.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health, Month 6 (n=192, 206, 194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.1" spread="11.08"/>
                    <measurement group_id="O2" value="50.3" spread="10.33"/>
                    <measurement group_id="O3" value="51.3" spread="10.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Functioning, Month 6 (n=193, 207, 194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.4" spread="9.13"/>
                    <measurement group_id="O2" value="48.3" spread="9.01"/>
                    <measurement group_id="O3" value="48.0" spread="8.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Emotional, Month 6 (n=192, 206, 191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.6" spread="12.31"/>
                    <measurement group_id="O2" value="46.0" spread="11.19"/>
                    <measurement group_id="O3" value="46.8" spread="10.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role-Physical, Month 6 (n=192, 207, 192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.2" spread="11.08"/>
                    <measurement group_id="O2" value="45.2" spread="10.34"/>
                    <measurement group_id="O3" value="46.7" spread="9.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Functioning, Month 6 (n=193, 207, 194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.5" spread="10.68"/>
                    <measurement group_id="O2" value="47.8" spread="10.41"/>
                    <measurement group_id="O3" value="47.9" spread="10.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality, Month 6 (n=192, 206, 194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.0" spread="10.27"/>
                    <measurement group_id="O2" value="55.5" spread="9.75"/>
                    <measurement group_id="O3" value="56.2" spread="9.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bodily Pain, Month 12 (n=200, 213, 199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.8" spread="10.79"/>
                    <measurement group_id="O2" value="52.7" spread="9.67"/>
                    <measurement group_id="O3" value="53.7" spread="9.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Health, Month 12 (n=200, 214, 199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.9" spread="9.98"/>
                    <measurement group_id="O2" value="48.8" spread="9.57"/>
                    <measurement group_id="O3" value="49.2" spread="8.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health, Month 12 (n=200, 213, 199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.8" spread="10.99"/>
                    <measurement group_id="O2" value="50.7" spread="10.64"/>
                    <measurement group_id="O3" value="50.3" spread="10.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Functioning, Month 12 (n=200, 214, 198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.2" spread="9.77"/>
                    <measurement group_id="O2" value="49.0" spread="8.88"/>
                    <measurement group_id="O3" value="48.1" spread="9.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Emotional, Month 12 (n=198, 213, 196)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.8" spread="11.36"/>
                    <measurement group_id="O2" value="46.8" spread="10.82"/>
                    <measurement group_id="O3" value="45.9" spread="11.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role-Physical, Month 12 (n=199, 213, 196)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.0" spread="10.78"/>
                    <measurement group_id="O2" value="47.1" spread="10.00"/>
                    <measurement group_id="O3" value="47.5" spread="9.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Functioning, Month 12 (n=200, 213, 199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.6" spread="10.26"/>
                    <measurement group_id="O2" value="48.4" spread="9.61"/>
                    <measurement group_id="O3" value="49.1" spread="9.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality, Month 12 (n=200, 213, 199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.3" spread="10.01"/>
                    <measurement group_id="O2" value="55.7" spread="9.81"/>
                    <measurement group_id="O3" value="56.0" spread="9.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bodily Pain, Month 24 (n=203, 219, 205)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.0" spread="10.82"/>
                    <measurement group_id="O2" value="51.4" spread="10.51"/>
                    <measurement group_id="O3" value="52.5" spread="10.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Health, Month 24 (n=203, 219, 205)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.2" spread="10.07"/>
                    <measurement group_id="O2" value="48.4" spread="9.61"/>
                    <measurement group_id="O3" value="48.7" spread="9.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health, Month 24 (n=201, 215, 199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.5" spread="11.13"/>
                    <measurement group_id="O2" value="49.7" spread="10.89"/>
                    <measurement group_id="O3" value="49.3" spread="10.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Functioning, Month 24 (n=203, 219, 205)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.5" spread="10.69"/>
                    <measurement group_id="O2" value="48.7" spread="9.76"/>
                    <measurement group_id="O3" value="48.0" spread="10.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Emotional, Month 24 (n=202, 218, 205)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.8" spread="12.54"/>
                    <measurement group_id="O2" value="46.4" spread="10.89"/>
                    <measurement group_id="O3" value="46.0" spread="10.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role-Physical, Month 24 (n=203, 219, 204)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.1" spread="11.61"/>
                    <measurement group_id="O2" value="46.6" spread="10.39"/>
                    <measurement group_id="O3" value="48.0" spread="9.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Functioning, Month 24 (n=203, 219, 205)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.3" spread="10.64"/>
                    <measurement group_id="O2" value="48.6" spread="10.28"/>
                    <measurement group_id="O3" value="47.7" spread="10.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality, Month 24 (n=201, 215, 200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.5" spread="10.58"/>
                    <measurement group_id="O2" value="54.5" spread="10.30"/>
                    <measurement group_id="O3" value="54.2" spread="10.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bodily Pain, Month 36 (n=204, 219, 205)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" spread="11.40"/>
                    <measurement group_id="O2" value="52.3" spread="10.40"/>
                    <measurement group_id="O3" value="51.0" spread="11.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Health, Month 36 (n=205, 219, 206)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.5" spread="10.12"/>
                    <measurement group_id="O2" value="47.7" spread="10.45"/>
                    <measurement group_id="O3" value="47.5" spread="9.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health, Month 36 (n=203, 219, 204)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.4" spread="11.64"/>
                    <measurement group_id="O2" value="48.9" spread="11.52"/>
                    <measurement group_id="O3" value="48.7" spread="11.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Functioning, Month 36 (n=204, 218, 206)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.8" spread="9.92"/>
                    <measurement group_id="O2" value="48.1" spread="10.22"/>
                    <measurement group_id="O3" value="47.8" spread="10.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Emotional, Month 36 (n=204, 219, 205)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.5" spread="12.18"/>
                    <measurement group_id="O2" value="46.0" spread="11.85"/>
                    <measurement group_id="O3" value="45.3" spread="11.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role-Physical, Month 36 (n=204, 219, 205)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.6" spread="10.73"/>
                    <measurement group_id="O2" value="46.3" spread="11.03"/>
                    <measurement group_id="O3" value="46.2" spread="10.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Functioning, Month 36 (n=204, 219, 206)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.6" spread="10.68"/>
                    <measurement group_id="O2" value="48.1" spread="10.28"/>
                    <measurement group_id="O3" value="47.1" spread="10.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality, Month 36 (n=203, 219, 204)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.4" spread="10.48"/>
                    <measurement group_id="O2" value="53.6" spread="11.38"/>
                    <measurement group_id="O3" value="53.4" spread="10.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Bodily Pain, Month 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0714</p_value>
            <method>ANOVA</method>
            <method_desc>Domain Score = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>3.9</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Bodily Pain, Month 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0536</p_value>
            <method>ANOVA</method>
            <method_desc>Domain score = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>2.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0</ci_lower_limit>
            <ci_upper_limit>4.1</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>General Health, Month 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7543</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>2.2</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>General Health, Month 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2499</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>3.0</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mental Health, Month 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8332</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.9</ci_lower_limit>
            <ci_upper_limit>2.3</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Mental Health, Month 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2523</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.9</ci_lower_limit>
            <ci_upper_limit>3.4</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Physical Functioning, Month 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3018</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>2.7</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Physical Functioning, Month 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5437</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.2</ci_lower_limit>
            <ci_upper_limit>2.3</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Role Emotional, Month 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2370</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.9</ci_lower_limit>
            <ci_upper_limit>3.6</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Role Emotional, Month 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0588</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>2.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1</ci_lower_limit>
            <ci_upper_limit>4.5</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Role Physical, Month 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0502</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>2.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0</ci_lower_limit>
            <ci_upper_limit>4.0</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Role-Physical, Month 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0007</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>3.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.5</ci_lower_limit>
            <ci_upper_limit>5.6</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Social Functioning, Month 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7637</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.8</ci_lower_limit>
            <ci_upper_limit>2.4</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Social Functioning, Month 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7006</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>2.5</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vitality, Month 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1222</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>3.4</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Vitality, Month 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0289</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>2.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.2</ci_lower_limit>
            <ci_upper_limit>4.1</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Bodily Pain, Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0571</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1</ci_lower_limit>
            <ci_upper_limit>3.8</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Bodily Pain, Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0042</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>2.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>4.9</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>General Health, Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0423</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1</ci_lower_limit>
            <ci_upper_limit>3.7</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>General Health, Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0174</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.4</ci_lower_limit>
            <ci_upper_limit>4.1</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mental Health, Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3630</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>3.0</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Mental Health, Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6319</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data were imputed by LOCF</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>2.6</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Physical Functioning, Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0503</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0</ci_lower_limit>
            <ci_upper_limit>3.7</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Physical Functioning, Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3291</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.9</ci_lower_limit>
            <ci_upper_limit>2.8</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Role Emotional, Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3860</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.2</ci_lower_limit>
            <ci_upper_limit>3.1</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Role Emotional, Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9672</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.2</ci_lower_limit>
            <ci_upper_limit>2.3</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Role-Physical, Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0392</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>2.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1</ci_lower_limit>
            <ci_upper_limit>4.1</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Role-Physical, Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0151</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>2.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5</ci_lower_limit>
            <ci_upper_limit>4.5</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Social Functioning, Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3978</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>2.7</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Social Functioning, Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1263</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>3.5</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vitality, Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0160</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.4</ci_lower_limit>
            <ci_upper_limit>4.2</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Vitality, Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0075</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>2.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7</ci_lower_limit>
            <ci_upper_limit>4.5</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Bodily Pain, Month 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6990</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>2.4</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Bodily Pain, Month 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1608</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>3.5</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>General Health, Month 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0214</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>2.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.3</ci_lower_limit>
            <ci_upper_limit>4.0</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>General Health, Month 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.00886</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>2.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6</ci_lower_limit>
            <ci_upper_limit>4.4</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mental Health, Month 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2555</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.9</ci_lower_limit>
            <ci_upper_limit>3.3</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Mental Health, Month 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4804</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.4</ci_lower_limit>
            <ci_upper_limit>2.9</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Physical Functioning, Month 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0276</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>2.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.2</ci_lower_limit>
            <ci_upper_limit>4.2</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Physical Functioning, Month 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1285</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>3.5</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Role Emotional, Month 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1352</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>3.9</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Role Emotional, Month 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2663</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>3.5</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Role-Physical, Month 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0164</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>2.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5</ci_lower_limit>
            <ci_upper_limit>4.5</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Role-Physical, Month 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>3.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.9</ci_lower_limit>
            <ci_upper_limit>5.9</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Social Functioning, Month 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1914</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>3.3</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Social Functioning, Month 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6882</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>2.4</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vitality, Month 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0547</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>2.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0</ci_lower_limit>
            <ci_upper_limit>4.0</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Vitality, Month 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0992</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>3.8</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Bodily Pain, Month 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0339</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.2</ci_lower_limit>
            <ci_upper_limit>4.4</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Bodily Pain, Month 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3572</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>3.1</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>General Health, Month 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0211</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.3</ci_lower_limit>
            <ci_upper_limit>4.2</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>General Health, Month 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0450</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>2.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0</ci_lower_limit>
            <ci_upper_limit>4.0</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mental Health, Month 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1710</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>3.7</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Mental Health, Month 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2484</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.9</ci_lower_limit>
            <ci_upper_limit>3.6</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Physical Functioning, Month 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1836</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>3.2</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Physical Functioning, Month 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3303</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>2.9</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Role Emotional, Month 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0299</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>2.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.2</ci_lower_limit>
            <ci_upper_limit>4.8</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Role Emotional, Month 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1141</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>4.2</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Role-Physical, Month 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0087</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>2.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7</ci_lower_limit>
            <ci_upper_limit>4.7</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Role-Physical, Month 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0128</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>2.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6</ci_lower_limit>
            <ci_upper_limit>4.7</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Social Functioning, Month 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1369</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>3.5</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Social Functioning, Month 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6331</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.5</ci_lower_limit>
            <ci_upper_limit>2.5</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vitality, Month 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0361</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>2.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1</ci_lower_limit>
            <ci_upper_limit>4.3</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Vitality, Month 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0525</p_value>
            <method>ANOVA</method>
            <method_desc>Missing data = treatment</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>2.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0</ci_lower_limit>
            <ci_upper_limit>4.2</ci_upper_limit>
            <estimate_desc>Missing data were imputed by LOCF</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Relative to an Identified Distribution (Ridit) Value of Symptom Occurrence and Symptom Distress Using Modified Transplant Symptom Occurrence and Symptom Distress Scale (MTSOSDS-59R)</title>
        <description>The Modified Transplant Symptom Occurrence and Symptom Distress Scale (MTSOSD-59R) was used to assess the occurrence (never, occasionally, regularly, almost always, always) and distress (0=no distress to 4=terrible distress) of symptoms associated with immunosuppressive therapies. Ridit (relative to an identified distribution) analysis (Fleiss JL. Statistical methods for rates and proportions. New York: John Wiley &amp; Sons, Inc. 1991) was used. Ridit scores were calculated at baseline and at 6, 12, 24, and 36 months for overall symptom occurrence score and overall symptom distress. The Ridit score reflects the probability that a score observed for an individual randomly selected from a group would be higher (worse symptom) than a score observed for a randomly selected individual from the reference group. The reference group was constituted by the frequency distribution of the responses of all participants on all items at baseline. The ridit of the reference group is by definition, 0.5.</description>
        <time_frame>Months 6, 12, 24, 36</time_frame>
        <population>All randomized and transplanted participants, intent to treat (ITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA): tablet, oral
1st month target: 150-300 nanogram/meter (ng/m) After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)</description>
          </group>
          <group group_id="O2">
            <title>Belatacept LI</title>
            <description>Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
          <group group_id="O3">
            <title>Belatacept MI</title>
            <description>Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 milligrams/kilogram (mg/kg) every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Relative to an Identified Distribution (Ridit) Value of Symptom Occurrence and Symptom Distress Using Modified Transplant Symptom Occurrence and Symptom Distress Scale (MTSOSDS-59R)</title>
          <description>The Modified Transplant Symptom Occurrence and Symptom Distress Scale (MTSOSD-59R) was used to assess the occurrence (never, occasionally, regularly, almost always, always) and distress (0=no distress to 4=terrible distress) of symptoms associated with immunosuppressive therapies. Ridit (relative to an identified distribution) analysis (Fleiss JL. Statistical methods for rates and proportions. New York: John Wiley &amp; Sons, Inc. 1991) was used. Ridit scores were calculated at baseline and at 6, 12, 24, and 36 months for overall symptom occurrence score and overall symptom distress. The Ridit score reflects the probability that a score observed for an individual randomly selected from a group would be higher (worse symptom) than a score observed for a randomly selected individual from the reference group. The reference group was constituted by the frequency distribution of the responses of all participants on all items at baseline. The ridit of the reference group is by definition, 0.5.</description>
          <population>All randomized and transplanted participants, intent to treat (ITT) population.</population>
          <units>Ridit score</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="197"/>
                <count group_id="O3" value="187"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Symptom Distress, Month 6 (n=157, 164, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4643" spread="0.00452"/>
                    <measurement group_id="O2" value="0.4407" spread="0.00404"/>
                    <measurement group_id="O3" value="0.4451" spread="0.00422"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptom Occurrence, Month 6 (n=166, 176, 165)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4721" spread="0.00463"/>
                    <measurement group_id="O2" value="0.4495" spread="0.00425"/>
                    <measurement group_id="O3" value="0.4459" spread="0.00432"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptom Distress, Month 12 (n=169, 185, 169)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4751" spread="0.00453"/>
                    <measurement group_id="O2" value="0.4510" spread="0.00397"/>
                    <measurement group_id="O3" value="0.4546" spread="0.00421"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptom Occurrence, Month 12 (n=173, 188, 173)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4776" spread="0.00458"/>
                    <measurement group_id="O2" value="0.4519" spread="0.00411"/>
                    <measurement group_id="O3" value="0.4525" spread="0.00430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptom Distress, Month 24 (n=182, 195, 179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4798" spread="0.00443"/>
                    <measurement group_id="O2" value="0.4584" spread="0.00397"/>
                    <measurement group_id="O3" value="0.4646" spread="0.00424"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptom Occurrence, Month 24 (n=184, 197, 184)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4804" spread="0.00446"/>
                    <measurement group_id="O2" value="0.4574" spread="0.00406"/>
                    <measurement group_id="O3" value="0.4593" spread="0.00423"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptom Distress, Month 36 (n=184, 196, 183)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5000" spread="0.00456"/>
                    <measurement group_id="O2" value="0.4746" spread="0.00408"/>
                    <measurement group_id="O3" value="0.4892" spread="0.00442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptom Occurrence, Month 36 (n=186, 197, 187)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5000" spread="0.00459"/>
                    <measurement group_id="O2" value="0.4732" spread="0.00421"/>
                    <measurement group_id="O3" value="0.4846" spread="0.00441"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Symptom Distress, Month 6. For calculation of symptom distress, those symptoms that never occurred will be converted to missing values, in order to avoid anticipatory symptom distress.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Missing data were imputed by LOCF. The ridit of the reference group is by definition 0.5.</p_value_desc>
            <method>z-test</method>
            <method_desc>The obtained ridits between treatment groups will be compared using z-test at 0.05 significance level for each year.</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>-0.024</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.032</ci_lower_limit>
            <ci_upper_limit>-0.015</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Symptom Distress, Month 6. For calculation of symptom distress, those symptoms that never occurred will be converted to missing values, in order to avoid anticipatory symptom distress.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Missing data were imputed by LOCF. The ridit of the reference group is by definition 0.5.</p_value_desc>
            <method>z-test</method>
            <method_desc>The obtained ridits between treatment groups will be compared using z-test at 0.05 significance level for each year.</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>-0.019</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.028</ci_lower_limit>
            <ci_upper_limit>-0.011</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Symptom Occurrence, Month 6.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Missing data were imputed by LOCF. The ridit of the reference group is by definition 0.5.</p_value_desc>
            <method>z-test</method>
            <method_desc>The obtained ridits between treatment groups will be compared using z-test at 0.05 significance level for each year.</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>-0.023</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.031</ci_lower_limit>
            <ci_upper_limit>-0.014</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Symptom Occurrence, Month 6.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Missing data were imputed by LOCF. The ridit of the reference group is by definition 0.5.</p_value_desc>
            <method>z-test</method>
            <method_desc>The obtained ridits between treatment groups will be compared using z-test at 0.05 significance level for each year.</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>-0.026</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.035</ci_lower_limit>
            <ci_upper_limit>-0.017</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Symptom Distress, Month 12. For calculation of symptom distress, those symptoms that never occurred will be converted to missing values, in order to avoid anticipatory symptom distress.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Missing data were imputed by LOCF. The ridit of the reference group is by definition 0.5.</p_value_desc>
            <method>z-test</method>
            <method_desc>The obtained ridits between treatment groups will be compared using z-test at 0.05 significance level for each year.</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>-0.024</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.032</ci_lower_limit>
            <ci_upper_limit>-0.016</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Symptom Distress, Month 12. For calculation of symptom distress, those symptoms that never occurred will be converted to missing values, in order to avoid anticipatory symptom distress.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Missing data were imputed by LOCF. The ridit of the reference group is by definition 0.5.</p_value_desc>
            <method>z-test</method>
            <method_desc>The obtained ridits between treatment groups will be compared using z-test at 0.05 significance level for each year.</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>-0.020</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.029</ci_lower_limit>
            <ci_upper_limit>-0.012</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Symptom Occurrence, Month 12.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Missing data were imputed by LOCF. The ridit of the reference group is by definition 0.5.</p_value_desc>
            <method>z-test</method>
            <method_desc>The obtained ridits between treatment groups will be compared using z-test at 0.05 significance level for each year.</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>-0.026</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.034</ci_lower_limit>
            <ci_upper_limit>-0.017</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Symptom Occurrence, Month 12.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Missing data were imputed by LOCF. The ridit of the reference group is by definition 0.5.</p_value_desc>
            <method>z-test</method>
            <method_desc>The obtained ridits between treatment groups will be compared using z-test at 0.05 significance level for each year.</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>-0.025</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.034</ci_lower_limit>
            <ci_upper_limit>-0.016</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Symptom Distress, Month 24. For calculation of symptom distress, those symptoms that never occurred will be converted to missing values, in order to avoid anticipatory symptom distress.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Missing data were imputed by LOCF. The ridit of the reference group is by definition 0.5.</p_value_desc>
            <method>z-test</method>
            <method_desc>The obtained ridits between treatment groups will be compared using z-test at 0.05 significance level for each year.</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>-0.021</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.030</ci_lower_limit>
            <ci_upper_limit>-0.013</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Symptom Distress, Month 24. For calculation of symptom distress, those symptoms that never occurred will be converted to missing values, in order to avoid anticipatory symptom distress.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Missing data were imputed by LOCF. The ridit of the reference group is by definition 0.5.</p_value_desc>
            <method>z-test</method>
            <method_desc>The obtained ridits between treatment groups will be compared using z-test at 0.05 significance level for each year.</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>-0.015</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.024</ci_lower_limit>
            <ci_upper_limit>-0.007</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Symptom Occurrence, Month 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Missing data were imputed by LOCF. The ridit of the reference group is by definition 0.5.</p_value_desc>
            <method>z-test</method>
            <method_desc>The obtained ridits between treatment groups will be compared using z-test at 0.05 significance level for each year.</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>-0.023</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.031</ci_lower_limit>
            <ci_upper_limit>-0.015</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Symptom Occurrence, Month 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Missing data were imputed by LOCF. The ridit of the reference group is by definition 0.5.</p_value_desc>
            <method>z-test</method>
            <method_desc>The obtained ridits between treatment groups will be compared using z-test at 0.05 significance level for each year.</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>-0.021</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.030</ci_lower_limit>
            <ci_upper_limit>-0.013</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Changes in the Value of Physical and Mental Components Using SF-36 From Baseline Up To Months 6, 12, 24, and 36</title>
        <description>SF-36 was a Participant-Reported Quality of Life (QoL) Short Form (SF) questionnaire measuring health-related quality of life (HRQL) covering 2 scale measures: physical component summary (PCS) and mental component summary (MCS). PCS represented by 4 domains: physical function, role limitations due to physical problems, pain, and general health perception. MCS represented by 4 domains: vitality, social function, role limitations due to emotional problems, and mental health. Their scores were computed based on weighted combinations of the 8 domain scores, which were transformed to a range from 0 to 100; 0= worst HRQL, 100=best HRQL. Higher scores reflect better health-related functional status. Scoring is standardized using the norm-based scoring method where data is scored in relation to the U.S. general population having a mean of 50 and a standard deviation of 10. Scores below 50 are below the U.S. general population norm and above 50 are above the U.S. general population norm.</description>
        <time_frame>Baseline to Months 6, 12, 24,and 36</time_frame>
        <population>All randomized and transplanted participants, intent to treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA): tablet, oral
1st month target: 150-300 nanogram/meter (ng/m) After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)</description>
          </group>
          <group group_id="O2">
            <title>Belatacept LI</title>
            <description>Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
          <group group_id="O3">
            <title>Belatacept MI</title>
            <description>Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 milligrams/kilogram (mg/kg) every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Changes in the Value of Physical and Mental Components Using SF-36 From Baseline Up To Months 6, 12, 24, and 36</title>
          <description>SF-36 was a Participant-Reported Quality of Life (QoL) Short Form (SF) questionnaire measuring health-related quality of life (HRQL) covering 2 scale measures: physical component summary (PCS) and mental component summary (MCS). PCS represented by 4 domains: physical function, role limitations due to physical problems, pain, and general health perception. MCS represented by 4 domains: vitality, social function, role limitations due to emotional problems, and mental health. Their scores were computed based on weighted combinations of the 8 domain scores, which were transformed to a range from 0 to 100; 0= worst HRQL, 100=best HRQL. Higher scores reflect better health-related functional status. Scoring is standardized using the norm-based scoring method where data is scored in relation to the U.S. general population having a mean of 50 and a standard deviation of 10. Scores below 50 are below the U.S. general population norm and above 50 are above the U.S. general population norm.</description>
          <population>All randomized and transplanted participants, intent to treat (ITT) population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="203"/>
                <count group_id="O3" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mental Component Score; Month 6 (n=187, 197, 184)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="0.714"/>
                    <measurement group_id="O2" value="6.2" spread="0.695"/>
                    <measurement group_id="O3" value="7.3" spread="0.720"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Score; Month 6 (n=187, 197, 184</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="0.580"/>
                    <measurement group_id="O2" value="6.2" spread="0.566"/>
                    <measurement group_id="O3" value="6.7" spread="0.585"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Score; Month 12 (n=192, 200, 189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="0.687"/>
                    <measurement group_id="O2" value="6.8" spread="0.673"/>
                    <measurement group_id="O3" value="6.2" spread="0.693"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Score; Month 12 (n=192,200,189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" spread="0.589"/>
                    <measurement group_id="O2" value="7.1" spread="0.577"/>
                    <measurement group_id="O3" value="7.8" spread="0.594"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Score; Month 24 (n=191,202,193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="0.732"/>
                    <measurement group_id="O2" value="5.7" spread="0.712"/>
                    <measurement group_id="O3" value="5.1" spread="0.728"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Score; Month 24 (n=191,202,193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="0.601"/>
                    <measurement group_id="O2" value="6.5" spread="0.584"/>
                    <measurement group_id="O3" value="7.3" spread="0.597"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Score; Month 36 (n=190,203,191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="0.756"/>
                    <measurement group_id="O2" value="5.1" spread="0.732"/>
                    <measurement group_id="O3" value="4.5" spread="0.754"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Score; Month 36 (n=190,203,191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="0.633"/>
                    <measurement group_id="O2" value="6.5" spread="0.612"/>
                    <measurement group_id="O3" value="6.1" spread="0.631"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mental Component Score; Month 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4498</p_value>
            <method>ANCOVA</method>
            <method_desc>Adjusted mean based on an ANCOVA model with treatment as factor, and baseline value as covariate.</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.2</ci_lower_limit>
            <ci_upper_limit>2.7</ci_upper_limit>
            <estimate_desc>Statistical tests comparing each belatacept regimen to the CsA regimen were conducted at a significance level of 0.05. Subjects with only baseline observations were excluded from these summaries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Mental Component Score; Month 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0584</p_value>
            <method>ANCOVA</method>
            <method_desc>Adjusted mean based on an ANCOVA model with treatment as factor, and baseline value as covariate.</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1</ci_lower_limit>
            <ci_upper_limit>3.9</ci_upper_limit>
            <estimate_desc>Statistical tests comparing each belatacept regimen to the CsA regimen were conducted at a significance level of 0.05. Subjects with only baseline observations were excluded from these summaries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Physical Component Score; Month 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1595</p_value>
            <method>ANCOVA</method>
            <method_desc>Adjusted mean based on an ANCOVA model with treatment as factor, and baseline value as covariate.</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>2.7</ci_upper_limit>
            <estimate_desc>Statistical tests comparing each belatacept regimen to the CsA regimen were conducted at a significance level of 0.05. Subjects with only baseline observations were excluded from these summaries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Physical Component Score; Month 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0457</p_value>
            <method>ANCOVA</method>
            <method_desc>Adjusted mean based on an ANCOVA model with treatment as factor, and baseline value as covariate.</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0</ci_lower_limit>
            <ci_upper_limit>3.3</ci_upper_limit>
            <estimate_desc>Statistical tests comparing each belatacept regimen to the CsA regimen were conducted at a significance level of 0.05. Subjects with only baseline observations were excluded from these summaries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mental Component Score; Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1729</p_value>
            <method>ANCOVA</method>
            <method_desc>Adjusted mean based on an ANCOVA model with treatment as factor, and baseline value as covariate.</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>3.2</ci_upper_limit>
            <estimate_desc>Statistical tests comparing each belatacept regimen to the CsA regimen were conducted at a significance level of 0.05. Subjects with only baseline observations were excluded from these summaries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Mental Component Score; Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4209</p_value>
            <method>ANCOVA</method>
            <method_desc>Adjusted mean based on an ANCOVA model with treatment as factor, and baseline value as covariate.</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>2.7</ci_upper_limit>
            <estimate_desc>Statistical tests comparing each belatacept regimen to the CsA regimen were conducted at a significance level of 0.05. Subjects with only baseline observations were excluded from these summaries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Physical Component Score; Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0526</p_value>
            <method>ANCOVA</method>
            <method_desc>Adjusted mean based on an ANCOVA model with treatment as factor, and baseline value as covariate.</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0</ci_lower_limit>
            <ci_upper_limit>3.2</ci_upper_limit>
            <estimate_desc>Statistical tests comparing each belatacept regimen to the CsA regimen were conducted at a significance level of 0.05. Subjects with only baseline observations were excluded from these summaries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Physical Component Score; Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0077</p_value>
            <method>ANCOVA</method>
            <method_desc>Adjusted mean based on an ANCOVA model with treatment as factor, and baseline value as covariate.</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>2.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6</ci_lower_limit>
            <ci_upper_limit>3.9</ci_upper_limit>
            <estimate_desc>Statistical tests comparing each belatacept regimen to the CsA regimen were conducted at a significance level of 0.05. Subjects with only baseline observations were excluded from these summaries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mental Component Score; Month 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1849</p_value>
            <method>ANCOVA</method>
            <method_desc>Adjusted mean based on an ANCOVA model with treatment as factor, and baseline value as covariate.</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>3.4</ci_upper_limit>
            <estimate_desc>Statistical tests comparing each belatacept regimen to the CsA regimen were conducted at a significance level of 0.05. Subjects with only baseline observations were excluded from these summaries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Mental Component Score; Month 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4633</p_value>
            <method>ANCOVA</method>
            <method_desc>Adjusted mean based on an ANCOVA model with treatment as factor, and baseline value as covariate.</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.3</ci_lower_limit>
            <ci_upper_limit>2.8</ci_upper_limit>
            <estimate_desc>Statistical tests comparing each belatacept regimen to the CsA regimen were conducted at a significance level of 0.05. Subjects with only baseline observations were excluded from these summaries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Physical Component Score; Month 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0971</p_value>
            <method>ANCOVA</method>
            <method_desc>Adjusted mean based on an ANCOVA model with treatment as factor, and baseline value as covariate.</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>3.0</ci_upper_limit>
            <estimate_desc>Statistical tests comparing each belatacept regimen to the CsA regimen were conducted at a significance level of 0.05. Subjects with only baseline observations were excluded from these summaries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Physical Component Score; Month 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0102</p_value>
            <method>ANCOVA</method>
            <method_desc>Adjusted mean based on an ANCOVA model with treatment as factor, and baseline value as covariate.</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>2.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5</ci_lower_limit>
            <ci_upper_limit>3.8</ci_upper_limit>
            <estimate_desc>Statistical tests comparing each belatacept regimen to the CsA regimen were conducted at a significance level of 0.05. Subjects with only baseline observations were excluded from these summaries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mental Component Score; Month 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0186</p_value>
            <method>ANCOVA</method>
            <method_desc>Adjusted mean based on an ANCOVA model with treatment as factor, and baseline value as covariate.</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>2.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.4</ci_lower_limit>
            <ci_upper_limit>4.5</ci_upper_limit>
            <estimate_desc>Statistical tests comparing each belatacept regimen to the CsA regimen were conducted at a significance level of 0.05. Subjects with only baseline observations were excluded from these summaries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Mental Component Score; Month 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0775</p_value>
            <method>ANCOVA</method>
            <method_desc>Adjusted mean based on an ANCOVA model with treatment as factor, and baseline value as covariate.</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>4.0</ci_upper_limit>
            <estimate_desc>Statistical tests comparing each belatacept regimen to the CsA regimen were conducted at a significance level of 0.05. Subjects with only baseline observations were excluded from these summaries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Physical Component Score; Month 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0768</p_value>
            <method>ANCOVA</method>
            <method_desc>Adjusted mean based on an ANCOVA model with treatment as factor, and baseline value as covariate.</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>3.3</ci_upper_limit>
            <estimate_desc>Statistical tests comparing each belatacept regimen to the CsA regimen were conducted at a significance level of 0.05. Subjects with only baseline observations were excluded from these summaries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Physical Component Score; Month 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1876</p_value>
            <method>ANCOVA</method>
            <method_desc>Adjusted mean based on an ANCOVA model with treatment as factor, and baseline value as covariate.</method_desc>
            <param_type>Mean Difference (Final Value)</param_type>
            <param_value>1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>2.9</ci_upper_limit>
            <estimate_desc>Statistical tests comparing each belatacept regimen to the CsA regimen were conducted at a significance level of 0.05. Subjects with only baseline observations were excluded from these summaries.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in the Value of the Eight Domain Scores Using SF-36 From Baseline Up To Months 6, 12, 24, and 36</title>
        <description>SF-36 was a Participant-Reported Quality of Life (QoL) Short Form (SF) questionnaire measuring health-related quality of life (HRQL) covering 2 scale measures: physical component summary (PCS) and mental component summary (MCS). PCS represented by 4 domains: physical function, role limitations due to physical problems, pain, and general health perception. MCS represented by 4 domains: vitality, social function, role limitations due to emotional problems, and mental health. Their scores were computed based on weighted combinations of the 8 domain scores, which were transformed to a range from 0 to 100; 0= worst HRQL, 100=best HRQL. Higher scores reflect better health-related functional status. Scoring is standardized using the norm-based scoring method where data is scored in relation to the U.S. general population having a mean of 50 and a standard deviation of 10. Scores below 50 are below the U.S. general population norm and above 50 are above the U.S. general population norm.</description>
        <time_frame>Baseline to Months 6, 12, 24, and 36</time_frame>
        <population>All randomized and transplanted participants, intent to treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA): tablet, oral
1st month target: 150-300 nanogram/meter (ng/m) After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)</description>
          </group>
          <group group_id="O2">
            <title>Belatacept LI</title>
            <description>Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
          <group group_id="O3">
            <title>Belatacept MI</title>
            <description>Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 milligrams/kilogram (mg/kg) every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in the Value of the Eight Domain Scores Using SF-36 From Baseline Up To Months 6, 12, 24, and 36</title>
          <description>SF-36 was a Participant-Reported Quality of Life (QoL) Short Form (SF) questionnaire measuring health-related quality of life (HRQL) covering 2 scale measures: physical component summary (PCS) and mental component summary (MCS). PCS represented by 4 domains: physical function, role limitations due to physical problems, pain, and general health perception. MCS represented by 4 domains: vitality, social function, role limitations due to emotional problems, and mental health. Their scores were computed based on weighted combinations of the 8 domain scores, which were transformed to a range from 0 to 100; 0= worst HRQL, 100=best HRQL. Higher scores reflect better health-related functional status. Scoring is standardized using the norm-based scoring method where data is scored in relation to the U.S. general population having a mean of 50 and a standard deviation of 10. Scores below 50 are below the U.S. general population norm and above 50 are above the U.S. general population norm.</description>
          <population>All randomized and transplanted participants, intent to treat (ITT) population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bodily Pain, Month 6 (n=189,201,189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="0.712"/>
                    <measurement group_id="O2" value="4.5" spread="0.691"/>
                    <measurement group_id="O3" value="4.6" spread="0.712"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Health, Month 6 (n=189,201,190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" spread="0.631"/>
                    <measurement group_id="O2" value="7.1" spread="0.612"/>
                    <measurement group_id="O3" value="7.3" spread="0.630"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health, Month 6 (n=188,198,190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="0.716"/>
                    <measurement group_id="O2" value="5.2" spread="0.698"/>
                    <measurement group_id="O3" value="6.1" spread="0.712"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Functioning, Month 6 (n=189,201,190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="0.610"/>
                    <measurement group_id="O2" value="5.3" spread="0.592"/>
                    <measurement group_id="O3" value="5.6" spread="0.610"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Emotional, Month 6 (n=188,200,186)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="0.767"/>
                    <measurement group_id="O2" value="5.8" spread="0.744"/>
                    <measurement group_id="O3" value="6.9" spread="0.772"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role-Physical, Month 6 (n=188,201,187)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" spread="0.718"/>
                    <measurement group_id="O2" value="8.4" spread="0.694"/>
                    <measurement group_id="O3" value="9.6" spread="0.720"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Functioning, Month 6 (n=189,201,190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" spread="0.724"/>
                    <measurement group_id="O2" value="6.8" spread="0.702"/>
                    <measurement group_id="O3" value="6.9" spread="0.722"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality, Month 6 (n=188,198,190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="0.668"/>
                    <measurement group_id="O2" value="9.0" spread="0.651"/>
                    <measurement group_id="O3" value="9.9" spread="0.665"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bodily Pain, Month 12 (n=194,205,195)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="0.665"/>
                    <measurement group_id="O2" value="4.8" spread="0.647"/>
                    <measurement group_id="O3" value="5.5" spread="0.664"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Health, Month 12 (n=194,206,195)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" spread="0.638"/>
                    <measurement group_id="O2" value="7.7" spread="0.619"/>
                    <measurement group_id="O3" value="7.6" spread="0.636"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health, Month 12 (n=194,203,195)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="0.685"/>
                    <measurement group_id="O2" value="6.0" spread="0.670"/>
                    <measurement group_id="O3" value="5.0" spread="0.684"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Functioning, Month 12 (n=194,206,194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="0.640"/>
                    <measurement group_id="O2" value="6.2" spread="0.621"/>
                    <measurement group_id="O3" value="5.8" spread="0.641"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Emotional, Month 12 (n=192,205,191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="0.765"/>
                    <measurement group_id="O2" value="6.6" spread="0.741"/>
                    <measurement group_id="O3" value="5.9" spread="0.768"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role-Physical, Month 12 (n=193,205,191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" spread="0.716"/>
                    <measurement group_id="O2" value="10.3" spread="0.695"/>
                    <measurement group_id="O3" value="10.4" spread="0.720"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Functioning, Month 12 (n=194,205,195)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" spread="0.669"/>
                    <measurement group_id="O2" value="7.7" spread="0.650"/>
                    <measurement group_id="O3" value="8.0" spread="0.667"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality, Month 12 (n=194,203,195)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" spread="0.651"/>
                    <measurement group_id="O2" value="9.2" spread="0.636"/>
                    <measurement group_id="O3" value="9.7" spread="0.649"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bodily Pain, Month 24 (n=192,207,197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="0.722"/>
                    <measurement group_id="O2" value="3.3" spread="0.696"/>
                    <measurement group_id="O3" value="4.1" spread="0.713"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Health, Month 24 (n=193,207,197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="0.641"/>
                    <measurement group_id="O2" value="7.2" spread="0.619"/>
                    <measurement group_id="O3" value="6.8" spread="0.635"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health, Month 24 (n=193,203,195)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="0.710"/>
                    <measurement group_id="O2" value="4.6" spread="0.692"/>
                    <measurement group_id="O3" value="4.0" spread="0.706"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Functioning, Month 24 (n=193,207,197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="0.685"/>
                    <measurement group_id="O2" value="5.7" spread="0.662"/>
                    <measurement group_id="O3" value="5.5" spread="0.679"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Emotional, Month 24 (n=192,206,196)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="0.793"/>
                    <measurement group_id="O2" value="6.0" spread="0.766"/>
                    <measurement group_id="O3" value="5.9" spread="0.785"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role-Physical, Month 24 (n=193,207,195)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" spread="0.740"/>
                    <measurement group_id="O2" value="9.4" spread="0.715"/>
                    <measurement group_id="O3" value="10.7" spread="0.737"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Functioning, Month 24 (n=193, 207,197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" spread="0.722"/>
                    <measurement group_id="O2" value="7.4" spread="0.697"/>
                    <measurement group_id="O3" value="6.3" spread="0.715"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality, Month 24 (n=193,203,196)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" spread="0.700"/>
                    <measurement group_id="O2" value="7.9" spread="0.682"/>
                    <measurement group_id="O3" value="8.0" spread="0.695"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bodily Pain, Month 36 (n=191,207,196)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="0.739"/>
                    <measurement group_id="O2" value="4.2" spread="0.710"/>
                    <measurement group_id="O3" value="3.0" spread="0.730"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Health, Month 36 (n=193,207,197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="0.681"/>
                    <measurement group_id="O2" value="6.6" spread="0.657"/>
                    <measurement group_id="O3" value="5.8" spread="0.674"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health, Month 36 (n=191,204,195)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="0.754"/>
                    <measurement group_id="O2" value="4.1" spread="0.729"/>
                    <measurement group_id="O3" value="3.4" spread="0.746"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Functioning, Month 36 (n=192,206,197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="0.692"/>
                    <measurement group_id="O2" value="5.3" spread="0.668"/>
                    <measurement group_id="O3" value="5.1" spread="0.684"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Emotional, Month 36 (n=192,207,195)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="0.830"/>
                    <measurement group_id="O2" value="5.6" spread="0.800"/>
                    <measurement group_id="O3" value="5.0" spread="0.824"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role-Physical, Month 36 (n=192,207,195)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" spread="0.754"/>
                    <measurement group_id="O2" value="9.2" spread="0.727"/>
                    <measurement group_id="O3" value="8.9" spread="0.749"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Functioning, Month 36 (n=192,207,197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="0.736"/>
                    <measurement group_id="O2" value="7.0" spread="0.708"/>
                    <measurement group_id="O3" value="5.6" spread="0.726"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality, Month 36 (n=191,204,195)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="0.721"/>
                    <measurement group_id="O2" value="7.3" spread="0.698"/>
                    <measurement group_id="O3" value="7.3" spread="0.714"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants Surviving With a Functioning Graft</title>
        <description>Graft loss was defined as either functional loss or physical loss (nephrectomy). Functional loss was defined as a sustained level of serum creatinine (SCr) ≥ 6.0 milligrams per deciliter (mg/dL) or 530 micromoles per liter (μmol/L) as determined by the central laboratory for ≥ 4 weeks or ≥ 56 consecutive days of dialysis or impairment of renal function to such a degree that the participant underwent retransplant.</description>
        <time_frame>Months 24, 36</time_frame>
        <population>All randomized and transplanted participants, intent to treat (ITT) population. For 95% CI within each group, normal approximation is used in N&gt;=5. Otherwise exact method is used.</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA): tablet, oral
1st month target: 150-300 nanogram/meter (ng/m) After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)</description>
          </group>
          <group group_id="O2">
            <title>Belatacept LI</title>
            <description>Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
          <group group_id="O3">
            <title>Belatacept MI</title>
            <description>Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 milligrams/kilogram (mg/kg) every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Surviving With a Functioning Graft</title>
          <description>Graft loss was defined as either functional loss or physical loss (nephrectomy). Functional loss was defined as a sustained level of serum creatinine (SCr) ≥ 6.0 milligrams per deciliter (mg/dL) or 530 micromoles per liter (μmol/L) as determined by the central laboratory for ≥ 4 weeks or ≥ 56 consecutive days of dialysis or impairment of renal function to such a degree that the participant underwent retransplant.</description>
          <population>All randomized and transplanted participants, intent to treat (ITT) population. For 95% CI within each group, normal approximation is used in N&gt;=5. Otherwise exact method is used.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="221"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.5" lower_limit="86.6" upper_limit="94.4"/>
                    <measurement group_id="O2" value="94.7" lower_limit="91.8" upper_limit="97.6"/>
                    <measurement group_id="O3" value="94.1" lower_limit="90.9" upper_limit="97.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.7" lower_limit="84.5" upper_limit="92.9"/>
                    <measurement group_id="O2" value="92.0" lower_limit="88.5" upper_limit="95.6"/>
                    <measurement group_id="O3" value="92.2" lower_limit="88.7" upper_limit="95.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Month 24</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A non-inferiority margin of 10% for the co-primary endpoint of participant and graft survival was used. Determination of a margin for non-inferiority based on 'preservation of benefit' is not feasible, given the low rate of patient death and/or graft loss in the first year post-transplantation, and the absence of published, adequately sized, parallel-group trials with which to assess the effect of CsA on patient death and/or graft loss in the setting of MMF/steroids/basiliximab.</non_inferiority_desc>
            <param_type>Difference in Percent</param_type>
            <param_value>4.2</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.3</ci_lower_limit>
            <ci_upper_limit>10.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Month 24</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A non-inferiority margin of 10% for the co-primary endpoint of participant and graft survival was used. Determination of a margin for non-inferiority based on 'preservation of benefit' is not feasible, given the low rate of patient death and/or graft loss in the first year post-transplantation, and the absence of published, adequately sized, parallel-group trials with which to assess the effect of CsA on patient death and/or graft loss in the setting of MMF/steroids/basiliximab.</non_inferiority_desc>
            <param_type>Difference in Percent</param_type>
            <param_value>3.6</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.2</ci_lower_limit>
            <ci_upper_limit>9.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Month 36</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A non-inferiority margin of 10% for the co-primary endpoint of participant and graft survival was used. Determination of a margin for non-inferiority based on 'preservation of benefit' is not feasible, given the low rate of patient death and/or graft loss in the first year post-transplantation, and the absence of published, adequately sized, parallel-group trials with which to assess the effect of CsA on patient death and/or graft loss in the setting of MMF/steroids/basiliximab.</non_inferiority_desc>
            <param_type>Difference in Percent</param_type>
            <param_value>3.3</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.9</ci_lower_limit>
            <ci_upper_limit>9.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A non-inferiority margin of 10% for the co-primary endpoint of participant and graft survival was used. Determination of a margin for non-inferiority based on 'preservation of benefit' is not feasible, given the low rate of patient death and/or graft loss in the first year post-transplantation, and the absence of published, adequately sized, parallel-group trials with which to assess the effect of CsA on patient death and/or graft loss in the setting of MMF/steroids/basiliximab.</non_inferiority_desc>
            <param_type>Difference in Percent</param_type>
            <param_value>3.5</param_value>
            <ci_percent>97.3</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.8</ci_lower_limit>
            <ci_upper_limit>10.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With Composite Endpoint or Death, Graft Loss or Acute Rejection by Month 36</title>
        <description>Graft loss was defined as either functional loss or physical loss (nephrectomy). Functional loss was defined as a sustained level of serum creatinine (SCr) ≥ 6.0 milligrams per deciliter (mg/dL) or 530 micromoles per liter (μmol/L) as determined by the central laboratory for ≥ 4 weeks or ≥ 56 consecutive days of dialysis or impairment of renal function to such a degree that the participant underwent retransplant. Acute rejection was defined as central biopsy proven rejection that was either (1) clinically suspected by protocol defined reasons or (2) clinically suspected by other reasons and treated. Death and graft loss were not imputed.</description>
        <time_frame>Randomization to Month 36</time_frame>
        <population>All randomized and transplanted participants, intent to treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA): tablet, oral
1st month target: 150-300 nanogram/meter (ng/m) After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)</description>
          </group>
          <group group_id="O2">
            <title>Belatacept LI</title>
            <description>Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
          <group group_id="O3">
            <title>Belatacept MI</title>
            <description>Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 milligrams/kilogram (mg/kg) every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Composite Endpoint or Death, Graft Loss or Acute Rejection by Month 36</title>
          <description>Graft loss was defined as either functional loss or physical loss (nephrectomy). Functional loss was defined as a sustained level of serum creatinine (SCr) ≥ 6.0 milligrams per deciliter (mg/dL) or 530 micromoles per liter (μmol/L) as determined by the central laboratory for ≥ 4 weeks or ≥ 56 consecutive days of dialysis or impairment of renal function to such a degree that the participant underwent retransplant. Acute rejection was defined as central biopsy proven rejection that was either (1) clinically suspected by protocol defined reasons or (2) clinically suspected by other reasons and treated. Death and graft loss were not imputed.</description>
          <population>All randomized and transplanted participants, intent to treat (ITT) population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="221"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6" lower_limit="9.1" upper_limit="18.1"/>
                    <measurement group_id="O2" value="19.5" lower_limit="14.3" upper_limit="24.6"/>
                    <measurement group_id="O3" value="25.1" lower_limit="19.4" upper_limit="30.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.1" lower_limit="13.0" upper_limit="23.2"/>
                    <measurement group_id="O2" value="19.9" lower_limit="14.7" upper_limit="25.1"/>
                    <measurement group_id="O3" value="27.9" lower_limit="21.9" upper_limit="33.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.9" lower_limit="14.6" upper_limit="25.2"/>
                    <measurement group_id="O2" value="20.8" lower_limit="15.5" upper_limit="26.1"/>
                    <measurement group_id="O3" value="28.3" lower_limit="22.3" upper_limit="34.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percent</param_type>
            <param_value>5.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>12.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percent</param_type>
            <param_value>11.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.2</ci_lower_limit>
            <ci_upper_limit>18.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Month 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percent</param_type>
            <param_value>1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.5</ci_lower_limit>
            <ci_upper_limit>9.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Month 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percent</param_type>
            <param_value>9.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.9</ci_lower_limit>
            <ci_upper_limit>17.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Month 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percent</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.6</ci_lower_limit>
            <ci_upper_limit>8.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Month 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percent</param_type>
            <param_value>8.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.4</ci_lower_limit>
            <ci_upper_limit>16.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Randomization to Long Term Extension, up to 84 Months</time_frame>
      <desc>Study start: March 2005; Study Completion: April 2015. All randomized, transplanted, and treated participants (ITT population)</desc>
      <group_list>
        <group group_id="E1">
          <title>Cyclosporine</title>
          <description>Cyclosporine (CsA): tablet, oral
1st month target: 150-300 nanogram/meter (ng/m) After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)</description>
        </group>
        <group group_id="E2">
          <title>Belatacept - LI</title>
          <description>Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
        </group>
        <group group_id="E3">
          <title>Belatacept - MI</title>
          <description>Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 milligrams/kilogram (mg/kg) every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="167" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="160" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="164" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Agranulocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Haemolytic uraemic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Bicytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Splenic cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Aplasia pure red cell</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Mitral valve disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Aortic valve disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Pulseless electrical activity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital cystic kidney disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Polycystic liver disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Patent ductus arteriosus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Motion sickness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Middle ear effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism tertiary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal vein occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Papilloedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Diabetic gastroparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Hernial eventration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Tongue ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Pancreatolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Volvulus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Incarcerated inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Gastric ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Thrombosis mesenteric vessel</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Abdominal compartment syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Mesenteric arterial occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Pneumatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Accidental death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Incarcerated hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Ischaemic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Hepatitis alcoholic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Hepatosplenomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Gallbladder disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Bile duct stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Transplant rejection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Renal transplant failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Chronic allograft nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Acinetobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Arteriovenous graft site infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Encephalitis meningococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Hepatitis E</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Histoplasmosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Tuberculosis gastrointestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Tuberculosis of intrathoracic lymph nodes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Urinary tract infection enterococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Varicella zoster virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Vulval abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Bone tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Campylobacter gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>H1N1 influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Meningitis cryptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Streptococcal urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Tubo-ovarian abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula site infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Blastomycosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Lymph node tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Ovarian abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Progressive multifocal leukoencephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Pseudomonas infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Psoas abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>West Nile viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Abdominal wall abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Diabetic foot infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Labyrinthitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Pneumonia influenzal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Polyomavirus-associated nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Parvovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Pneumocystis jirovecii pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Candida infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Cryptococcosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Hepatic cyst infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Necrotising fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Peritonitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Strongyloidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Bursitis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus viraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Gastrointestinal viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Parasitic encephalitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Pyelonephritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Streptococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Wound sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>BK virus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Bacterial diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Bacterial pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary aspergillosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Chest wall abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Escherichia infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Gastroenteritis norovirus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Pertussis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Pneumonia cytomegaloviral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Pneumonia legionella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Sepsis syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Sialoadenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Tuberculous pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous fistula thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Delayed graft function</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Postoperative wound complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Renal lymphocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Transplant dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Transplant failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Ureteric anastomosis complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Face injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Graft complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Post procedural haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Chest injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Complications of transplanted kidney</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Transfusion reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Wound evisceration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Complications of transplant surgery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Post procedural inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Urinary anastomotic leak</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Vascular graft complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Stenosis of vesicourethral anastomosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Carbon monoxide poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Graft loss</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Postoperative ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Procedural hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood glucose fluctuation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Blood creatine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Blood culture positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Polyomavirus test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Pneumocystis test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Ultrasound kidney abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Blood glucose decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Coagulation test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Staphylococcus test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Diastasis recti abdominis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Neuropathic arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Lip squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Metastatic uterine cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Renal oncocytoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Anogenital warts</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Iris neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Pancreatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Sarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Throat cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Adenoma benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Basosquamous carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Metastatic malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Hepatic adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Post transplant lymphoproliferative disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Acanthoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Benign breast neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Bladder adenocarcinoma stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Chronic myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Thymic cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Metastatic squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Haemangioma of liver</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Keratoacanthoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Malignant pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Parathyroid tumour benign</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Bladder papilloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Renal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Generalised tonic-clonic seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Intracranial pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Central nervous system lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Pineal gland cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Action tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Myasthenic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Cerebral haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Mononeuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mania</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Acute psychosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Hypomania</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Renal artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Ureteric obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Glomerulonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Renal tubular disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Tubulointerstitial nephritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Obstructive uropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Renal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Ureteric stenosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Vesicoureteric reflux</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Nephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Renal artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Renal mass</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Renal tubular necrosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Acute prerenal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Glomerulonephritis membranous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Renal cyst ruptured</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Renal vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Urinary bladder polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Ureteric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Focal segmental glomerulosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Renal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Renal tubular atrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Urinary fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Urinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Anuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Bladder neck sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Ureteral necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Urinary bladder haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Acquired hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Breast calcifications</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Priapism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Laryngeal oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Bullous lung disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Ingrowing nail</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Subcutaneous emphysema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Actinic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Femoral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Arterial stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Lymphocele</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Arterial thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Embolism venous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Pelvic venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Peripheral artery dissection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Vascular compression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Phlebitis superficial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Capillary leak syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Extremity necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="213" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="222" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="216" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Polycythaemia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="92" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="85" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="59" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Gingival hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="83" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="65" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="92" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="115" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="118" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Aphthous ulcer</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="64" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic allograft nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Onychomycosis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Tinea versicolour</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="60" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Candida infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="91" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="71" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>BK virus infection</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Delayed graft function</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Transplant dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Incision site pain</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Complications of transplanted kidney</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Complications of transplant surgery</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="62" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Iron deficiency</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Osteopenia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="65" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Leukocyturia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Renal tubular necrosis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="69" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Hypertrichosis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="70" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bristol-Myers Squibb Study Director</name_or_title>
      <organization>Bristol-Myers Squibb</organization>
      <email>Clinical.Trials@bms.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

